Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
Optimized CRISPR complexes with hybridized guide sequences and Cas9 orthologs enhance genome editing precision and versatility, addressing limitations of current CRISPR/Cas systems for targeted genetic manipulation.
Patent Information
- Application Number
- JP2024128853
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2013-06-17
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current genome editing techniques, such as CRISPR/Cas systems, require custom proteins for sequence targeting and lack robustness and versatility in targeting multiple locations within the nuclear genome, limiting their effectiveness in classifying and mapping genetic factors associated with biological functions and diseases.
Development of CRISPR complexes using guide sequences hybridized to target sequences, combined with optimized CRISPR enzymes like Cas9 orthologs and chimeric Cas9 proteins, to enhance specificity and efficiency in genome editing and regulation.
The CRISPR complexes provide broad utility in modifying polynucleotides, enabling precise gene editing, regulation, and therapeutic applications with reduced off-target effects and improved targeting capabilities.
Smart Images

Figure 2024163122000047 
Figure 2024163122000048 
Figure 2024163122000049
Abstract
Description
[Technical Field]
[0001] Related Applications and Incorporation by Reference This application claims priority to U.S. Provisional Patent Application No. 61 / 836,101, filed June 17, 2013, entitled ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION. This application also claims priority to U.S. Provisional Patent Applications Nos. 61 / 758,468; 61 / 769,046; 61 / 802,174; 61 / 806,375; 61 / 814,263; 61 / 819,803 and 61 / 828,130, each entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, which were filed on January 30, 2013; February 25, 2013; March 15, 2013; March 28, 2013; April 20, 2013; May 6, 2013 and May 28, 2013, respectively. This application also claims priority to U.S. Provisional Patent Applications Nos. 61 / 736,527 and 61 / 748,427, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed December 12, 2012 and January 2, 2013, respectively. Priority is also claimed to U.S. Provisional Patent Applications Nos. 61 / 791,409 and 61 / 835,931, filed March 15, 2013 and June 17, 2013, respectively. Reference is made to U.S. Provisional Patent Applications Nos. 61 / 836,127, 61 / 835,936, 61 / 836,080, 61 / 836,123, and 61 / 835,973, each filed on June 17, 2013.
[0002] The above applications, and all documents cited in those applications or during their prosecution ("application cited documents"), and all documents cited or referenced in those application cited documents, as well as all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in the herein cited documents, together with any manufacturer's instructions, manuals, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated by reference and may be used in the practice of this invention. More specifically, all references are incorporated by reference to the same extent as if each individual document were individually and specifically indicated to be incorporated by reference.
[0003] The present invention relates generally to the engineering and optimization of systems, methods and compositions used in the control of gene expression, including sequence targeting, e.g., genomic perturbation or gene editing, involving Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and its components.
[0004] STATEMENT REGARDING FEDERALLY FUNDED RESEARCH This invention was made with government support under an NIH Pioneer Award (1DP1MH100706) awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. [Background technology]
[0005] Recent advances in genome sequencing technology and analytical methods have significantly accelerated the ability to classify and map genetic factors related to a wide range of biological functions and diseases.Accurate genome targeting technology is needed to enable the systematic reverse engineering of causal gene mutations by enabling the selective perturbation of individual genetic elements, and to advance synthetic biology, biotechnology and pharmaceutical applications.Genome editing technology, such as designer zinc finger, transcription activator-like effector (TALE), or homing meganuclease, can be used to produce targeted genome perturbations, but there is still a need for new genome engineering technology that is inexpensive, easy to set up, scalable, and easy to target multiple locations in eukaryotic genomes. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 97 / 03211 Brochure Summary of the Invention [Problem to be solved by the invention]
[0007] Rather than requiring the generation of custom proteins to target specific sequences, CRISPR / Cas or CRISPR-Cas systems (both terms are used interchangeably throughout this application) allow a single Cas enzyme to be programmed with a short RNA molecule to recognize a specific DNA target; in other words, the Cas enzyme can be recruited to a specific DNA target using the short RNA molecule. The addition of CRISPR-Cas systems to the repertoire of genome sequencing technologies and analytical methods significantly simplifies methodology and accelerates the ability to classify and map genetic factors associated with a diverse range of biological functions and diseases. To effectively utilize CRISPR-Cas systems for genome editing without adverse effects, it is important to understand the engineering and optimization aspects of these genome engineering tools, which are an embodiment of the claimed invention. [Means for solving the problem]
[0008] Therefore, there is an urgent need for alternative and robust systems and techniques for versatile sequence targeting. Aspects of the present invention address this need and provide related advantages. Exemplary CRISPR complexes include a CRISPR enzyme complexed with a guide sequence that hybridizes to a target sequence within a target polynucleotide, the CRISPR enzyme being a member of the genera Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flavivora, and the like. and Cas orthologs, e.g., Cas9 orthologs, from genera including Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter. The guide sequence is linked to a tracr mate sequence, which then hybridizes to the tracr sequence.
[0009] In one embodiment, the present invention provides the method of using one or more elements of CRISPR system.The CRISPR complex of the present invention provides an effective means for modifying target polynucleotide.The CRISPR complex of the present invention has a wide range of usefulness, for example, the modification of target polynucleotide in a large number of cell types (for example, deletion, insertion, translocation, inactivation, activation, suppression, methylation change, transfer of specified part).Therefore, the CRISPR complex of the present invention has a wide range of applications, for example, in gene or genome editing, gene regulation, gene therapy, drug delivery, drug screening, disease diagnosis and prognosis. In a preferred embodiment of the present invention, the CRISPR complex is selected from the group consisting of, but not limited to, bacteria of the genus Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, and the like. Cas enzymes from genera including Bacillus subtilis, ...
[0010] Aspects of the present invention relate to CRISPR enzymes with optimized function.For CRISPR enzymes that are Cas enzymes, a preferred embodiment of the present invention relates to Cas9 orthologues with improved target specificity in CRISPR-Cas9 systems.This can be achieved by approaches including, but not limited to, designing and preparing guide RNAs with optimal activity, selecting Cas9 enzymes with defined lengths, truncating Cas9 enzymes (by truncating the nucleic acid molecule encoding Cas9, thereby shortening the length of Cas9 compared to the corresponding wild-type Cas9 enzyme), and generating chimeric Cas9 enzymes (different parts of the enzyme are swapped or exchanged between different orthologues to obtain chimeric enzymes with tailored specificity). Embodiments of the invention also relate to methods for improving the target specificity of a Cas9 orthologous enzyme or for designing a CRISPR-Cas9 system, comprising designing or preparing a guide RNA with optimal activity and / or selecting or preparing a Cas9 orthologous enzyme that has a smaller size or length than the corresponding wild-type Cas9 (which improves packaging of the nucleic acid encoding it into a delivery vector due to its shorter coding sequence in the delivery vector than the corresponding wild-type Cas9), and / or generating a chimeric Cas9 enzyme.
[0011] Also provided is the use of the sequences, vectors, enzymes or systems of the present invention in medicine. Also provided is the use of the sequences, vectors, enzymes or systems of the present invention in gene or genome editing. Also provided is the use of the sequences, vectors, enzymes or systems of the present invention in the manufacture of medicines for gene or genome editing, for example, gene or genome editing therapy. Also provided is the use of the sequences, vectors, enzymes or systems of the present invention in therapy.
[0012] In another embodiment of the present invention, CRISPR enzyme, for example, Cas9 enzyme, can contain one or more mutations, and can be used as a global DNA binding protein with or without fusion with functional domain, or operably linked thereto.Mutation can be an artificially introduced mutation, and can include, but is not limited to, one or more mutations in catalytic domain.Examples of catalytic domains for Cas9 enzymes include, but are not limited to, RuvCI, RuvCII, RuvCIII and HNH domain.Preferred examples of suitable mutations are catalytic residues in the N-terminal RuvCI domain of Cas9 or catalytic residues in the internal HNH domain.In some embodiments, Cas9 is (or is derived from) Streptococcus pyogenes Cas9 (SpCas9). In such embodiments, preferred mutations are at any or all of positions 10, 762, 840, 854, 863, and / or 986 of SpCas9 or at corresponding positions in other Cas9 orthologs relative to the SpCas9 position numbering (e.g., as can be confirmed using standard sequence comparison tools, such as ClustalW or MegAlign in the Lasergene 10 suite). In particular, any or all of the following mutations in SpCas9 are preferred: D10A, E762A, H840A, N854A, N863A, and / or D986A; conservative substitutions for any of the substituted amino acids are also contemplated. Identical mutations (or conservative substitutions of those mutations) at corresponding positions relative to the SpCas9 position numbering in other Cas9 orthologs are also preferred. D10 and H840 in SpCas9 are particularly preferred. However, residues corresponding to SpCas9 D10 and H840 in other Cas9s are also preferred. These are advantageous because, when mutated alone, they provide nickase activity, and when both mutations are present, they convert Cas9 into a catalytically ineffective mutant useful for global DNA binding. Additional mutations have been identified and characterized.Other aspects of the invention relate to mutant Cas9 enzymes fused to or operably linked to domains including, but not limited to, transcriptional activators, transcriptional repressors, recombinases, transposases, histone remodelers, DNA methyltransferases, cryptochromes, light-inducible / regulatory domains, or chemical-inducible / regulatory domains.
[0013] Further aspects of the present invention provide chimeric Cas9 proteins and methods for generating chimeric Cas9 proteins. Chimeric Cas9 proteins are proteins containing fragments originating from different Cas9 orthologs. For example, the N-terminus of a first Cas9 ortholog can be fused to the C-terminus of a second Cas9 ortholog to generate chimeric Cas9 proteins. These chimeric Cas9 proteins may have higher specificity or efficiency than the original specificity or efficiency of either of the individual Cas9 enzymes from which the chimeric proteins are generated. These chimeric proteins may also contain one or more mutations or be linked to one or more functional domains. Thus, aspects of the present invention relate to chimeric Cas enzymes containing one or more fragments from a first Cas ortholog and one or more fragments from a second Cas ortholog. In one embodiment of the present invention, the one or more fragments from the first or second Cas ortholog are from the C- or N-terminus of the first or second Cas ortholog.In further embodiments, the first or second Cas ortholog is selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacteriu, and the like. The bacterium is selected from the genera Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.
[0014] In a further embodiment, the present invention provides a method for generating mutant components of a CRISPR complex containing a Cas enzyme, e.g., a Cas9 orthologue. The mutant components can include, but are not limited to, mutant tracrRNAs and tracr mate sequences or mutant chimeric guide sequences that enable improved performance of these RNAs in cells. Use of the compositions or enzymes in the preparation of pharmaceuticals for target sequence modification is also provided.
[0015] In a still further aspect, the present invention provides a method for producing a composition comprising: A)-I. CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell; (b) tracr mate sequence, and (c) tracr sequence a polynucleotide sequence comprising: II. Polynucleotide sequence encoding a CRISPR enzyme containing at least one nuclear localization sequence Including, (a), (b), and (c) are arranged in a 5' to 3' orientation; Upon transcription, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence; The CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to a target sequence and (2) a tracr mate sequence hybridized to a tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA. Non-Naturally Occurring or Engineered Compositions or (B) I. A polynucleotide comprising: (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one tracr mate sequence a polynucleotide comprising II. Polynucleotide sequences encoding CRISPR enzymes, and III. Polynucleotide sequences containing the tracr sequence Including, When transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific target binding of the CRISPR complex to the target sequence; The CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to a target sequence, and (2) a tracr mate sequence hybridized to a tracr sequence, wherein the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA; CRISPR enzymes are active against the genera Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, and Flavobacterium. Cas9 orthologs in genera belonging to the group consisting of Rium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter. Compositions and methods relating to non-naturally occurring or engineered compositions are provided.
[0016] In still a further aspect, the present invention provides a method for producing a CRISPR-Cas system comprising: (A) I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence (the polynucleotide sequence comprising (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence); and II.and a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b), and (c) are arranged in a 5' to 3' orientation, and components I and II are on the same or different vectors of the system, wherein, when transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and the CRISPR complex comprises (1) the guide sequence hybridized to the target sequence, and (2) the t The CRISPR enzyme complexed with a tracr mate sequence hybridized to the racr sequence, the CRISPR enzyme being a CRISPR enzyme that is specific for bacteria of the genera Corynebacter, Sutterella, Legionella, Treponema, Filifactr, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, and the like. Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors that are Cas9 orthologs of a genera belonging to the group consisting of: Bacillus subtilis, Nitratifractor, Mycoplasma, and Campylobacter; or (B) I. (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) a first regulatory element operably linked to at least one or more tracr mate sequences; II.a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and a third regulatory element operably linked to a tracr sequence, wherein components I, II, and III are on the same or different vectors of the system, and when transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence, and the CRISPR enzyme is selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, and the like. Non-naturally occurring or engineered compositions are provided that include a vector system comprising one or more vectors that are Cas9 orthologs from a genera belonging to the group consisting of Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter, and where at least one of the following criteria is met:
[0017] The criteria are as follows, it being recognized that any number of them may apply, preferably one or more, preferably two or more, preferably three or more, four or more, or five or more, or all may apply: - CRISPR enzymes having a defined size are selected, having a length of at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids, or at least 2000 amino acids; and / or the CRISPR enzyme is truncated compared to the corresponding wild-type CRISPR enzyme; and / or the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence; and / or the guide sequence comprises at least 10, at least 15 or at least 20 nucleotides; and / or the CRISPR enzyme is codon-optimized or codon-optimized for expression in eukaryotic cells; and / or the CRISPR enzyme contains one or more mutations; and / or the CRISPR enzyme comprises a chimeric CRISPR enzyme; -and / or the CRISPR enzyme has one or more other properties discussed herein.
[0018] In some embodiments, the CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme, or the CRISPR enzyme comprises at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids, or at least 2000 amino acids. In a preferred embodiment, the CRISPR enzyme is a Cas enzyme, e.g., a Cas9 ortholog.
[0019] In some embodiments, CRISPR enzyme is a nuclease that directs the cleavage of both strands at the location of target sequence, or CRISPR enzyme is a nickase that directs the cleavage of one strand at the location of target sequence.In further embodiments, CRISPR enzyme is a catalytically ineffective mutant of global DNA binding protein.In preferred embodiments, CRISPR enzyme is a Cas enzyme, for example, Cas9 ortholog.
[0020] In some embodiments, the guide sequence comprises at least 15 nucleotides. In some embodiments, the CRISPR enzyme is codon-optimized or codon-optimized for expression in eukaryotic cells. In some embodiments, the CRISPR enzyme comprises one or more mutations. In some embodiments, the CRISPR enzyme comprises a chimeric CRISPR enzyme. In some embodiments, the CRISPR enzyme has one or more other characteristics discussed herein. In a preferred embodiment, the CRISPR enzyme is a Cas enzyme, for example, a Cas9 ortholog.
[0021] In some embodiments, the CRISPR enzyme comprises one or more mutations. One or more mutations may be present in a specific domain of the enzyme. In a preferred embodiment, one or more mutations may be present in the catalytic domain. In a more preferred embodiment, the catalytic domain is the RuvCI, RuvCII, RuvCIII or HNH domain. In a more preferred embodiment, one or more mutations are present in the RuvC1 or HNH domain of the CRISPR enzyme. In a more preferred embodiment, the CRISPR enzyme is a Cas enzyme, for example, a Cas9 ortholog, and the mutation may be at one or more positions, including but not limited to, positions corresponding to D10A, E762A, H840A, N854A, N863A or D986A in terms of the position numbering of SpCas9, and / or any other mutation discussed herein. In some embodiments, the CRISPR enzyme has one or more mutations in a specific domain of the enzyme, and when transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs the sequence-specific binding of the CRISPR complex to the target sequence, and the enzyme further comprises a functional domain, which may include, but is not limited to, a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light-inducible / regulatory domain, or a chemical-inducible / regulatory domain.
[0022] In some embodiments, the functional domain is the transcriptional activator domain VP64. In some embodiments, the functional domain is the transcriptional repressor domain KRAB. In some embodiments, the transcriptional repressor domain is SID or a concatemer of SID (i.e., SID4X). In some embodiments, an epigenetic modification enzyme, such as a histone modification protein or an epigenetic chromatin modification protein, is provided. In some embodiments, an activator domain is provided that can be a P65 activator domain.
[0023] Further aspects of the present invention include a method for modifying two or more genomic loci of interest.In a preferred embodiment of the present invention, two or more genomic loci are separately modulated by utilizing one or more CRISPR enzymes, for example, two or more Cas9 orthologs, each ortholog being operably linked to one or more functional domains.In one aspect, the present invention provides a method for modifying two or more genomic loci in eukaryotic cells.Therefore, an aspect of the present invention is a method for modulating the expression of two or more genomic loci of interest in an organism, comprising: I. A first regulatory element operably linked to a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence is (i) a first guide sequence capable of hybridizing to a first target sequence at a first genomic locus in a cell of the organism; (ii) a first tracr mate sequence, and (iii) the first tracr sequence ), and II. A second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the second polynucleotide sequence is (i) a second guide sequence capable of hybridizing to a second target sequence at a second genomic locus in a cell of the organism; (ii) a second tracr mate sequence, and (iii) Second tracr sequence ), and III. A third regulatory element operably linked to an enzyme coding sequence encoding a first CRISPR enzyme, the third regulatory element comprising at least one nuclear localization sequence and operably linked to a first functional domain; IV. A fourth regulatory element operably linked to an enzyme coding sequence encoding a second CRISPR enzyme that includes at least one nuclear localization sequence and is operably linked to a second functional domain. wherein (i), (ii), and (iii) of I and II are arranged in a 5' to 3' orientation, and components I, II, III, and IV are on the same or different vectors of the system, and when transcribed, hybridize to their respective tracr mate sequences and gcr sequences, and the first and second guide sequences direct sequence-specific binding of first and second CRISPR complexes to first and second target sequences, and the CRISPR complexes comprise (1) a guide sequence hybridized to a target sequence, and (2) a tracr sequence hybridized to a tracr sequence. and a CRISPR enzyme complexed with a mate sequence, wherein expression of the CRISPR enzyme provides for manipulation of the target sequence, wherein the first and second CRISPR enzymes each comprise two or more mutations, and the first and second CRISPR enzymes are selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, and Streptococcus. tococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Pervibacilla and delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors that are Cas9 orthologs of a genera belonging to the group consisting of Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter, wherein a first genomic locus is modulated by the activity of a first functional domain and a second genomic locus is modulated by the activity of a first functional domain.The present invention provides a method for modulating the activity of a second functional domain. In a further embodiment, the first functional domain is selected from the group consisting of a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, and a light-inducible / regulatory domain or a chemically inducible / regulatory domain. In a further embodiment, the second functional domain is selected from the group consisting of a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, and a light-inducible / regulatory domain or a chemically inducible / regulatory domain. In a preferred embodiment, the first or second CRISPR enzyme is selected from the group consisting of Sutterella wadsworthensis Cas9, Filifactor alocis Cas9, Lactobacillus johnsonii Cas9, Campylobacter lari Cas9, Corynebacter diptheriae Cas9, Parvibaculum lavamentivorans Cas9, Mycoplasma gallisepticum Cas9, Staphylococcus aureus Cas9, Legionella pneumophila Cas9, and the like. Cas9, Treponema denticola Cas9, Staphylococcus pseudintermedius Cas9, and Neisseria cinerea Cas9.
[0024] In some embodiments, the CRISPR enzyme is a type I, II, or III CRISPR enzyme, preferably a type II CRISPR enzyme. This type II CRISPR enzyme can be any Cas enzyme. The Cas enzyme can be identified as Cas9, as this can refer to a general class of enzymes that share homology with the largest nuclease with multiple nuclease domains from the type II CRISPR system. Most preferably, the Cas9 enzyme is from or derived from SpCas9 or Staphylococcus aureus subsubspecies Aureus SaCas9. Derived means that the majority of the derived enzyme is based on the wild-type enzyme, in the sense that it has a high degree of sequence homology with the wild-type enzyme, but it has been mutated (modified) by some of the methods described herein.
[0025] It is recognized that the terms Cas and CRISPR enzyme are generally used interchangeably herein unless otherwise clear. As noted above, much of the residue numbering used herein refers to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes. However, the present invention is also directed to the production of other microbial species, such as Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, and the like. It is recognized that the term includes many more Cas9s from those belonging to the genera Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, or Campylobacter, such as SpCas9, SaCas9, St1Cas9, St3Cas9, etc., where St is Streptococcus thermophilus.
[0026] In this case, an example of a codon-optimized sequence that is human-optimized (i.e., optimized for expression in humans) is provided herein (see SaCas9 human codon-optimized sequence). While this is preferred, it will be understood that other examples are possible, and codon optimization for host species is known.
[0027] Further aspects of the present invention relate to improved cleavage specificity, optimized tracr sequences, optimized chimeric guide RNAs, co-folding of tracrRNA and tracr mate sequences, stabilization of the secondary structure of tracrRNA, tracrRNA with shortened base-pairing regions, tracrRNA with fusion RNA elements, simplified cloning and delivery, reduced toxicity, and / or inducible systems. Another aspect of the present invention relates to stabilization of chimeric RNAs and / or guide sequences and / or portions thereof of CRISPR complexes, where the CRISPR enzyme is a CRISPR ortholog, and the chimeric RNAs and / or guide sequences and / or portions thereof are stabilized with synthetic or chemically modified nucleotides (e.g., LNA / BNA: thiol-modified, 2' / 3'-OH bridge-modified), modified to be degradation / hydrolysis-resistant, and / or have structural stability elements added thereto.
[0028] In some embodiments, the present invention further encompasses a method for modifying organisms or non-human organisms by manipulating target sequences in target genomic loci, comprising delivering a non-naturally occurring or engineered composition comprising a vector system, comprising one or more vectors that are operable to encode the compositions discussed herein for their expression.Preferably, the vector is a viral vector, such as a lentivirus or baculovirus, or preferably an adenovirus / adeno-associated virus vector, although other delivery means are known and provided (for example, yeast system, microvesicle, gene gun / vector attached to gold nanoparticles).
[0029] A variety of delivery means are described herein and further discussed in this section.
[0030] Viral delivery: CRISPR enzymes, such as Cas9, and / or any of the RNAs, such as guide RNAs, can be delivered using adeno-associated viruses (AAVs), lentiviruses, adenoviruses, or other viral vector types, or combinations thereof. Cas9 and one or more guide RNAs can be packaged into one or more viral vectors. In some embodiments, the viral vector is delivered to the target tissue, for example, by intramuscular injection, while in other cases, viral delivery is via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods. Such delivery may be via a single dose or multiple doses. Those skilled in the art will understand that the actual dosage delivered herein may vary significantly depending on various factors, such as the choice of vector, the target cell, organism, or tissue, the general condition of the subject, the degree of transformation / modification desired, the route and method of administration, and the type of transformation / modification desired.
[0031] Such dosages may further contain, for example, carriers (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), diluents, pharmaceutically acceptable carriers (e.g., phosphate-buffered saline), pharmaceutically acceptable excipients, adjuvants that enhance antigenicity, immunostimulatory compounds or molecules, and / or other compounds known in the art. Adjuvants herein may include suspensions of minerals (alum, aluminum hydroxide, aluminum phosphate) to which the antigen adsorbs; or water-in-oil emulsions (MF-59, Freund's incomplete adjuvant) in which an antigen solution is emulsified in oil (sometimes containing killed mycobacteria (Freund's complete adjuvant)) to further enhance antigenicity (to inhibit antigen degradation and / or induce macrophage influx). Adjuvants also include immunostimulatory molecules, such as cytokines, costimulatory molecules, and, for example, immunostimulatory DNA or RNA molecules, such as CpG oligonucleotides. Such dosage formulations can be easily ascertained by those skilled in the art. The dosage may further contain one or more pharmaceutically acceptable salts, such as mineral acid salts, such as hydrochloride, hydrobromide, phosphate, sulfate, and the like; and organic acid salts, such as acetate, propionate, malonate, benzoate, and the like. In addition, auxiliary substances, such as wetting agents or emulsifiers, pH buffering substances, gels or gelling materials, flavorings, coloring agents, microspheres, polymers, suspending agents, and the like, may also be present herein. In addition, one or more other conventional pharmaceutical ingredients, such as preservatives, humectants, suspending agents, surfactants, antioxidants, anti-caking agents, fillers, chelating agents, coating agents, chemical stabilizers, and the like, may also be present, especially when the dosage form is a reconstitutable form. Suitable exemplary ingredients include microcrystalline cellulose, sodium carboxymethylcellulose, polysorbate 80, phenylethyl alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerin, phenol, parachlorophenol, gelatin, albumin, and combinations thereof.For a thorough discussion of pharmaceutically acceptable excipients, reference may be made to REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., NJ 1991), which is incorporated herein by reference.
[0032] In certain embodiments herein, delivery is via adenovirus, which delivers at least 1 x 10 5 In certain embodiments herein, the dose is preferably at least about 1 x 10 6 particles (e.g., about 1 × 10 6 ~1×10 12 particles), more preferably at least about 1×10 7 particles, more preferably at least about 1×10 8 particles (e.g., about 1 × 10 8 ~1×10 11 particles or approximately 1 x 10 8 ~1×10 12 particles), and most preferably at least about 1×10 0 particles (e.g., about 1 × 10 9 ~1×10 10 particles or approximately 1 x 10 9 ~1×10 12 particles), or even at least about 1 × 10 10 particles (e.g., about 1 × 10 10 ~1×10 12 particles) of adenoviral vector. Alternatively, the dose is about 1 x 10 14 particles or less, preferably about 1 x 10 13 particles or less, and even more preferably about 1×10 12 particles or less, and even more preferably about 1×10 11 particles or less, and most preferably about 1×10 10 particles or less (e.g., about 1 × 10 9 Thus, the dose may be, for example, about 1×10 6 Particle unit (pu), approximately 2 x 10 6 pu, approx. 4×10 6 pu, about 1×107 pu, approx. 2×10 7 pu, approx. 4×10 7 pu, about 1×10 8 pu, approx. 2×10 8 pu, approx. 4×10 8 pu, about 1×10 9 pu, approx. 2×10 9 pu, approx. 4×10 9 pu, about 1×10 10 pu, approx. 2×10 10 pu, approx. 4×10 10 pu, about 1×10 11 pu, approx. 2×10 11 pu, approx. 4×10 11 pu, about 1×10 12 pu, approx. 2×10 12 pu, or approximately 4 × 10 12 The adenovirus vector may contain a single dose of the adenovirus vector, including the adenovirus vector of pu. See, for example, the adenovirus vectors and dosage amounts at column 29, lines 36-58 of U.S. Patent No. 8,454,972 B2 to Nabel, et al., granted June 4, 2013 (incorporated herein by reference). In some embodiments herein, the adenovirus is delivered in multiple doses.
[0033] In certain embodiments herein, delivery is via AAV. The therapeutically effective dosage for in vivo delivery of AAV to humans is about 1×10 10 ~Approx. 1×10 10 The dosage is expected to be in the range of about 20 to about 50 ml of saline containing 1×10 functional AAV / ml solution. Dosage can be adjusted to balance the therapeutic benefit versus any adverse effects. In certain embodiments herein, the AAV dose is generally about 1×10 5 ~1×10 50 AAV genome, approximately 1 x 10 8 ~1×10 20 AAV genome, approximately 1 x 10 10 ~Approx. 1×10 16 genome, or approximately 1 × 10 11 ~Approx. 1×10 16 The concentration range of AAV genome is approximately 1 x 1013 The AAV may be a genome-wide AAV. Such concentrations can be delivered in about 0.001 ml to about 100 ml, about 0.05 ml to about 50 ml, or about 10 ml to about 25 ml of carrier solution. Other effective dosages can be readily established by those skilled in the art through routine testing to generate dose-response curves. See, for example, U.S. Patent No. 8,404,658 B2 to Hajjar, et al., issued March 26, 2013, column 27, lines 45-60.
[0034] In some embodiments of the present disclosure, delivery is via a plasmid. In such plasmid compositions, the dosage must be a sufficient amount of plasmid to induce a response. For example, a suitable amount of plasmid DNA in a plasmid composition may be about 0.1 to about 2 mg, or about 1 μg to about 10 μg.
[0035] Dosages herein are based on an average 70 kg individual. The frequency of administration is within the discretion of a medical or veterinary practitioner (e.g., physician, veterinarian), or scientist of ordinary skill in the art.
[0036] The viral vector can be injected into the target tissue. For cell-type-specific genome modification, Cas9 expression can be driven by a cell-type-specific promoter. For example, liver-specific expression can be achieved using the albumin promoter, and neuronal-specific expression can be achieved using the synapsin I promoter.
[0037] RNA delivery: CRISPR enzymes, such as Cas9, and / or any of the RNAs, such as guide RNA, can also be delivered in the form of RNA. Cas9 mRNA can be produced using in vitro transcription. For example, Cas9 mRNA can be synthesized from a β-globin-polyA tail (a series of 120 or more adenines) using a PCR cassette containing the following elements: T7 promoter-Kozak sequence (GCCACC)-Cas9-3'UTR. This cassette can be used for transcription with T7 polymerase. Guide RNA can also be transcribed using in vitro transcription from a cassette containing a T7 promoter-GG-guide RNA sequence.
[0038] To enhance expression and reduce toxicity, the CRISPR enzyme and / or guide RNA can be modified with pseudo-U or 5-methyl-C.
[0039] The CRISPR enzyme mRNA and guide RNA may be delivered simultaneously using nanoparticles or lipid envelopes.
[0040] For example, Su X, Fricke J, Kavanagh DG, and Irvine DJ ("In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles," Mol Pharm. 2011 Jun 6;8(3):774-87. doi:10.1021 / mp100390w. Epub 2011 Apr 1) describe biodegradable core-shell nanoparticles in which a poly(β-amino ester) (PBAE) core is surrounded by a phospholipid bilayer shell. These were developed for in vivo mRNA delivery. The pH-responsive PBAE component was selected to promote endosomal disruption, while the lipid surface layer was selected to minimize the toxicity of the polycation core. Therefore, this is preferred for delivering the RNA of the present invention.
[0041] Furthermore, Michael S.D. Kormann et al. ("Expression of therapeutic proteins after delivery of chemically modified mRNA in mice": Nature Biotechnology, Volume: 29, Pages: 154-157 (2011), published online January 9, 2011) describe the delivery of RNA using a lipid envelope. The use of a lipid envelope is also preferred in the present invention.
[0042] mRNA delivery methods currently show particular promise for liver delivery.
[0043] The CRISPR enzyme mRNA and guide RNA may also be delivered separately. To allow time for the CRISPR enzyme to be expressed, the CRISPR enzyme mRNA may be delivered before the guide RNA. The CRISPR enzyme mRNA may be administered 1 to 12 hours (preferably about 2 to 6 hours) before the guide RNA.
[0044] Alternatively, the CRISPR enzyme mRNA and guide RNA can be administered together. Advantageously, a second booster dose of guide RNA can be administered 1-12 hours (preferably about 2-6 hours) after the initial administration of the CRISPR enzyme mRNA + guide RNA.
[0045] To achieve the most efficient level of genome modification, additional administration of CRISPR enzyme mRNA and / or guide RNA may be useful.
[0046] To minimize toxicity and off-target effects, it is important to control the concentration of the delivered CRISPR enzyme mRNA and guide RNA. The optimal concentration of CRISPR enzyme mRNA and guide RNA can be determined by testing various concentrations in cells or animal models and using deep sequencing to analyze the degree of modification at potential off-target genomic loci. For example, for a guide sequence targeting 5'-GAGTCCGAGCAGAAGAAGAA-3' of the EMX1 gene in the human genome, deep sequencing can be used to evaluate the modification levels at the following two off-target loci: 1:5'-GAGTCCTAGCAGGAGAAGAA-3' and 2:5'-GAGTCTAAGCAGAAGAAGAA-3'. The concentration that achieves the highest on-target modification level while minimizing off-target modification level should be selected for in vivo delivery.
[0047] Alternatively, to minimize toxicity levels and off-target effects, a CRISPR enzyme nickase mRNA (e.g., S. pyogenes Cas9 with a D10A mutation) can be delivered along with a pair of guide RNAs targeting the desired site. The two guide RNAs must be separated as follows: red (single-underlined) and blue (double-underlined) guide sequences, respectively (these examples are based on the PAM requirements of Streptococcus pyogenes Cas9).
[0048] [Table 1]
[0049] [Table 2]
[0050] [Table 3]
[0051] Further investigation of this system has provided Applicants with evidence of 5' overhangs (see, e.g., Ran et al., Cell. 2013 Sep 12;154(6):1380-9 and U.S. Provisional Patent Application No. 61 / 871,301, filed August 28, 2013). Applicants have further identified parameters associated with efficient cleavage by Cas9 nickase mutants in combination with two guide RNAs, including, but not limited to, the length of the 5' overhang. In embodiments of the invention, the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention, the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs, or more preferably 34-50 base pairs or 1-34 base pairs. In another preferred method of the invention, a first guide sequence directs cleavage of one strand of a DNA duplex near a first target sequence, and a second guide sequence directs cleavage of the other strand near a second target sequence, resulting in a blunt end or a 3' overhang. In embodiments of the invention, the 3' overhang is at most 150, 100, or 25 base pairs, or at least 15, 10, or 1 base pair. In preferred embodiments, the 3' overhang is 1 to 100 base pairs.
[0052] Aspects of the invention relate to reducing the expression of a gene product, or introducing a template polynucleotide into a DNA molecule encoding the gene product, or precisely excising an intervening sequence by reannealing and ligating two 5' overhangs, or altering the activity or function of a gene product, or increasing the expression of a gene product. In one embodiment of the invention, the gene product is a protein.
[0053] Only sgRNA pairs that create 5' overhangs with less than 8 bp overlap (greater than -8 bp offset) between the guide sequences were able to mediate detectable indel formation. Importantly, each guide used in these assays was able to efficiently induce indels when paired with wild-type Cas9, indicating that the relative position of the guide pair is the most important parameter in predicting double-nicking activity.
[0054] Because Cas9n and Cas9H840A nick opposite strands of DNA, replacement of Cas9n with Cas9H840A with a given sgRNA pair should result in an inversion of the overhanging sequence. For example, an sgRNA pair that can generate a 5' overhang with Cas9n should, in principle, generate a corresponding 3' overhang instead. Thus, an sgRNA pair that results in the generation of a 3' overhang with Cas9n could be used to generate a 5' overhang with Cas9H840A. Unexpectedly, we tested Cas9H840A with a set of sgRNA pairs designed to generate both 5' and 3' overhangs (offset range -278 to +58 bp) but did not observe indel formation. Further research may be required to identify the design criteria necessary to combine sgRNA pairs to enable double nicking by Cas9H840A.
[0055] Additional brain delivery options include CRISPR enzyme and guide RNA in either DNA or RNA form, encapsulated in liposome, and conjugated with molecular Trojan horse, and delivered through the blood-brain barrier (BBB).Molecular Trojan horse has been shown to be effective in delivering B-gal expression vector to the brain of non-human primates.The same method can be used to deliver the vector that contains CRISPR enzyme and guide RNA. For example, Xia CF and Boado RJ, Pardridge WM ("Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology," Mol Pharm. 2009 May-Jun;6(3):747-51. doi:10.1021 / mp800194) describe how the combination of a receptor-specific monoclonal antibody (mAb) and avidin-biotin technology enables delivery of small interfering RNA (siRNA) to cells in culture and in vivo. The authors also report that the bond between the targeting mAb and siRNA is stable with avidin-biotin technology, and that RNAi effects are observed in vivo at distant sites, such as the brain, after intravenous administration of the targeted siRNA.
[0056] Zhang Y, Schlachetzki F, Pardridge WM. ("Global non-viral gene transfer to the primate brain following intravenous administration." Mol Ther. 2003 Jan;7(1):11-8.) describes how an expression plasmid encoding a reporter, e.g., luciferase, was packaged inside an "artificial virus" containing 85 nm pegylated immunoliposomes that were targeted in vivo to the rhesus monkey brain by a monoclonal antibody (MAb) against the human insulin receptor (HIR). The HIRMAb enables liposomes carrying the exogenous gene to undergo transcytosis across the blood-brain barrier and endocytosis across neuronal membranes after intravenous injection. The level of luciferase gene expression in the brain was 50-fold higher in rhesus monkeys compared with rats. Widespread neuronal expression of the β-galactosidase gene in the primate brain was demonstrated by both histochemistry and confocal microscopy. The authors demonstrate that this technique allows for reversible adult transgenics in 24 hours. Therefore, the use of immunoliposomes is preferred. They are used in conjunction with antibodies to target specific tissues or cell surface proteins.
[0057] Other delivery means or RNA are also preferred, such as via nanoparticles (Cho, S., Goldberg, M., Son, S., Xu, Q., Yang, F., Mei, Y., Bogatyrev, S., Langer, R. and Anderson, D., "Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells", Advanced Functional Materials, 19:3112-3118, 2010) or exosomes (Schroeder, A., Levins, C., Cortez, C., Langer, R., and Anderson, D., "Lipid-based nanotherapeutics for siRNA delivery", Journal of Internal Medicine, 267:9-21, 2010, PMID:20059641). Indeed, exosomes have been shown to be particularly useful in the delivery of siRNA, a system somewhat similar to the CRISPR system. For example, El-Andaloussi S, et al. ("Exosome-mediated delivery of siRNA in vitro and in vivo," Nat Protoc. 2012 Dec;7(12):2112-26. doi:10.1038 / nprot.2012.131. Epub 2012 Nov 15) describe how exosomes are a promising tool for drug delivery across various biological barriers and can be used to deliver siRNA in vitro and in vivo. The authors' approach involves generating targeted exosomes by transfection with an expression vector containing an exosomal protein fused to a peptide ligand. The exosomes are then purified and characterized from the supernatant of transfected cells, and then loaded with siRNA.
[0058] One aspect of target sequence manipulation also relates to epigenetic manipulation of the target sequence, which can be, for example, altering the methylation state of the target sequence (i.e., adding or removing methylation or methylation patterns or CpG islands), histone modifications, increasing or decreasing the accessibility of the target sequence, or promoting or decreasing 3D folding of the chromatin state of the target sequence.
[0059] A vector can refer not only to viral or yeast systems (e.g., where a nucleic acid of interest can be operably linked to a promoter and under the control of the promoter (for expression, e.g., to ultimately provide processed RNA), but also to the direct delivery of a nucleic acid into a host cell.
[0060] The present invention also includes, in certain embodiments, a method of treating or inhibiting a pathology caused by an abnormality in a target sequence in a genomic locus of interest in a subject or non-human subject in need thereof, the pathology caused by an abnormality in a target sequence in a genomic locus of interest, comprising modifying the subject or non-human subject by manipulation of the target sequence, comprising providing treatment comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors operably encoding a composition as discussed herein for expression thereof, wherein the pathology is susceptible to treatment or inhibition by manipulation of the target sequence, and the method comprises manipulating the target sequence with the composition when expressed.
[0061] In some embodiments of the methods herein, the method may include inducing expression, which may be inducing expression of a CRISPR enzyme and / or inducing expression of a guide, tracr, or tracr mate sequence. In some embodiments of the methods herein, the organism or subject is a eukaryote or a non-human eukaryote. In some embodiments of the methods herein, the organism or subject is a plant. In some embodiments of the methods herein, the organism or subject is a mammal or a non-human mammal. In some embodiments of the methods herein, the organism or subject is algae.
[0062] In the method herein, vector can be a viral vector, and it is advantageously AAV, while other viral vectors discussed herein can be used.For example, baculovirus can be used for expression in insect cell.These insect cells can then be used to produce a large amount of additional vector, for example, the AAV vector that is adapted for delivery of the present invention.
[0063] Also contemplated are methods of delivering the present CRISPR enzymes, comprising delivering to a cellular mRNA encoding the CRISPR enzyme. It is recognized that the CRISPR enzyme may be truncated, of a defined size as described herein, a nuclease or nickase or global DNA-binding protein, codon-optimized, contain one or more mutations, and / or include chimeric CRISPR enzymes, or other options discussed herein.
[0064] Methods for preparing vectors for delivering the compositions or CRISPR enzymes of the invention and for use in the methods are also contemplated.
[0065] AAV viral vectors are preferred.Therefore, in a further aspect, a method for preparing AAV viral vectors is provided, comprising: transfecting a plasmid that contains or essentially consists of a nucleic acid molecule encoding AAV into AAV-infected cells, and providing the AAVrep and / or cap that are essential for AAV replication and packaging.In this regard, it is recognized that CRISPR enzyme is truncated, comprises less than 1000 amino acids or less than 4000 amino acids, is a nuclease or nickase, is codon-optimized, comprises one or more mutations, and / or comprises the chimeric CRISPR enzyme discussed herein.In some embodiments, cells are transfected with helper plasmid or helper virus to provide the AAVrep and / or cap that are essential for AAV replication and packaging.In some embodiments, the helper virus is poxvirus, adenovirus, herpesvirus or baculovirus.In some embodiments, the poxvirus is cowpox virus.In some embodiments, the cell is a mammalian cell. In some embodiments, the cells are insect cells and the helper virus is a baculovirus.
[0066] In some embodiments, the present invention further encompasses modified CRISPR enzymes. Differences from wild-type CRISPR enzymes may include the following: the modified CRISPR enzyme is truncated compared to the wild-type CRISPR enzyme, or the CRISPR enzyme is of a defined size, for example, at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids, or at least 2000 amino acids; and / or the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence, or the CRISPR enzyme is a catalytically disabled mutant that functions as a DNA binding protein; and / or the CRISPR enzyme is codon-optimized or codon-optimized for expression in eukaryotic cells, and / or the CRISPR enzyme comprises one or more mutations, and / or the CRISPR enzyme comprises a chimeric CRISPR enzyme, and / or the CRISPR enzyme has one or more other attributes discussed herein. Thus, in some embodiments, the CRISPR enzyme comprises one or more mutations in catalytic residues, e.g., spCa9D10A, E762A, H840A, N854A, N863A, or D986A, or those corresponding to those in other Cas enzymes (described herein) with respect to position numbering in SpCas9, and / or has one or more mutations in the RuvCI, RuvCII, RuvCIII, HNH, or other domains described herein of the CRISPR enzyme, and / or the CRISPR enzyme has one or more mutations in the catalytic domain, wherein, upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and the enzyme further comprises a functional domain.The functional domain can include, but is not limited to, a transcription activator, a transcription repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light-inducible / regulatory domain, or a chemical-inducible / regulatory domain. In some embodiments, a CRISPR enzyme can have a functional domain that is a transcription activator domain, for example, VP64. In some embodiments, the transcription repressor domain is KRAB. In some embodiments, the transcription repressor domain is SID or a concatemer of SID (i.e., SID4X). In some embodiments, an epigenetic modification enzyme is provided.
[0067] In a preferred embodiment, the CRISPR enzyme is a Cas enzyme, e.g., a Cas9 ortholog.
[0068] Embodiments of the present invention also encompass identifying novel orthologs of CRISPR enzymes. A method for identifying novel orthologs of CRISPR enzymes can include identifying tracr sequences in a genome of interest. Identifying tracr sequences can involve the following steps: searching for direct repeat or tracr mate sequences in databases to identify CRISPR regions containing CRISPR enzymes, for example, as shown in Figure 18; searching for homologous sequences in CRISPR regions flanking the CRISPR enzyme in both sense and antisense orientations; searching for transcription terminators and secondary structures; identifying any sequences that are not direct repeat or tracr mate sequences but have more than 50% identity with direct repeat or tracr mate sequences as potential tracr sequences; extracting potential tracr sequences and analyzing their associated transcription terminator sequences.
[0069] In some embodiments, the present invention encompasses the use of compositions or CRISPR enzymes described herein in medical treatment.In some embodiments, the present invention further encompasses the use of compositions or CRISPR enzymes of the present invention in methods of the present invention.In some embodiments, the present invention also encompasses the use of compositions or CRISPR enzymes of the present invention in ex vivo gene or genome editing, or preferably in ex vivo gene or genome editing methods.Therefore, in some embodiments, the present invention also encompasses the use of compositions or CRISPR enzymes of the present invention in the manufacture of medicines for ex vivo gene or genome editing, or for use in the methods discussed herein.
[0070] Furthermore, the present invention encompasses, in certain embodiments, compositions or CRISPR enzymes of the invention in which the target sequence is flanked by, or followed at its 3' end by, a PAM suitable for the CRISPR enzyme, typically a Cas, and particularly a Cas9. This PAM sequence is specific to each Cas9, but can be readily determined by the methods described herein.
[0071] For example, a suitable PAM is 5'-NRG or 5'-NNGRR for the SpCas9 or SaCas9 enzyme (or derived enzyme), respectively. It is recognized that references herein are made to Staphylococcus aureus, preferably, by way of example, Staphylococcus aureus subspecies Aureus.
[0072] Accordingly, it is not the object of the present invention to encompass any previously known products, methods of making the products, or methods of using the products, and consequently, applicants hereby reserve the right to, and hereby disclose a disclaimer of, any previously known products, methods of making the products, or methods of using the products. It is further noted that the present invention does not encompass within its scope any products, methods, or methods of making or using the products that do not meet the description and enablement requirements of the USPTO (35 U.S.C. § 112, first paragraph) or the EPO (European Patent Convention, Article 83), and consequently, applicants hereby reserve the right to, and hereby disclose a disclaimer of, any previously described products, methods of making the products, or methods of using the products.
[0073] It is noted that in this disclosure, and particularly in the claims and / or paragraphs, terms such as "comprises," "comprised," "comprising," and the like, may have the meaning ascribed to them in U.S. patent law; for example, they may mean "includes," "included," "including," and the like; and terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. patent law, for example, they permit elements not expressly recited, but exclude elements found in the prior art or that affect a basic or novel characteristic of the invention.
[0074] These and other embodiments are disclosed or are apparent from and encompassed by the following detailed description.
[0075] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings. [Brief explanation of the drawings]
[0076] [Figure 1] A schematic diagram of the RNA-guided Cas9 nuclease is shown. Cas9 nuclease from Streptococcus pyogenes is targeted to genomic DNA by a synthetic guide RNA (sgRNA) consisting of a 20-nt guide sequence and a scaffold. The guide sequence base-pairs with the DNA target immediately upstream of the required 5'-NGG protospacer adjacent motif (PAM), and Cas9 mediates a double-strand break (DSB) (indicated by a triangle) approximately 3 bp upstream of the PAM. [Figure 2A] Shown are an exemplary CRISPR system and potential mechanism of action (A), exemplary adaptations for expression in eukaryotic cells, and results of studies assessing nuclear localization and CRISPR activity (B-F). [Figure 2B] Shown are an exemplary CRISPR system and potential mechanism of action (A), exemplary adaptations for expression in eukaryotic cells, and results of studies assessing nuclear localization and CRISPR activity (B-F). [Figure 2C] Shown are an exemplary CRISPR system and potential mechanism of action (A), exemplary adaptations for expression in eukaryotic cells, and results of studies assessing nuclear localization and CRISPR activity (B-F). [Figure 2D] Shown are an exemplary CRISPR system and potential mechanism of action (A), exemplary adaptations for expression in eukaryotic cells, and results of studies assessing nuclear localization and CRISPR activity (B-F). [Figure 2E] Shown are an exemplary CRISPR system and potential mechanism of action (A), exemplary adaptations for expression in eukaryotic cells, and results of studies assessing nuclear localization and CRISPR activity (B-F). [Figure 2F] Shown are an exemplary CRISPR system and potential mechanism of action (A), exemplary adaptations for expression in eukaryotic cells, and results of studies assessing nuclear localization and CRISPR activity (B-F). [Figure 3]1 shows a schematic representation of an AAV in vivo delivery plasmid utilizing inverted terminal repeat (ITR) sequences and a guide chimeric RNA to preferably support delivery by AAV or AAV-related systems. [Figure 4A] A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 4B] A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 4C] A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 4D] A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 5A] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 5B] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 5C] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 5D] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 5E]A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 5F] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) is shown. [Figure 6] A graph showing the length distribution of Cas9 orthologs is shown. [Figure 7] 1 shows the representation of the sequence logo of the PAM of a Cas9 ortholog as the reverse complement. [Figure 8A] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8B] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8C] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8D] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8E] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8F]Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8G] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8H] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8I] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 8J] Eighteen chimeric RNA structures are presented that preserve the sequence and secondary structure of the tracr mate:tracr sequence duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop. [Figure 9A] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9B] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9C] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9D] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9E] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9F]A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9G] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9H] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9I] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9J] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9K] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9L] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9M] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9N] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 9O] A list of human codon-optimized Cas9 sequences for pairing with the chimeric guide RNAs provided in Figures 8A-J is shown. [Figure 10A] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10B] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10C] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10D] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10E]The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10F] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10G] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10H] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10I] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10J] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10K] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10L] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 10M] The sequence where the mutation site is located within the SpCas9 gene is shown. [Figure 11] 1 shows type II CRISPR loci in different organisms. [Figure 12] The guide RNA sequences corresponding to CRISPR loci in different organisms are shown. [Figure 13A] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13B] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13C] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13D] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13E] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13F] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13G]FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13H] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13I] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13J] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13K] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13L] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13M] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13N] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13O] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13P] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13Q] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13R] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13S] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13T] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13U] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13V] A table listing Cas9 orthologs and their corresponding PAM sequences is provided. [Figure 13W]FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13X] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13Y] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13Z] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13AA] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13BB] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13CC] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13DD] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13EE] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13FF] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13GG] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13HH] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 13II] FIG. 1 shows a table listing Cas9 orthologs and their corresponding PAM sequences. [Figure 14] We show that the PAM for Staphylococcus aureus subspecies Aureus Cas9 is NNGRR. [Figure 15] Single and multiple vector designs for SaCas9 are shown. [Figure 16]1 shows the vector design and gel images for the Cas9 orthologs and their respective sgRNAs being used to cleave two candidate targets present in a pUC19-based library. [Figure 17] Figure 1 shows in vitro cleavage by SpCas9, St3Cas9, Sp_St3 chimera, and St3_Sp chimera. The PAM for St3Cas9 and St3_Sp chimeric Cas9 is NGG. [Figure 18] An image of the CRISPR web server is shown. [Figure 19A] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19B] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19C] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19D]A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19E] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19F] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19G] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19H]A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19I] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19J] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19K] A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 19L]A multiple sequence alignment of 12 Cas9 orthologs is shown. Two catalytic residues are highlighted. The first highlighted residue is the catalytic Asp residue in the RuvCI domain, and the second highlighted residue is the catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically ineffective mutant useful for global DNA binding. [Figure 20] Western blots showing that Cas9 orthologs are expressed in HEK293FT cells are shown; DNA plasmids encoding Cas9 orthologs were transfected into HEK293FT cells, and cell lysates were collected for Western blot. No DNA was transfected for Cas9 ortholog #8. [Figure 21] We demonstrate in vitro cleavage of candidate targets on the pUC19 plasmid by 10 Cas9 orthologs. Consensus PAMs were predicted by sequence logos (Figure 7), and candidate targets on pUC19 were selected based on this. Seven of the nine new Cas9 orthologs tested successfully cleaved at least one pUC19 target. SpCas9 can also cleave NGA in vitro. [Figure 22] A representative Surveyor gel showing genome cleavage by SaCas9 is shown. [Figure 23] The genome cleavage efficiency of PAM sequences (all targets) is shown. [Figure 24] The PAM sequence (cleavage target) genome cleavage efficiency is shown. [Figure 25] Genome cleavage efficiency of PAM sequences (all targets, low efficiency and orphan targets discarded) is shown. [Figure 26] The genome cleavage efficiency of the PAM sequences (cleavage targets, low efficiency and orphan targets discarded) is shown. [Figure 27] The sequence logo for the functional cleavage spacer and PAM (a new endogenous genomic test showing that T is not required) is shown. DETAILED DESCRIPTION OF THE INVENTION
[0077] The drawings herein are for illustrative purposes only and are not necessarily drawn to scale.
[0078] The present invention relates to the engineering and optimization of systems, methods and compositions used to control gene expression, including sequence targeting, e.g., genome perturbation or gene editing, involving CRISPR-Cas systems and their components. In an advantageous embodiment, the CRISPR enzyme is a Cas enzyme, e.g., a Cas9 ortholog.
[0079] The present invention uses nucleic acids to bind target DNA sequences. This is advantageous because nucleic acids are much easier and cheaper to make than, for example, peptides, and the specificity can be varied depending on the length of the stretch of homology desired. For example, complex three-dimensional arrangements of multiple fingers are not required.
[0080] The terms "polynucleotide," "nucleotide," "nucleotide sequence," "nucleic acid," and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or their analogs. Polynucleotides can have any three-dimensional structure and can perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. This term also encompasses nucleic acid-like structures with synthetic backbones, see, for example, Eckstein, 1991; Baserga et al., 1992; Milligan, 1993; WO 97 / 03211; WO 96 / 39154; Mata, 1997; Strauss-Soukup, 1997; and Samstag, 1996. A polynucleotide can contain one or more modified nucleotides, such as methylated nucleotides or nucleotide analogs. Modifications to the nucleotide structure, if present, can be imparted before or after assembly of the polymer. The sequence of nucleotides can be interrupted by non-nucleotide components. A polynucleotide can be further modified after polymerization, for example, by conjugation with a labeling component.
[0081] In embodiments of the present invention, the terms "chimeric RNA," "chimeric guide RNA," "guide RNA," "single guide RNA," and "synthetic guide RNA" are used interchangeably to refer to a polynucleotide sequence comprising a guide sequence, a tracr sequence, and a tracr mate sequence. The term "guide sequence" refers to an approximately 20-bp sequence within the guide RNA that defines the target site, and can be used interchangeably with the terms "guide" or "spacer." The term "tracr mate sequence" can also be used interchangeably with the term "direct repeat."
[0082] The term "wild-type" as used herein is a term of the art understood by those skilled in the art and means the typical form of an organism, strain, gene or characteristic as it occurs in nature, as distinguished from mutant or variant forms.
[0083] The term "variant" as used herein should be taken to mean a display of qualities having a pattern that deviates from that occurring in nature.
[0084] The terms "non-naturally occurring" and "engineered" are used interchangeably and refer to artificial involvement. When referring to a nucleic acid molecule or polypeptide, the term means that the nucleic acid molecule or polypeptide is at least substantially free from at least one other component with which it is naturally associated or found in the natural state.
[0085] "Complementarity" refers to the ability of a nucleic acid to form hydrogen bonds with another nucleic acid sequence, either through classical Watson-Crick base pairing or other non-classical types. The percent complementarity indicates the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Fully complementary" means that all consecutive residues of a nucleic acid sequence will hydrogen bond with the same number of consecutive residues in a second nucleic acid sequence. As used herein, "substantially complementary" refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.
[0086] As used herein, "stringent conditions" for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence hybridizes predominantly with the target sequence and does not substantially hybridize with non-target sequences. Stringent conditions are generally sequence-dependent and vary depending on numerous factors. Generally, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes with its target sequence. Non-limiting examples of stringent conditions are detailed in Tijssen (1993), Laboratory Techniques in Biochemistry and Molecular Biology - Hybridization With Nucleic Acid Probes Part I, Second Chapter "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, NY. When a polynucleotide sequence is mentioned, complementary or partially complementary sequences are also envisioned. They can preferably hybridize to a reference sequence under highly stringent conditions. Generally, to maximize the rate of hybridization, hybridization conditions of relatively low stringency are selected: the thermal melting point (T m ) is about 20 to 25°C lower than T m is the temperature at which 50% of a specific target sequence hybridizes to a perfectly complementary probe in a solution of defined ionic strength and pH. Generally, to obtain at least about 85% nucleotide complementarity of hybridized sequences, T m Highly stringent washing conditions are selected that are about 5-15°C lower than T. To require at least about 70% nucleotide complementarity of hybridized sequences, m Moderately stringent wash conditions are selected at approximately 15-30°C lower than T. Highly permissive (very low stringency) wash conditions are selected at approximately 15-30°C lower than T. mThe temperature may be as much as 50°C lower, allowing for a high degree of mismatch between hybridized sequences. Those skilled in the art will recognize that other physical and chemical parameters in the hybridization and washing steps can also be varied to affect the outcome of a detectable hybridization signal depending on the particular level of homology between the target and probe sequences. Preferred highly stringent conditions include incubation in 50% formamide, 5xSSC, and 1% SDS at 42°C, or incubation in 5xSSC and 1% SDS at 65°C, followed by a wash in 0.2xSSC and 0.1% SDS at 65°C.
[0087] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex stabilized through hydrogen bonding between the bases of nucleotide residues. Hydrogen bonding can occur through Watson-Crick base pairing, Hoogsteen binding, or any other sequence-specific manner. The complex can contain two strands forming a double-stranded structure, three or more strands forming a multistranded complex, a single self-hybridizing strand, or any combination thereof. A hybridization reaction can constitute a step in a more extensive process, such as the initiation of PCR or the cleavage of a polynucleotide by an enzyme. A sequence that can hybridize to a given sequence is referred to as the "complementary strand" of the given sequence.
[0088] As used herein, the term "genomic locus" or "locus" (plural loci) refers to the specific location of a gene or DNA sequence on a chromosome. A "gene" refers to a stretch of DNA or RNA that encodes a polypeptide, or an RNA strand that serves a functional role in an organism and is thus the molecular unit of heredity in an organism. For purposes of the present invention, a gene may be considered to include regions that regulate the production of a gene product (whether or not such regulatory sequences are adjacent to the coding and / or transcribed sequence). Thus, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences, such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, origins of replication, matrix attachment sites, and locus control regions.
[0089] As used herein, "expression of a genomic locus" or "gene expression" is the process by which information from a gene is used in the synthesis of a functional gene product. The product of gene expression is often a protein, but for non-protein-coding genes, such as rRNA or tRNA genes, the product is functional RNA. The gene expression process is used by all known life forms—eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea), and viruses—to generate functional products for survival. As used herein, "expression" of a gene or nucleic acid encompasses not only cellular gene expression but also the transcription and translation of nucleic acids in cloning systems and any other context. As used herein, "expression" also refers to the process by which a polynucleotide is transcribed from a DNA template (e.g., into mRNA or other RNA transcript) and / or the process by which the transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein. The transcript and the encoded polypeptide may collectively be referred to as the "gene product." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.
[0090] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term also encompasses amino acid polymers that have undergone modifications, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein, the term "amino acid" includes natural and / or unnatural or synthetic amino acids, including glycine and both D- and L-optical isomers, as well as amino acid analogs and peptidomimetics.
[0091] As used herein, the term "domain" or "protein domain" refers to a portion of a protein sequence that can exist and function independently of the rest of the protein chain.
[0092] As described in the embodiments of the present invention, sequence identity is related to sequence homology. Homology comparison can be performed by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate the percent (%) homology between two or more sequences, as well as the sequence identity shared by two or more amino acid or nucleic acid sequences. Sequence homology can be generated by any of many computer programs known in the art, such as BLAST or FASTA. A suitable computer program for performing such alignments is the GCG Wisconsin Bestfit package (University of Wisconsin, USA; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of other software capable of performing sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999, op. cit. - Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410), and the comparison tools in the GENEWORKS suite. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, op. cit., pp. 7-58 to 7-60). However, it is preferred to use the GCG Bestfit program.
[0093] Percent sequence identity can be calculated over contiguous sequences, i.e., one sequence is aligned with the other sequence, and each amino acid or nucleotide in one sequence is directly compared to the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively small number of residues.
[0094] While this is a very simple and consistent method, it fails to take into account that, for example, in a pair of otherwise identical sequences, a single insertion or deletion can cause a shift in the alignment of subsequent amino acid residues, which in turn can significantly reduce the percent homology when a global alignment is performed. Consequently, many sequence comparison methods are designed to produce optimal alignments that take into account possible insertions and deletions without unduly penalizing the overall homology or identity score. This is achieved by inserting "gaps" in the sequence alignment to attempt to maximize local homology or identity.
[0095] However, these more complex methods assign a "gap penalty" to each gap that appears in the alignment; thus, for the same number of identical amino acids, a sequence alignment with as few gaps as possible—reflecting a higher relatedness between the two compared sequences—can achieve a higher score than one with many gaps. An "affinity gap cost" is typically used, which imposes a relatively high cost on the existence of a gap and a smaller penalty on each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties can, of course, result in an optimized alignment with fewer gaps. Many alignment programs allow the gap penalty to be changed; however, it is preferred to use the default values when using software for sequence comparison. For example, when using the GCG Wisconsin Bestfit package, the default gap penalty for amino acid sequences is −12 for a gap and −4 for each extension.
[0096] Calculation of maximum % homology therefore first requires the creation of an optimal alignment, taking into account gap penalties. A suitable computer program for performing such an alignment is the GCG Wisconsin Bestfit package (Devereux et al., 1984 Nuc. Acids Research 12 p387). Other examples of software capable of performing sequence comparisons include, but are not limited to, the BLAST package (Ausubel et al., 1999 Short Protocols in Molecular Biology, 4 th Examples of comparison tools include the BLAST (see Ed.-Chapter 18), FASTA (Altschul et al., 1990 J. Mol. Biol. 403-410), and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pp. 7-58 to 7-60). However, for some applications, it may be preferable to use the GCG Bestfit program. A new tool called BLAST 2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol Lett. 1999 174(2):247-50; FEMS Microbiol Lett. 1999 177(1):187-8 and the website of the National Center for Biotechnology Information at the website of the National Institutes for Health).
[0097] Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pairwise comparison. Instead, a scaled similarity score matrix is generally used that assigns a score to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix—the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use published default values or, if supplied, custom symbol comparison tables (see user manuals for further details). Depending on the application, it may be preferable to use the published default values of the GCG package, or, in the case of other software, default matrices such as BLOSUM62.
[0098] Alternatively, percentage homology can be calculated using the multiple alignment function of DNASIS™ (Hitachi Software), based on an algorithm similar to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244). Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.
[0099] The sequences may also have deletions, insertions, or substitutions of amino acid residues, which produce silent changes and result in functionally equivalent substances. Deliberate amino acid substitutions may be made based on similarity in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues), and it is therefore useful to group amino acids together by functional group. Amino acids may also be grouped based solely on the properties of their side chains. However, it is more useful to include mutational data as well. The resulting set of amino acids is likely to be conserved for structural reasons. These sets can be described in the form of Venn diagrams (Livingstone CD and Barton GJ (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation." Comput. Appl. Biosci. 9:745-756) (Taylor WR (1986) "The classification of amino acid conservation." J. Theor. Biol. 119;205-218). Conservative substitutions can be made, for example, according to the following table, which sets out the commonly accepted Venn diagram classification of amino acids:
[0100] [Table 4]
[0101] Embodiments of the invention include sequences (both polynucleotides or polypeptides) that may contain homologous substitutions (substitution and replacement are used herein to mean the interchange of an existing amino acid residue or nucleotide with an alternative residue or nucleotide), i.e., like-for-like substitutions in the case of amino acids, such as basic for basic, acidic for acidic, polar for polar, etc. Non-homologous substitutions, i.e., substitutions of one class of residue for another, or involving the incorporation of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyridylalanine, thienylalanine, naphthylalanine, and phenylglycine, may also occur.
[0102] The variant amino acid sequence may contain suitable spacer groups, such as glycine or β-alanine residues, that can be inserted between any two amino acid residues in the sequence, including alkyl groups such as methyl, ethyl, or propyl groups. Another type of variation, involving the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art. For the avoidance of doubt, the term "peptoid form" is used to refer to variant amino acid residues in which the α-carbon substituent is not on the α-carbon but rather on the nitrogen atom of the residue. Methods for preparing peptides in peptoid form are known in the art (e.g., Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134).
[0103] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA, which are within the skill of one in the art. See Sambrook, Fritsch, and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F.M.A.usubel, et al. eds., (1987)); series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (M.J. MacPherson, B.D. Hames, and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988), ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R.I. Freshney, ed. (1987)).
[0104] In one aspect, the present invention provides vectors for use in the engineering and optimization of CRISPR-Cas systems.
[0105] As used herein, a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. A vector is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment can be inserted, resulting in replication of the inserted segment. Generally, a vector is capable of replication when associated with appropriate control elements. In general, the term "vector" refers to a nucleic acid molecule that is capable of transporting another nucleic acid to which it is linked. Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules that contain one or more free ends, or no free ends (e.g., circular); nucleic acid molecules comprising DNA, RNA, or both; and other polynucleotide variants known in the art. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, in which a viral-derived DNA or RNA sequence for packaging into a virus (e.g., retrovirus, replication-defective retrovirus, adenovirus, replication-defective adenovirus, and adeno-associated virus) is present in the vector. Viral vectors also include polynucleotides carried by viruses for transfection into host cells. Certain vectors have the ability to autonomously replicate in the host cell into which they are introduced (e.g., bacterial vectors with a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell, and thus replicate along with the host genome. Furthermore, certain vectors have the ability to direct the expression of genes to which they are operably linked. Such vectors are referred to herein as "expression vectors." Common expression vectors useful in recombinant DNA techniques are often in the form of plasmids. Further discussion of vectors is provided herein.
[0106] A recombinant expression vector may contain the nucleic acid of the present invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector contains one or more regulatory elements operably linked to the nucleic acid sequence to be expressed, and the regulatory elements may be selected based on the host cell used for expression. "Operably linked" within a recombinant expression vector is intended to mean that the nucleotide sequence of interest is linked to a regulatory element in a manner that allows expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). For recombination and cloning methods, reference is made to U.S. Patent Application No. 10 / 815,730, published on September 2, 2004 as U.S. Patent Application Publication No. 2004-0171156 A1, the contents of which are incorporated herein by reference in their entirety.
[0107] Aspects and embodiments of the present invention relate to bicistronic vectors for chimeric RNA and Cas9 or a Cas9 ortholog. In some embodiments, Cas9 is driven by a CBh promoter. In some embodiments, the chimeric RNA is driven by a U6 promoter. Preferably, CBh and U6 are used together, meaning that Cas9 is driven by a CBh promoter and the chimeric RNA is driven by a U6 promoter. In some embodiments, the chimeric guide RNA consists of a 20-bp guide sequence (N) linked to a truncated tracr sequence (extending from the first "U" on the lower strand to the end of the transcript) at various positions as indicated. The guide and tracr sequences are preferably separated by a tracr mate sequence. A preferred example of a tracr mate sequence is GUUUUAGAGCUA. This is preferably followed by a loop sequence. The loop is preferably, but not limited to, GAAA, or indeed only 4 bp long. In practice, the preferred loop-forming sequence used in the hairpin structure is 4 nucleotides long and most preferably has the sequence GAAA. However, longer or shorter loop sequences can be used, as can alternative sequences. The sequence preferably includes a nucleotide triplet (e.g., AAA) and an additional nucleotide (e.g., C or G). Examples of loop-forming sequences include CAAA and AAAG. Throughout this application, chimeric RNAs can also be referred to as single guide or synthetic guide RNAs (sgRNAs).
[0108] For example, as specifically detailed in Example 2, chimeric guide RNAs can be designed as shown in Figure 8. CRISPR loci in some of these families are shown in Figure 11. The corresponding guide RNA sequences are shown in Figure 12. Applicants analyzed genomic DNA sequences within approximately 2 kb of the Cas9 protein and identified direct repeats ranging from 35 to 50 bp with intervening spacers ranging from 29 to 35 bp. Based on the direct repeat sequences, Applicants searched for candidate tracrRNA sequences that met the following criteria: outside the crRNA array but containing a high degree of homology to the direct repeats (direct repeats required for tracrRNA base pairing; custom computational analysis), outside the coding region for the protein component, containing a Rho-independent transcription termination signal approximately 60 to 120 bp downstream from the region of homology to the direct repeat, cofolding with the direct repeat to form a duplex, followed by two or more hairpin structures at the distal end of the tracrRNA sequence. Based on these prediction criteria, we selected an initial set of 18 Cas9 proteins and their uniquely associated direct repeats, as well as tracrRNAs distributed across all five Cas9 families. We further generated a set of 18 chimeric RNA structures that preserved the sequence and secondary structure of the native direct repeat:tracrRNA duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop (Figure 6A-J).
[0109] The term "regulatory element" is intended to include promoters, enhancers, internal ribosome entry sites (IRES), and other expression control elements (e.g., transcription termination signals such as polyadenylation signals and polyU sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of a nucleotide sequence only in specific host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can direct expression primarily in a desired tissue of interest, such as muscle, neurons, bone, skin, blood, a specific organ (e.g., liver, pancreas), or a specific cell type (e.g., lymphocytes). Regulatory elements can also direct expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not also be tissue- or cell-type-specific. In some embodiments, the vector comprises one or more pol III promoters (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or a combination thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters.Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al., Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter. The term "regulatory element" also encompasses enhancer elements, such as the WPRE; the CMV enhancer; the R-U5' segment in the LTR of HTLV-I (Mol. Cell. Biol., Vol. 8 (1), p. 466-472, 1988); the SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78 (3), p. 1527-31, 1981). Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of host cell to be transformed and the desired expression level. The vector can be introduced into a host cell to produce a transcript, protein, or peptide, such as a fusion protein or peptide, encoded by a nucleic acid as described herein (e.g., a clustered regularly interspaced short repeat (CRISPR) transcript, protein, enzyme, mutant form thereof, fusion protein thereof, etc.). For regulatory sequences, see U.S. Patent Application No. 10 / 491,026 (the contents of which are incorporated herein by reference in their entirety). For promoters, see WO 2011 / 028929 and U.S. Patent Application No. 12 / 511,940 (the contents of which are incorporated herein by reference in their entirety).
[0110] Vectors can be designed for the expression of CRISPR transcripts (e.g., nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells. For example, CRISPR transcripts can be expressed in bacterial cells, such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are further discussed in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, recombinant expression vectors can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase.
[0111] Vectors can be introduced into and propagated within prokaryotes or prokaryotic cells. In some embodiments, prokaryotes are used to amplify copies of vectors to be introduced into eukaryotic cells or as intermediate vectors in the production of vectors to be introduced into eukaryotic cells (e.g., amplifying plasmids as part of a viral vector packaging system). In some embodiments, prokaryotes are used to amplify copies of vectors, express one or more nucleic acids, and provide a source of one or more proteins, for example, for delivery to a host cell or host organism. Protein expression in prokaryotes is most often carried out in Escherichia coli using vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add multiple amino acids to the encoded protein, for example, to the amino terminus of the recombinant protein. Such fusion vectors can serve one or more purposes, for example, (i) increasing the expression of the recombinant protein; (ii) increasing the solubility of the recombinant protein; and (iii) aiding in the purification of the recombinant protein by acting as a ligand in affinity purification. In fusion expression vectors, a proteolytic cleavage site is often introduced at the junction of the fusion moiety and the recombinant protein to allow separation of the recombinant protein from the fusion moiety after purification of the fusion protein. Such enzymes and their cognate recognition sequences include factor Xa, thrombin, and enterokinase. Exemplary fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.), and pRIT5 (Pharmacia, Piscataway, NJ), which fuse glutathione S-transferase (GST), maltose E-binding protein, or protein A to the target recombinant protein, respectively.
[0112] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
[0113] In some embodiments, the vector is a yeast expression vector. Examples of vectors for expression in the yeast Saccharomyces cerevisiae include pYepSec1 (Baldari, et al., 1987. EMBO J. 6:229-234), pMFa (Kuijan and Herskowitz, 1982. Cell 30:933-943), pJRY88 (Schultz et al., 1987. Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).
[0114] In some embodiments, the vector drives protein expression in insect cells using a baculovirus expression vector. Baculovirus vectors available for protein expression in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith et al., 1983. Mol. Cell. Biol. 3:2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170:31-39).
[0115] In some embodiments, the vector may drive expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329:840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6:187-195). When used in mammalian cells, expression vector control functions are typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus type 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, see, for example, Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
[0116] In some embodiments, the recombinant mammalian expression vector can direct expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987, Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton, 1988, Adv. Immunol. 43:235-275), promoters of T-cell receptors in particular (Winoto and Baltimore, 1989, EMBO J. 8:729-733) and immunoglobulins (Baneiji, et al., 1983, Cell 33:729-740; Queen and Baltimore, 1983, Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989, Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreatic-specific promoters (Edlund, et al., 1989, Proc. Natl. Acad. Sci. USA 86:5473-5477), and the like. al., 1985, Science 230:912-916), and mammary gland-specific promoters (e.g., whey promoters; U.S. Pat. No. 4,873,316 and European Patent Application Publication No. 264,166). Developmentally regulated promoters, such as murine hox promoters (Kessel and Gruss, 1990, Science 249:374-379) and the alpha-fetoprotein promoter (Campes and Tilghman, 1989, Genes Dev. 3:537-546), are also encompassed. Regarding these prokaryotic and eukaryotic vectors, reference is made to U.S. Pat. No. 6,750,059, the contents of which are incorporated herein by reference in their entirety. Other embodiments of the present invention may relate to the use of viral vectors, and reference is made to U.S. Patent Application No. 13 / 092,085, the contents of which are incorporated herein by reference in their entirety.Tissue-specific regulatory elements are known in the art; see, for example, US Pat. No. 7,776,321, the contents of which are incorporated herein by reference in their entirety.
[0117] In some embodiments, the regulatory element is operably linked to one or more elements of the CRISPR system, so as to drive the expression of one or more elements of the CRISPR system.Generally, CRISPR (Clustered Regularly Interspaced Short Repeats), also known as SPIDR (Spacer Interspersed Direct Repeat), constitutes a family of DNA loci that are usually specific to certain bacterial species.CRISPR loci include a distinct class of interspersed short sequence repeats (SSRs) recognized in Escherichia coli (E. coli) (Ishino et al., J. Bacteriol.,169:5429-5433
[1987] ; and Nakata et al., J. Bacteriol.,171:3553-3556
[1989] ) and related genes. Similar interspersed SSRs have been identified in Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (see Groenen et al., Mol. Microbiol., 10:1057-1065
[1993] ; Hoe et al., Emerg. Infect. Dis., 5:254-263
[1999] ; Masepohl et al., Biochim. Biophys. Acta 1307:26-30
[1996] ; and Mojica et al., Mol. Microbiol., 17:85-93
[1995] ). CRISPR loci typically differ from other SSRs in the structure of their repeats, which are termed short regularly interspaced repeats (SRSRs) (Janssen et al., OMICS J. Integ. Biol., 6:23-33
[2002] ; and Mojica et al., Mol. Microbiol., 36:244-246
[2000] ). Generally, repeats are short elements that occur in clusters regularly spaced by unique intervening sequences of substantially constant length (Mojica et al.,
[2000] , supra). Repeat sequences are highly conserved between strains, butThe number of interspersed repeats and the sequence of the spacer region typically vary from strain to strain (van Embden et al., J. Bacteriol., 182:2393-2401
[2000] ). CRISPR loci have been identified in over 40 prokaryotes (e.g., Jansen et al., Mol. Microbiol., 43:1565-1575
[2002] ; and Mojica et al. See, e.g., et al.,
[2005] , including, but not limited to, the genera Aeropyrum, Pyrobaculum, Sulfolobus, Archaeoglobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, and the like. fex), Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium, Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter,The genera Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, Photobacterium, Salmonella, Xanthomonas, Yersinia, Treponema, and Thermotoga.
[0118] Generally, a "CRISPR system" collectively refers to transcripts and other elements involved in directing the expression or activity of CRISPR-associated ("Cas") genes, e.g., sequences encoding Cas genes, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr mate sequences (including "direct repeats" and partial direct repeats processed by tracrRNA in the context of endogenous CRISPR systems), guide sequences (also referred to as "spacers" in the context of endogenous CRISPR systems), or other sequences and transcripts from a CRISPR locus. In some embodiments, one or more elements of a CRISPR system are derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system are derived from a particular organism that contains an endogenous CRISPR system, e.g., Streptococcus pyogenes. Generally, CRISPR system is characterized by the element that promotes the formation of CRISPR complex in target sequence (also referred to as protospacer in endogenous CRISPR system).With respect to the formation of CRISPR complex, " target sequence " refers to the sequence that guide sequence is designed to have complementarity with, and the hybridization between target sequence and guide sequence promotes the formation of CRISPR complex.Target sequence can comprise any polynucleotide, for example, DNA or RNA polynucleotide.In some embodiments, target sequence is located in the nucleus or cytoplasm of cell.
[0119] In a preferred embodiment of the present invention, the CRISPR system is a type II CRISPR system and the Cas enzyme is Cas9, which catalyzes DNA cleavage. Enzymatic action by Cas9 from SpCas9 (S. pyogenes) or any closely related Cas9 hybridizes to a 20-nucleotide guide sequence and generates a double-stranded break at a target site sequence having a protospacer adjacent motif (PAM) sequence NGG / NRG (e.g., as discussed elsewhere, a suitable PAM is 5'-NRG or 5'-NNGRR for the SpCas9 or SaCas9 enzyme (or derived enzyme), respectively) following the 20-nucleotide target sequence. CRISPR activity through Cas9 for site-specific DNA recognition and cleavage is defined by the guide sequence, a tracr sequence that partially hybridizes to the guide sequence, and the PAM sequence. More aspects of the CRISPR system are described in Karginov and Hannon, The CRISPR system: small RNA-guided defense in bacteria and archae, Mole Cell 2010, January 15;37(1):7.
[0120] The type II CRISPR locus from Streptococcus pyogenes SF370 contains a cluster of four genes, Cas9, Cas1, Cas2, and Csn1, as well as two non-coding RNA elements, tracrRNA, and a characteristic array of direct repeats separated by short, non-repetitive sequences (spacers, approximately 30 bp each). In this system, targeted DNA double-strand breaks (DSBs) are created in four sequential steps (Figure 2A). First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of the pre-crRNA, which is then processed to mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of the target DNA upstream of the PAM, creating a DSB within the protospacer (Figure 2A). Figure 2B demonstrates the nuclear localization of codon-optimized Cas9. To promote accurate transcription initiation, an RNA polymerase III-based U6 promoter was selected to drive tracrRNA expression (Figure 2C). Similarly, a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr-mate sequence"; Figure 2C). The initial spacer was designed to target a 33-base pair (bp) target site (30-bp protospacer + 3-bp CRISPR motif (PAM) sequence that satisfies the NGG recognition motif of Cas9) in the human EMX1 locus, a gene important for cerebral cortical development (Figure 2C).
[0121] Figure 16 shows the use of Cas9 orthologs and their respective sgRNAs to cleave two candidate targets present in a pUC19-based library. Target 1 is followed by a randomized PAM containing seven degenerate bases (5'-NNNNNNN-3'), and target 1', which contains a target sequence identical to target 1, is followed by a fixed PAM (5'-TGGAGAAT-3'). The sgRNA for each Cas9 ortholog contains a guide sequence for target 1 or target 1'. The gel image shows successful cleavage by the 20 Cas9 orthologs, indicating that the sgRNA designs are functional for their respective Cas9 enzymes.
[0122] In some embodiments, direct repeat or tracr mate sequences are downloaded from a CRISPR database or identified in silico by searching for repeat motifs found in a 2 kb window of genomic sequences flanking the type II CRISPR locus, spanning 2.20 to 50 bp, and 3.20 to every 50 bp. In some embodiments, two of these criteria can be used, for example, 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all three criteria can be used.
[0123] In some embodiments, candidate tracrRNAs are then predicted based on: 1. sequence homology with the direct repeat (motif search in Geneious with a maximum mismatch of 18 bp), 2. the presence of a predicted Rho-independent transcription terminator in the direction of transcription, and 3. a stable hairpin secondary structure between the tracrRNA and the direct repeat. In some embodiments, two of these criteria can be used, e.g., 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all three criteria can be used. In some embodiments, the chimeric synthetic guide RNA (sgRNA) design incorporates at least 8 bp of double-stranded structure between the direct repeat and the tracrRNA.
[0124] Some aspects of the CRISPR system can be further improved to increase the efficiency and versatility of CRISPR targeting.Optimal Cas9 activity can depend on the availability of free Mg2+ at levels higher than those present in mammalian nuclei (see, for example, Jinek et al., 2012, Science, 337:816), and the preference for downstream NGG / NRG motifs adjacent to protospacers limits targeting ability to an average of every 12 bp in the human genome.
[0125] Typically, with respect to endogenous CRISPR systems, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs therefrom). Without being bound by theory, the tracr sequence may comprise or consist of all or a portion of the wild-type tracr sequence (e.g., more than about or about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of the wild-type tracr sequence), and may also form part of a CRISPR complex, for example, by hybridization along at least a portion of the tracr sequence with all or a portion of a tracr mate sequence operably linked to the guide sequence. In some embodiments, one or more vectors that drive the expression of one or more elements of the CRISPR system are introduced into host cells, so that the expression of the elements of the CRISPR system directs the formation of a CRISPR complex at one or more target sites.For example, the Cas enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence can each be operably linked to separate regulatory elements on separate vectors.Alternatively, two or more elements expressed from the same or different regulatory elements can be combined in a single vector, and one or more additional vectors that provide any component of the CRISPR system are not included in the first vector.The CRISPR system elements combined in a single vector can be arranged in any suitable orientation, for example, an element can be located on the 5' side (upstream) or 3' side (downstream) of the second element.The coding sequence of an element can be located on the same or opposite strand of the coding sequence of the second element, and can be oriented in the same or opposite direction.In some embodiments, a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of a guide sequence, a tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence (e.g., each in a different intron, two or more in at least one intron, or all in a single intron) embedded within one or more intron sequences. In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.
[0126] In some embodiments, a vector comprises one or more insertion sites, such as restriction endonuclease recognition sequences (also referred to as "cloning sites"). In some embodiments, one or more insertion sites (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and / or downstream of one or more sequence elements of one or more vectors. In some embodiments, a vector comprises an insertion site upstream of a tracr mate sequence and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that after insertion of the guide sequence into the insertion site and upon expression, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell. In some embodiments, a vector comprises two or more insertion sites, each located between two tracr mate sequences to allow insertion of a guide sequence at the respective site. In such an arrangement, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or a combination thereof. When using multiple different guide sequences, can use a single expression construct to target the CRISPR activity to multiple different corresponding target sequences in cells.For example, a single vector can comprise about or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more guide sequences.In some embodiments, about or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of these guide sequence-containing vectors can be provided and optionally delivered into cells.
[0127] In some embodiments, the vector comprises regulatory elements operably linked to an enzyme coding sequence that encodes a CRISPR enzyme, e.g., a Cas protein. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Csel, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. In some embodiments, unmodified CRISPR enzyme has DNA cleavage activity, for example, Cas9.In some embodiments, CRISPR enzyme directs cleavage of one or both strands at the location of target sequence, for example, within target sequence and / or the complementary strand of target sequence.In some embodiments, CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500 or more base pairs from the first or last nucleotide of target sequence.In some embodiments, vector encodes a CRISPR enzyme that is mutated with respect to corresponding wild-type enzyme, so that mutant CRISPR enzyme lacks the ability to cleave one or both strands of target polynucleotide containing target sequence. For example, an aspartate to alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that make Cas9 a nickase include, but are not limited to, H840A, N854A, and N863A in SpCas9.As discussed herein, corresponding positions may be conserved in other Cas9s from or derived from other bacterial species, i.e., Cas9 orthologs, relative to the position numbering of SpCas9. (Figure 19) shows a multiple sequence alignment of 12 Cas9 orthologs, showing the conserved catalytic Asp residue in the RuvCI domain and the conserved catalytic His residue in the HNH domain. Mutation of one or the other residue to Ala can convert a Cas9 ortholog into a nickase. Mutation of both residues can convert a Cas9 ortholog into a catalytically ineffective mutant useful for global DNA binding. As a further example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III or HNH domains) can be mutated to produce mutant Cas9 orthologs that substantially lack all DNA cleavage activity. In some embodiments, the D10A mutation is combined with one or more of the H840A, N854A, or N863A mutations to produce a Cas9 enzyme that substantially lacks all DNA cleavage activity. In some embodiments, a CRISPR enzyme is considered to substantially lack all DNA cleavage activity if the DNA cleavage activity of the mutant enzyme is less than about 25%, 10%, 5%, 1%, 0.1%, 0.01%, or less, relative to its non-mutated form.
[0128] An aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of SpCas9 was engineered to convert the nuclease into a nickase (see, e.g., Sapranauskas et al., 2011, Nucleic Acids Research, 39:9275; Gasiunas et al., 2012, Proc. Natl. Acad. Sci. USA, 109:E2579), enabling high-fidelity homology-directed repair (HDR) of nicked genomic DNA. Applicants confirmed by Surveyor assay that SpCas9n does not generate indels at the EMX1 protospacer target. Coexpression of an EMX1-targeting chimeric crRNA (also containing tracrRNA components) with SpCas9, but not with SpCas9n, generated indels at the target site (n=3). Furthermore, sequencing of 327 amplicons did not detect any SpCas9n-induced indels. Using the same locus, we tested CRISPR-mediated HR by co-transfecting HEK293FT cells with a chimeric RNA targeting EMX1, hSpCas9, or hSpCas9n, and an HR template to introduce a pair of restriction sites (HindIII and NheI) near the protospacer. SpCas9 and SpCas9n indeed catalyzed integration of the HR template into the EMX1 locus. PCR amplification of the target region followed by restriction digestion with HindIII revealed cleavage products corresponding to the predicted fragment sizes, indicating that SpCas9 and SpCas9n mediated similar levels of HR efficiency. We further confirmed the HR using Sanger sequencing of genomic amplicons, demonstrating the utility of CRISPR for facilitating targeted gene insertion in mammalian genomes. Given the 14-bp target specificity of wild-type SpCas9 (12 bp from the spacer and 2 bp from the PAM), the availability of a nickase could significantly reduce the likelihood of off-target modifications, as the single-strand break is not a substrate for the error-prone NHEJ pathway.Figures 10A-M provide a schematic showing the location of mutations in SpCas9. Cas9 orthologs typically share a common organization of three to four RuvC domains and an HNH domain. The 5'-most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand.
[0129] The catalytic residues in the 5' RuvC domain were identified through homology comparison between the target Cas9 and other Cas9 orthologs (from the S. pyogenes type II CRISPR locus, S. thermophilus CRISPR locus 1, S. thermophilus CRISPR locus 3, and Franciscilla novicida type II CRISPR locus), and the conserved Asp residue was mutated to alanine to convert Cas9 into a complementary strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domain were mutated to alanine to convert Cas9 into a non-complementary strand nicking enzyme.
[0130] In some embodiments, the enzyme coding sequence that encodes CRISPR enzyme is codon-optimized for expression in particular cells, for example, eukaryotic cells.Eukaryotic cells can be of or derived from specific organisms, for example, mammals, for example, non-human mammals, including but not limited to humans, mice, rats, rabbits, dogs, or non-human primates.In some embodiments, the method of modifying the genetic identity of human germline and / or the method of modifying the genetic identity of animals, which may cause suffering to people or animals without any substantial medical benefit to them, and the animals obtained from such methods can also be excluded.
[0131] Generally, codon optimization refers to the process of modifying a nucleic acid sequence to improve expression in a target host cell by replacing at least one codon (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of a native sequence with a more frequently or most frequently used codon in the host cell's genes while maintaining the native amino acid sequence. Various species exhibit specific biases for certain codons of specific amino acids. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of messenger RNA (mRNA) translation, which in turn is thought to depend, among other things, on the properties of the codon being translated and the availability of specific transfer RNA (tRNA) molecules. The dominance of tRNAs selected in a cell generally reflects the codons most frequently used in peptide synthesis. Thus, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, in the "Codon Usage Database" available at www.kazusa.orjp / codon / (accessed July 9, 2002), and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000," Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon-optimizing a particular sequence for expression in a particular host cell are also available, for example, Gene Forge (Aptagen; Jacobus, PA). In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.
[0132] In some embodiments, the vector encodes a CRISPR enzyme that comprises one or more nuclear localization sequences (NLSs), for example, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLSs. In some embodiments, the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLSs at or near the amino terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLSs at or near the carboxy terminus, or a combination thereof (for example, one or more NLSs at the amino terminus and one or more NLSs at the carboxy terminus). When two or more NLSs are present, each can be selected independently from the others, so that a single NLS can exist in two or more copies, and / or in combination with one or more other NLSs that exist in one or more copies. In a preferred embodiment of the present invention, the CRISPR enzyme comprises at most six NLSs. In some embodiments, an NLS is considered to be near the N- or C-terminus if the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus.Non-limiting examples of NLSs include the NLS of the SV40 virus large T antigen, which has the amino acid sequence PKKKRKV; an NLS from nucleoplasmin (e.g., the nucleoplasmin bipartite NLS, which has the sequence KRPAATKKAGQAKKKK); a c-myc NLS, which has the amino acid sequence PAAKRVKLD or RQRRNELKRSP; an hRNPA1 M9 NLS, which has the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY; an IBB domain from importin alpha, which has the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV; the sequences VSRKRPRP and PPKKARED of the fibroid T protein; the sequence POPKKKPL of human p53; and a mouse c-abl IV sequence SALIKKKKKMAP; influenza virus NS1 sequences DRLRR and PKQKKRK; hepatitis virus delta antigen sequence RKLKKKIKKL; mouse Mx1 protein sequence REKKKFLKRR; human poly(ADP-ribose) polymerase sequence KRKGDEVDGVDEVAKKKSKK; and steroid hormone receptor (human) glucocorticoid sequence RKCLQAGMNLEARKTKK.
[0133] Generally, one or more NLSs are strong enough to drive the accumulation of detectable amounts of CRISPR enzyme in the nucleus of eukaryotic cells.Generally, the strength of nuclear localization activity can be derived from the number of NLSs in CRISPR enzyme, the specific NLS used, or a combination of these factors.Detection of nuclear accumulation can be carried out by any suitable technique.For example, detectable marker can be fused to CRISPR enzyme, so that intracellular localization can be visualized, for example, by combining with a means for detecting nuclear localization (for example, nuclear-specific staining, for example, DAPI).Cell nuclei can also be isolated from cells, and then their contents can be analyzed by any suitable process for detecting protein, for example, immunohistochemical analysis, Western blotting, or enzyme activity assay. Accumulation in the nucleus can also be measured indirectly, for example, by assaying for the effect of CRISPR complex formation (e.g., assaying for DNA cleavage or mutation at the target sequence, or assaying for changes in gene expression activity affected by CRISPR complex formation and / or CRISPR enzymatic activity), compared to a control exposed to neither the CRISPR enzyme nor the complex, or to a CRISPR enzyme lacking one or more NLSs.
[0134] Generally, a guide sequence is any polynucleotide sequence that has sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is greater than about or about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99% or more when optimally aligned using a suitable alignment algorithm. Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, the guide sequence is about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence can be assessed by any suitable assay.For example, the components of the CRISPR system sufficient to form a CRISPR complex, for example, the guide sequence to be tested, can be provided to a host cell having the corresponding target sequence, for example, by transfection with a vector encoding the components of the CRISPR sequence, and then the preferential cleavage in the target sequence can be evaluated, for example, by the Surveyor assay described herein.Similarly, the cleavage of the target polynucleotide sequence can be evaluated by providing the target sequence, the components of the CRISPR complex, for example, the guide sequence to be tested and a control guide sequence that is different from the test guide sequence in a test tube, and comparing the binding or cleavage rate in the target sequence between the test and control guide sequence reactions.Other assays are conceivable, and those skilled in the art will recognize them.
[0135] Multiplexed nickases: The Cas9 optimization aspects and teachings detailed in this application can also be used to generate Cas9 nickases. Cas9 nickases can advantageously be used in combination with a pair of guide RNAs to generate DNA double-strand breaks with defined overhangs. When two pairs of guide RNAs are used, it is possible to excise an intervening DNA fragment. When an exogenous DNA piece is cleaved by two pairs of guide RNAs to generate overhangs compatible with genomic DNA, the exogenous DNA fragment can be ligated into genomic DNA to replace the excised fragment. For example, this can be used to remove trinucleotide repeat expansions in the Huntington (HTT) gene to treat Huntington's disease.
[0136] Cas9 and its chimeric guide RNA, or the combination of tracrRNA and crRNA, can be delivered as either DNA or RNA.The delivery of both Cas9 and guide RNA as RNA (normal or containing base or backbone modifications) molecules can be used to reduce the amount of time that Cas9 protein persists in cells.This can reduce the level of off-target cleavage activity in target cells.Because the delivery of Cas9 as mRNA requires time to be translated into protein, it can be advantageous to deliver guide RNA several hours after the delivery of Cas9 mRNA to maximize the level of guide RNA available for interaction with Cas9 protein.
[0137] In situations where the amount of guide RNA is limiting, it may be desirable to introduce the guide RNA in the form of a DNA expression cassette with a promoter driving expression of Cas9 as mRNA and the DNA guide RNA, thus amplifying the amount of available guide RNA via transcription.
[0138] Various delivery systems can be introduced to introduce Cas9 (DNA or RNA) and guide RNA (DNA or RNA) into host cells. These include the use of liposomes, viral vectors, electroporation, nanoparticles, nanowires (Shalek et al., Nano Letters, 2012), and exosomes. Molecular Trojan horse liposomes (Pardridge et al., Cold Spring Harb Protoc; 2010; doi:10.1101 / pdb.prot5407) can be used to deliver Cas9 and guide RNA across the blood-brain barrier.
[0139] Guide RNA considerations for orthologs: In some embodiments, the guide sequence is selected to reduce the degree of secondary structure within the guide RNA. In some embodiments, less than about or about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less of the nucleotides of the guide RNA are involved in self-complementary base pairing when optimally folded. Optimal folding can be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimum Gibbs free energy. An example of such an algorithm is mFold, described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another exemplary folding algorithm is the online web server RNAfold, developed at the Institute for Theoretical Chemistry at the University of Vienna, which uses a centroid structure prediction algorithm (see, for example, A. R. Gruber et al., 2008, Cell 106(1):23-24; and P. A. Carr and G. M. Church, 2009, Nature Biotechnology 27(12):1151-62). A method for optimizing the guide RNA of a Cas9 ortholog includes disrupting the polyU tract in the guide RNA. The polyU tract that can be disrupted can include a series of 4, 5, 6, 7, 8, 9, or 10 U.
[0140] Generally, the tracr mate sequence includes any sequence that has sufficient complementarity with the tracr sequence to promote one or more of the following: (1) excision of the guide sequence flanked by the tracr mate sequence in cells containing the corresponding tracr sequence; and (2) formation of a CRISPR complex in the target sequence (the CRISPR complex includes the tracr mate sequence hybridized to the tracr sequence). Generally, the degree of complementarity is based on optimal alignment of the tracr mate sequence and the tracr sequence along the shorter length of the two sequences. Optimal alignment can be determined by any suitable alignment algorithm and can further account for secondary structures, such as self-complementarity within the tracr sequence or the tracr mate sequence. In some embodiments, the degree of complementarity between the tracr sequence and the tracr mate sequence along the shorter length of the two sequences is greater than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or more when optimally aligned. In some embodiments, the tracr sequence is about or greater than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and the tract mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript with a secondary structure, e.g., a hairpin. In one embodiment of the present invention, the transcript or transcribed polynucleotide sequence has at least two or more hairpins. In preferred embodiments, the transcript has two, three, four, or five hairpins. In further embodiments of the present invention, the transcript has at most five hairpins. In the hairpin structure, the portion of the sequence 5' upstream of the final "N" and the loop corresponds to the tracr mate sequence, and the portion of the sequence 3' upstream of the loop corresponds to the tracr sequence.A further non-limiting example of a single polynucleotide comprising a guide sequence, a tracr mate sequence, and a tracr sequence is as follows (listed 5' to 3'), where "N" represents bases of the guide sequence, the first block of lowercase letters represents the tracr mate sequence, the second block of lowercase letters represents the tracr sequence, and the final poly-T sequence represents the transcription terminator: [ka] In some embodiments, sequences (1) through (3) are used in combination with Cas9 from S. thermophilus CRISPR1. In some embodiments, sequences (4) through (6) are used in combination with Cas9 from S. pyogenes. In some embodiments, the tracr sequence is a separate transcript from the transcript containing the tracr mate sequence.
[0141] Consideration of tracr mate sequences for orthologs: In some embodiments, a recombination template is also provided. The recombination template can be a component of another vector described herein, contained in a separate vector, or provided as a separate polynucleotide. In some embodiments, the recombination template is designed to function as a template for homologous recombination within or near a target sequence that is nicked or cleaved by a CRISPR enzyme as part of a CRISPR complex, for example. The template polynucleotide can be of any suitable length, for example, about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length. In some embodiments, the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence. When optimally aligned, the template polynucleotide can overlap one or more nucleotides of the target sequence (e.g., about or more than about 1, 5, 10, 15, 20, or more nucleotides). In some embodiments, when polynucleotides comprising a template sequence and a target sequence are optimally aligned, the nearest neighbor nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides of the target sequence.
[0142] In some embodiments, the CRISPR enzyme is part of a fusion protein containing one or more heterologous protein domains (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more other domains of the CRISPR enzyme). The CRISPR enzyme fusion protein can include any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that can be fused to the CRISPR enzyme include, but are not limited to, epitope tags, reporter gene sequences, and protein domains with one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tag, V5 tag, FLAG tag, influenza hemagglutinin (HA) tag, Myc tag, VSV-G tag, and thioredoxin (Trx) tag. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins, such as blue fluorescent protein (BFP). CRISPR enzymes can be fused to gene sequences encoding proteins or protein fragments that bind to DNA molecules or other cellular molecules, such as, but not limited to, maltose binding protein (MBP), S-tags, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that can form part of fusion proteins comprising CRISPR enzymes are described in U.S. Patent Application Publication No. 20110059502, which is incorporated herein by reference. In some embodiments, tagged CRISPR enzymes are used to identify the location of the target sequence.
[0143] In some embodiments, CRISPR enzymes can form a component of an inducible system. The inducible nature of the system allows for spatiotemporal control of gene editing or gene expression using energy forms. Energy forms can include, but are not limited to, electromagnetic radiation, acoustic energy, chemical energy, and thermal energy. Examples of inducible systems include tetracycline-inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activation systems (FKBP, ABA, etc.), or light-inducible systems (phytochrome, LOV domain, or cryptochrome). In some embodiments, CRISPR enzymes can be part of a light-inducible transcriptional effector (LITE) to direct changes in transcriptional activity in a sequence-specific manner. The light component can include a CRISPR enzyme, a light-responsive cytochrome heterodimer (e.g., from Arabidopsis thaliana), and a transcription activation / repression domain. Further examples of inducible DNA binding proteins and methods of their use are provided in U.S. Provisional Patent Application Nos. 61 / 736465 and 61 / 721,283, which are incorporated by reference in their entireties.
[0144] In some embodiments, the present invention provides methods comprising delivering one or more polynucleotides, such as, for example, one or more vectors described herein, one or more transcripts thereof, and / or one or more proteins transcribed therefrom, to a host cell. In some embodiments, the present invention further provides cells produced by such cells, and animals comprising or produced therefrom. In some embodiments, a CRISPR enzyme in combination with (and optionally complexed with) a guide sequence is delivered to the cell. Conventional viral and non-viral gene transfer methods can be used to introduce nucleic acids into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a CRISPR system to cells in culture or into a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g., transcripts of vectors described herein), naked nucleic acids, and nucleic acids complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses with episomal or integrated genomes after delivery to a cell.For an overview of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Felgner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51(1):31-44 (1995); Haddada et al., in Current Topics in Microbiology and See Immunology, Doerfler and Boehm (eds) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).
[0145] Non-viral delivery methods of nucleic acid include lipofection, microinjection, gene gun, virosome, liposome, immunoliposome, polycation or lipid:nucleic acid conjugate, naked DNA, artificial virion, and drug-enhanced DNA uptake.Lipofection is described, for example, in U.S. Patent Nos. 5,049,386, 4,946,787; and 4,897,355, and lipofection reagents are commercially available (for example, Transfectam™ and Lipofectin™).Cationic and neutral lipids suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, WO 91 / 17424; WO 91 / 16024.Delivery can be to cells (for example, in vitro or ex vivo administration) or target tissue (for example, in vivo administration).
[0146] The preparation of lipid:nucleic acid complexes, including targeted liposomes, e.g., immunolipid complexes, is well known to those skilled in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); see U.S. Patent Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).
[0147] The use of RNA or DNA virus-based systems for nucleic acid delivery takes advantage of a highly evolved process that targets viruses to specific cells in the body and transports the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or used to treat cells in vitro, and the modified cells can then be administered to patients (ex vivo). Conventional virus-based systems include retroviral, lentiviral, adenoviral, adeno-associated, and herpes simplex virus vectors for gene transfer. Integration into the host genome is possible with retroviral, lentiviral, and adeno-associated virus gene transfer methods, often resulting in long-term expression of the inserted transgene. Furthermore, high transduction efficiencies have been observed in many different cell types and target tissues.
[0148] The tropism of retroviruses can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that can transduce or infect non-dividing cells and typically produce high viral titers. Therefore, the choice of retroviral gene transfer system depends on the target tissue. Retroviral vectors contain cis-acting long terminal repeats (LTRs) that have packaging capacity for foreign sequences up to 6-10 kb. The minimal cis-acting LTRs are sufficient for vector replication and packaging, which are then used to integrate therapeutic genes into target cells to provide permanent transgene expression. Widely used retroviral vectors include those based on murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), or combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J. Virol. 66:1635-1640 (1992); Sommnerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); PCT / US94 / 05700).
[0149] In applications where transient expression is preferred, adenovirus-based systems can be used. Adenovirus-based vectors can exhibit extremely high transduction efficiency in many cell types and do not require cell division. High titers and expression levels have been obtained with such vectors. This vector can be produced in large quantities using a relatively simple system.
[0150] For example, adeno-associated virus ("AAV") vectors can also be used to transduce cells with target nucleic acids in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93 / 24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994). Construction of recombinant AAV vectors is described in numerous publications, e.g., U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al. al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989).
[0151] Typically, packaging cells are used to form viral particles that can infect host cells. Such cells include 293 cells, which package adenovirus, and ψ2 or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually produced by creating cell lines that package nucleic acid vectors into viral particles. The vector typically contains the minimum viral sequences required for packaging and subsequent integration into the host, with other viral sequences replaced by an expression cassette for the polynucleotide to be expressed. Defective viral functions are typically provided in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically contain only the ITR sequences from the AAV genome required for packaging and integration into the host genome. Viral DNA is packaged into a cell line containing a helper plasmid encoding other AAV genes, i.e., rep and cap, but lacking the ITR sequences. The cell line can also be infected with adenovirus as a helper. Helper virus promotes the replication of AAV vector and the expression of AAV gene from helper plasmid.Helper plasmid is not packaged in significant amounts due to the lack of ITR sequence.Contamination by adenovirus can be reduced, for example, by heat treatment, to which adenovirus is more sensitive than AAV.Additional methods for delivering nucleic acid to cells are known to those skilled in the art.For example, see US Patent Application Publication No. 20030087817, which is incorporated herein by reference.
[0152] Therefore, AAV is considered an ideal candidate for use as a transduction vector. Such AAV transduction vectors can contain sufficient cis-acting functions to replicate in the presence of adenovirus or herpesvirus or poxvirus (e.g., vaccinia virus) helper functions provided in trans. Recombinant AAV (rAAV) can be used to deliver foreign genes to cells of various lineages. In these vectors, the AAV cap and / or rep genes are deleted from the viral genome and replaced with a DNA segment of choice. Current AAV vectors can accommodate insert DNA of up to 4,300 bases.
[0153] There are many methods for producing rAAV, and the present invention provides rAAV and methods for preparing rAAV. For example, one or more plasmids containing or consisting essentially of the desired viral construct are transfected into AAV-infected cells. In addition, a second or additional helper plasmid is co-transfected into these cells to provide the AAV rep and / or cap genes essential for replication and packaging of the recombinant viral construct. Under these conditions, the AAV rep and / or cap proteins act in trans to stimulate replication and packaging of the rAAV construct. The rAAV is harvested 2-3 days after transfection. Traditionally, rAAV is harvested from cells along with adenovirus. Contaminating adenovirus is then inactivated by heat treatment. In the present invention, rAAV is advantageously harvested from the cell supernatant rather than from the cells themselves.Thus, in a first aspect, the invention provides for preparing rAAV, and in addition to the foregoing, rAAV can be prepared by a method comprising or consisting essentially of: infecting susceptible cells with rAAV containing exogenous DNA, including expression DNA, and a helper virus (e.g., a poxvirus, such as adenovirus, herpesvirus, or vaccinia virus), wherein the rAAV lacks functional cap and / or rep (and the helper virus (e.g., a poxvirus, such as adenovirus, herpesvirus, or vaccinia virus) provides the cap and / or rev functions that the rAAV lacks); or infecting susceptible cells with rAAV containing exogenous DNA, including expression DNA, wherein the recombinant lacks functional cap and / or rep. or infecting susceptible cells with rAAV containing foreign DNA, including expression DNA, wherein the recombinant is deficient in functional cap and / or rep, and the cell provides the cap and / or rep functions that are deficient in the recombinant; or transfecting susceptible cells with AAV lacking functional cap and / or rep and a plasmid for inserting foreign DNA into the recombinant so that the foreign DNA is expressed by the recombinant, and for providing the rep and / or cap functions, thereby resulting in rAAV containing foreign DNA, including expression DNA, that is deficient in functional cap and / or rep.
[0154] The rAAV may be derived from AAV as described herein, and may advantageously be rAAV1, rAAV2, AAV5, or rAAV having a hybrid or capsid that may include AAV1, AAV2, AAV5, or any combination thereof. The AAV of the rAAV may be selected in relation to the cells that the rAAV targets; for example, for targeting brain or neural cells, AAV serotype 1, 2, 5, or hybrid or capsid AAV1, AAV2, AAV5, or any combination thereof may be selected; and for targeting cardiac tissue, AAV4 may be selected, and for targeting liver tissue, AAV8 may be selected.
[0155] In addition to 293 cells, other cells that can be used to practice the present invention and the relative infectivity of particular AAV serotypes in vitro for those cells (see Grimm, D. et al., J. Virol. 82:5887-5911 (2008)) are as follows:
[0156] [Table 5]
[0157] The present invention relates to a vector comprising an exogenous nucleic acid molecule encoding a CRISPR (clustered regularly interspaced short round repeats) system, for example, a first cassette comprising or essentially consisting of a promoter, a nucleic acid molecule encoding a CRISPR-associated (Cas) protein (a putative nuclease or helicase protein), for example, Cas9, and a terminator, and two or more cassettes, advantageously up to the packaging size limit of the vector, for example, a total of five cassettes (including the first cassette) comprising or essentially consisting of a promoter, a nucleic acid molecule encoding a guide RNA (gRNA), and a terminator (for example, each cassette is roughly structured as promoter-gRNA1-terminator, promoter-gRNA2-terminator... promoter-gRNA(N)-terminator, where N is the number of inserts that can be inserted, which is the upper limit of the packaging size limit of the vector). and two or more individual rAAVs, each comprising one or more cassettes of a CRISPR system, e.g., a first rAAV comprising a first cassette comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a Cas, e.g., Cas9, and a terminator, and a second rAAV comprising a plurality of four cassettes comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a guide RNA (gRNA), and a terminator (e.g., each cassette generally represented as promoter-gRNA1-terminator, promoter-gRNA2-terminator... promoter-gRNA(N)-terminator, where N is the number of inserts that is the upper limit of the packaging size limit of the vector). Because rAAVs are DNA viruses, the nucleic acid molecules in the AAV or rAAV discussion herein are advantageously DNA. The promoter is advantageously in some embodiments the human synapsin I promoter (hSyn).
[0158] Two approaches are preferred for packaging Cas9-encoding nucleic acid molecules, e.g., DNA, into viral vectors to mediate genome modification in vivo: To achieve NHEJ-mediated gene knockout: Single viral vector: Vectors containing two or more expression cassettes: Promoter-Cas9-encoding nucleic acid molecule-terminator Promoter-gRNA1-terminator Promoter-gRNA2-terminator Promoter-gRNA(N)-terminator (up to the vector size limit) Dual viral vectors: Vector 1 contains one expression cassette to drive the expression of Cas9 Promoter-Cas9-encoding nucleic acid molecule-terminator Vector 2 containing another expression cassette to drive expression of one or more guide RNAs Promoter-gRNA1-terminator Promoter-gRNA(N)-terminator (up to the vector size limit)
[0159] To mediate homology-directed repair. In addition to the single and dual viral vector approaches described above, an additional vector is used to deliver the homology-directed repair template.
[0160] Promoters used to drive expression of Cas9-encoding nucleic acid molecules can include: The AAV ITRs can function as promoters; this has the advantage of eliminating the need for additional promoter elements (which may occupy space in the vector). The additional space can be used to drive the expression of additional elements (such as gRNA). Furthermore, ITR activity is relatively weak, and therefore can be used to reduce toxicity caused by overexpression of Cas9.
[0161] For ubiquitous expression, promoters such as CMV, CAG, CBh, PGK, SV40, ferritin heavy or light chain, etc. can be used.
[0162] For brain expression, promoters such as synapsin I for all neurons, CaMKII alpha for excitatory neurons, GAD67 or GAD65 or VGAT for GABAergic neurons can be used. For hepatic expression, the albumin promoter can be used. For pulmonary expression, SP-B can be used. For endothelial cells, ICAM can be used. For hematopoietic cells, IFN beta or CD45 can be used. For osteoblasts, OG-2 can be used. The promoter used to drive the guide RNA may include: Pol III promoters, e.g., U6 or H1 Use of Pol II promoters and intronic cassettes to express gRNAs
[0163] With respect to AAV, AAV may be AAV1, AAV2, AAV5, or any combination thereof. The AAV of the AAV can be selected according to the cell to be targeted; for example, AAV serotype 1, 2, 5, or hybrid or capsid AAV1, AAV2, AAV5, or any combination thereof can be selected for targeting the brain or nerve cells; AAV4 can be selected for targeting cardiac tissue. AAV8 is useful for delivery to the liver. The above promoters and vectors are individually preferred.
[0164] Additional methods for delivering nucleic acids to cells are known to those of skill in the art, see, for example, U.S. Patent Application Publication No. 20030087817, incorporated herein by reference.
[0165] In some embodiments, host cells are transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, cells are transfected as they naturally occur in a subject. In some embodiments, the transfected cells are harvested from a subject. In some embodiments, the cells are derived from cells harvested from a subject, e.g., cell lines. A wide variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, HeLa-S3, Huh1, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Panc1, PC-3, TF1, CTLL-2, C1R, Rat6, CV1, RPTE, A10, T24, J82, A375, ARH-77, Calu1, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.01, LRMB, Bcl-1, BC-3, IC21, DLD2, Raw264.7, NRK, NRK-52E, MRC5, MEF, and Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelium, BALB / 3T3 mouse embryonic fibroblasts, 3T3Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis , A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1 cells, BEAS-2B, bEnd.3, BHK-21, BR29 3, BxPC3, C3H-10T1 / 2, C6 / 36, Cal-27, CHO, CHO-7, CHO-IR, CHO-K1, CHO-K2, CHO-T, CHO Dhfr- / -, COR-L23, COR-L23 / CPR, COR-L23 / 5010, COR-L23 / R23, COS-7, COV-434, CML T1, CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6 / AR1, EMT6 / AR10.0, FM3, H1299, H69, HB54, HB55, HCA2, HEK-293, HeLa, Hepa1c1c7, HL-60, HMEC, HT-29, Jurkat, JY cells, K562 cells, Ku 812, KCL22, KG1, KYO1, LNCap, Ma-Mel1-48, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK II, MDCK II, MOR / 0.2R, MONO-MAC6, MTD-1A, MyEnd, NCI-H69 / CPR, NCI-H69 / LX10, NCI-H69 / LX20, NCI-H69 / LX4, NIH-3T3, NALM-1, NW-145, OPCN / OPCT cell lines, Peer, PNT-1A / PNT2, RenCa, RIN-5F, RMA / RMAS, Saos-2 cells, Sf-9, SkBr3, T2, T-47D, T84, THP1 cell lines, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-1, YAR, and transgenic variants thereof. Cell lines are available from a variety of sources known to those of skill in the art (see, e.g., American Type Culture Collection (ATCC), Manassus, Va.). In some embodiments, cells transfected with one or more vectors described herein are used to establish new cell lines comprising one or more vector-derived sequences. In some embodiments, cells transiently transfected with components of a CRISPR system described herein (e.g., by transient transfection of one or more vectors or transfection with RNA) and modified through the activity of a CRISPR complex are used to establish new cell lines comprising cells containing the modification but lacking any other exogenous sequences. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells, are used in the evaluation of one or more test compounds.
[0166] In some embodiments, one or more vectors described herein are used to produce non-human transgenic animals or transgenic plants.In some embodiments, transgenic animals are mammals, such as mice, rats or rabbits.The method of producing transgenic plants and animals is known in the art, and generally starts from, for example, the method of cell transfection described herein.
[0167] With recent advances in crop genomics, the ability to use CRISPR-Cas systems to perform efficient and cost-effective gene editing and manipulation allows for the rapid selection and comparison of single and multiplexed genetic manipulations to transform such genomes for improved production and trait enhancement. In this regard, reference is made to U.S. patents and publications: U.S. Patent No. 6,603,061 - Agrobacterium-Mediated Plant Transformation Method; U.S. Patent No. 7,868,149 - Plant Genome Sequences and Uses Thereof and U.S. Patent Application Publication No. 2009 / 0100536 - Transgenic Plants with Enhanced Agronomic Traits, the entire contents and disclosures of each of which are incorporated herein by reference in their entirety. In implementing the present invention, the contents and disclosures of Morrell et al. "Crop genomics: advances and applications" Nat Rev Genet. 2011 Dec 29; 13(2): 85-96 are also incorporated herein by reference in their entirety. In an advantageous embodiment of the present invention, the CRISPR / Cas9 system is used to engineer microalgae (Example 7). Thus, references herein to animal cells may, mutatis mutandis, also apply to plant cells unless otherwise indicated.
[0168] In one aspect, the present invention provides a method for modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo, or in vitro. In some embodiments, the method includes sampling a cell or a population of cells from a human or non-human animal or plant (including microalgae) and modifying one or more cells. Culturing can be performed ex vivo at any stage. One or more cells can also be reintroduced into a non-human animal or plant (including microalgae). For the reintroduced cells, it is particularly preferred that the cells are stem cells.
[0169] In some embodiments, the methods comprise binding a CRISPR complex to a target polynucleotide to cause cleavage of said target polynucleotide, thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence that is hybridized to a target sequence within said target polynucleotide, said guide sequence being bound to a tracr mate sequence that in turn hybridizes to a tracr sequence.
[0170] In one aspect, the present invention provides a method for modifying the expression of polynucleotide in eukaryotic cells.In some embodiments, the method comprises: allowing CRISPR complex to bind to polynucleotide, and thereby, said binding causes the expression of said polynucleotide to increase or decrease; said CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence that hybridizes with the target sequence in said target polynucleotide, and said guide sequence is then bound to the tracr mate sequence that hybridizes with the tracr sequence.Similar considerations apply to the method for modifying target polynucleotide as described above.Indeed, these sampling, culturing and reintroduction options apply to all aspects of the present invention.
[0171] In one aspect, the present invention provides a kit containing any one or more of the elements disclosed in the above methods and compositions.The elements can be provided individually or in combination, and can be provided in any suitable container, such as a vial, bottle, or tube.In some embodiments, the kit includes instructions in one or more languages, for example, in two or more languages.
[0172] In some embodiments, the kit includes one or more reagents used in a process utilizing one or more of the elements described herein. The reagents can be provided in any suitable container. For example, the kit may provide one or more reaction or storage buffers. The reagents can be provided in a form usable in a particular assay or in a form that requires the addition of one or more other components prior to use (e.g., a concentrate or lyophilized form). The buffer can be any buffer, including, but not limited to, sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH of about 7 to about 10. In some embodiments, the kit includes one or more oligonucleotides corresponding to the guide sequence for insertion into a vector to operably link the guide sequence and regulatory elements. In some embodiments, the kit includes a homologous recombination template polynucleotide.
[0173] In one embodiment, the present invention provides a method for using one or more elements of the CRISPR system.The CRISPR complex of the present invention provides an effective means for modifying target polynucleotide.The CRISPR complex of the present invention has a wide range of uses, for example, modifying (for example, deletion, insertion, translocation, inactivation, activation) target polynucleotide in a large number of cell types.Therefore, the CRISPR complex of the present invention has a wide range of applications, for example, in gene therapy, drug screening, disease diagnosis and prognosis.An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence that hybridizes to a target sequence in a target polynucleotide.The guide sequence is then linked to a tracr mate sequence that hybridizes to a tract sequence.
[0174] In one embodiment, the present invention provides a method for cleaving target polynucleotide.This method comprises using CRISPR complex to modify target polynucleotide, and this CRISPR complex binds to target polynucleotide and causes the cleavage of said target polynucleotide.Usually, when the CRISPR complex of the present invention is introduced into cell, it creates breaks (for example, single-strand or double-strand breaks) in genome sequence.For example, this method can be used to cleave disease genes in cell.
[0175] The break created by CRISPR complex can be repaired by repair processes such as error-prone non-homologous end joining (NHEJ) or high-fidelity homology-directed repair (HDR).During these repair processes, exogenous polynucleotide template can be introduced into genome sequence.In some methods, genome sequence is modified using HDR process.For example, exogenous polynucleotide template is introduced into cell, which comprises the sequence to be integrated, flanked by upstream sequence and downstream sequence.Upstream and downstream sequence share sequence similarity with both sides of the integration site in chromosome.
[0176] If desired, the donor polynucleotide may be DNA, such as a DNA plasmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a PCR fragment, naked nucleic acid, or a nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer.
[0177] The exogenous polynucleotide template comprises the sequence to be integrated (for example, a mutant gene). The sequence to be integrated may be an endogenous or exogenous sequence to the cell. Examples of the sequence to be integrated include a polynucleotide that encodes a protein or a non-coding RNA (for example, microRNA). Therefore, the sequence to be integrated may be operably linked to one or more suitable control sequences. Alternatively, the sequence to be integrated may provide a regulatory function.
[0178] The upstream and downstream sequences in the exogenous polynucleotide template are selected to promote recombination between the target chromosomal sequence and the donor polynucleotide.The upstream sequence is a nucleic acid sequence that shares sequence similarity with the genomic sequence upstream of the target integration site.Similarly, the downstream sequence is a nucleic acid sequence that shares sequence similarity with the chromosomal sequence downstream of the target integration site.The upstream and downstream sequences in the exogenous polynucleotide template can have 75%, 80%, 85%, 90%, 95%, or 100% sequence identity with the target genomic sequence.Preferably, the upstream and downstream sequences in the exogenous polynucleotide template have about 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the target genomic sequence.In some methods, the upstream and downstream sequences in the exogenous polynucleotide template have about 99% or 100% sequence identity with the target genomic sequence.
[0179] The upstream or downstream sequence can comprise from about 20 bp to about 2500 bp, e.g., about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp. In some methods, exemplary upstream or downstream sequences have from about 200 bp to about 2000 bp, from about 600 bp to about 1000 bp, or more particularly from about 700 bp to about 1000 bp.
[0180] In some methods, the exogenous polynucleotide template can further comprise a marker. Such a marker can facilitate the screening of target integration. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers. The exogenous polynucleotide template of the present invention can be constructed using recombinant technology (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996).
[0181] In an exemplary method for modifying a target polynucleotide by integrating an exogenous polynucleotide template, a double-strand break is introduced into the genome sequence by the CRISPR complex, and the break is repaired by homologous recombination with the exogenous polynucleotide template, integrating the template into the genome. The presence of the double-strand break promotes the integration of the template.
[0182] In another embodiment, the invention provides a method for modifying expression of a polynucleotide in a eukaryotic cell, the method comprising increasing or decreasing expression of a target polynucleotide using a CRISPR complex that binds to the polynucleotide.
[0183] In some methods, target polynucleotide can be inactivated to achieve the expression modification in cell.For example, when CRISPR complex is bound to target sequence in cell, target polynucleotide is inactivated, so that sequence is not transcribed, or encoded protein is not produced, or sequence does not function as wild-type sequence functions.For example, protein or microRNA coding sequence can be inactivated, so that protein is not produced.
[0184] In some methods, the control sequence can be inactivated so that it no longer functions as a control sequence.As used herein, "control sequence" refers to any nucleic acid sequence that realizes the transcription, translation or accessibility of nucleic acid sequence.Examples of control sequence include promoter, transcription terminator, and enhancer are control sequences.
[0185] The inactivated target sequence may comprise a deletion mutation (i.e., deletion of one or more nucleotides), an insertion mutation (i.e., insertion of one or more nucleotides), or a nonsense mutation (i.e., substitution of a single nucleotide for another such that a stop codon is introduced). In some methods, inactivation of the target sequence results in a "knockout" of the target sequence.
[0186] Altered expression of one or more genomic sequences associated with a signaling biochemical pathway can be determined by assaying for differences in mRNA levels of the corresponding genes between test model cells and control cells upon contact with a candidate agent. Alternatively, differences in expression of sequences associated with a signaling biochemical pathway can be determined by detecting differences in the levels of the encoded polypeptide or gene product.
[0187] To assay for drug-induced changes in mRNA transcript or corresponding polynucleotide levels, nucleic acids contained in a sample are first extracted according to standard methods in the art. For example, mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures set forth in Sambrook et al. (1989), or extracted with nucleic acid-binding resins according to the accompanying instructions provided by the manufacturer. The mRNA contained in the extracted nucleic acid sample is then detected by amplification procedures or conventional hybridization assays (e.g., Northern blot analysis) according to methods commonly known in the art or as exemplified herein.
[0188] For the purposes of this invention, amplification refers to any method using primers and polymerases capable of replicating a target sequence with reasonable fidelity. Amplification can be performed by natural or recombinant DNA polymerases, such as TaqGold™, T7 DNA polymerase, the Klenow fragment of E. coli DNA polymerase, and reverse transcriptase. A preferred amplification method is PCR. Specifically, isolated RNA can be subjected to a reverse transcription assay combined with quantitative polymerase chain reaction (RT-PCR) to quantify the expression level of sequences related to biochemical signaling pathways.
[0189] Detection of gene expression levels can be performed in real time during amplification assays. In one embodiment, amplification products can be directly visualized with fluorescent DNA-binding agents, such as, but not limited to, DNA intercalating agents and DNA groove binders. Because the amount of intercalating agent incorporated into double-stranded DNA molecules is typically proportional to the amount of amplified DNA product, the amount of amplified product can be conveniently determined by quantifying the fluorescence of the intercalating dye using conventional optical systems in the art. DNA-binding dyes suitable for this application include SYBR Green, SYBR Blue, DAPI, propidium iodide, Hoeste, SYBR Gold, ethidium bromide, acridine, proflavine, acridine orange, acriflavine, fluorescent coumarin, ellipticine, daunomycin, chloroquine, distamycin D, chromomycin, homidine, mithramycin, ruthenium polypyridyl, anthramycin, and the like.
[0190] In another embodiment, other fluorescent labels, such as sequence-specific probes, can be used in the amplification reaction to facilitate the detection and quantification of amplification products. Probe-based quantitative amplification relies on the sequence-specific detection of desired amplification products. This amplification utilizes fluorescent target-specific probes (e.g., TaqMan® probes), which provide increased specificity and sensitivity. Methods for performing probe-based quantitative amplification are well established in the art and are taught in U.S. Patent No. 5,210,015.
[0191] In yet another embodiment, conventional hybridization assays can be carried out using hybridization probes that share sequence homology with sequences associated with biochemical signaling pathways.Typically, the probe can form a stable complex with the sequences associated with biochemical signaling pathways contained in the biological sample obtained from the test subject through hybridization reaction.It will be understood by those skilled in the art that when antisense is used as probe nucleic acid, the target polynucleotide provided in the sample is selected to be complementary to the sequence of antisense nucleic acid.On the other hand, when the nucleotide probe is a sense nucleic acid, the target polynucleotide is selected to be complementary to the sequence of sense nucleic acid.
[0192] Hybridization can be carried out under various stringency conditions, for example, as described herein.The hybridization conditions suitable for carrying out the present invention are those in which the recognition interaction between the probe and the sequence related to biochemical signal transduction pathway is sufficiently specific and sufficiently stable.Conditions that increase the stringency of hybridization reactions are widely known and published in the art.See, for example, (Sambrook, et al., (1989); Nonradioactive In Situ Hybridization Application Manual, Boehringer Mannheim, second edition).Hybridization assays can be formed using probes immobilized on any solid support, including but not limited to, nitrocellulose, glass, silicon, and various gene arrays.Preferred hybridization assays are carried out on high-density gene chips, as described in U.S. Patent No. 5,445,934.
[0193] In order to conveniently detect the probe-target complex formed during hybridization assay, the nucleotide probe is conjugated to a detectable label. Detectable labels suitable for use in the present invention include any composition that can be detected by photochemical, biochemical, spectroscopic, immunochemical, electrical, optical or chemical means. A wide variety of suitable detectable labels are known in the art, including fluorescent or chemiluminescent labels, radioisotope labels, enzymes or other ligands. In a preferred embodiment, it may be desirable to use fluorescent labels or enzyme tags, such as digoxigenin, β-galactosidase, urease, alkaline phosphatase or peroxidase, avidin / biotin complex, etc.
[0194] The detection method used to detect or quantitate hybridization intensity will typically depend on the label selected above. For example, radiolabels can be detected using photographic film or a phosphoimager. Fluorescent markers can be detected and quantitated using a photodetector to detect emitted light. Enzyme labels are typically detected by providing the enzyme with a substrate and measuring the reaction product produced by the action of the enzyme on the substrate; and finally, colorimetric labels are simply detected by the addition of a colored label. The label is detected by visualizing it.
[0195] Drug-induced changes in expression of sequences associated with a signaling biochemical pathway can also be determined by examining the corresponding gene product. Determining protein levels typically involves (a) contacting proteins contained in a biological sample with an agent that specifically binds to a protein associated with a signaling biochemical pathway; and (b) identifying any agent:protein complexes thus formed. In one aspect of this embodiment, the agent that specifically binds to a protein associated with a signaling biochemical pathway is an antibody, preferably a monoclonal antibody.
[0196] The reaction is carried out by contacting a sample of a protein associated with a biochemical signaling pathway obtained from a test sample with an agent under conditions that allow for the formation of a complex between the agent and the protein associated with the biochemical signaling pathway. Complex formation can be detected directly or indirectly according to standard procedures in the art. In direct detection methods, the agent is provided with a detectable label, allowing unreacted agent to be removed from the complex; the amount of label remaining indicates the amount of complex formed. For such methods, it is preferable to select a label that remains bound to the agent even under stringent washing conditions. It is preferable that the label does not interfere with the binding reaction. Alternatively, indirect detection procedures can use agents containing labels introduced chemically or enzymatically. Desirable labels generally do not interfere with the binding or stability of the resulting agent:polypeptide complex. However, the label is typically designed to be accessible to an antibody for effective binding and thus generation of a detectable signal.
[0197] A wide variety of labels suitable for detecting protein levels are known in the art, non-limiting examples include radioisotopes, enzymes, colloidal metals, fluorescent compounds, bioluminescent compounds, and chemiluminescent compounds.
[0198] The amount of drug:polypeptide complex formed during the binding reaction can be quantified by standard quantitative assays. As explained above, drug:polypeptide complex formation can be measured directly by the amount of label remaining at the binding site. In an alternative example, a protein associated with a biochemical signaling pathway is tested for its ability to compete with a labeled analog for binding sites on a particular drug. In this competitive assay, the amount of label captured is inversely proportional to the amount of protein sequence associated with a biochemical signaling pathway present in the test sample.
[0199] Many protein analytical techniques based on the general principles outlined above are available in the art, including, but not limited to, radioimmunoassays, ELISAs (enzyme-linked immunoradiometric assays), "sandwich" immunoassays, immunoradiometric assays, in situ immunoassays (using, for example, colloidal gold, enzyme or radioisotope labels), Western blot analysis, immunoprecipitation assays, immunofluorescence assays, and SDS-PAGE.
[0200] Antibodies that specifically recognize or bind to proteins associated with biochemical signaling pathways are preferred for conducting the aforementioned protein analyses. If desired, antibodies that recognize specific types of post-translational modifications (e.g., biochemical signaling pathway-induced modifications) can be used. Post-translational modifications include, but are not limited to, glycosylation, lipidation, acetylation, and phosphorylation. These antibodies may be purchased from commercial suppliers. For example, anti-phosphotyrosine antibodies that specifically recognize tyrosine-phosphorylated proteins are available from many suppliers, including Invitrogen and Perkin Elmer. Anti-phosphotyrosine antibodies are particularly useful in detecting proteins that are differentially phosphorylated on their tyrosine residues in response to ER stress. Such proteins include, but are not limited to, eukaryotic translation initiation factor 2α (eIF-2α). Alternatively, these antibodies can be generated by immunizing host animals or antibody-producing cells with a target protein exhibiting the desired post-translational modification using conventional polyclonal or monoclonal antibody techniques.
[0201] In practicing the subject methods, it may be desirable to identify expression patterns of proteins associated with biochemical signaling pathways in different body tissues, different cell types, and / or different subcellular structures. Such tests can be performed using tissue-, cell-, or subcellular structure-specific antibodies capable of binding to protein markers preferentially expressed in particular tissues, cell types, or subcellular structures.
[0202] Changes in the expression of genes involved in biochemical signaling pathways can also be determined by examining changes in the activity of gene products compared to control cells. Assays for changes in the activity of proteins involved in biochemical signaling pathways caused by drugs can depend on the biological activity and / or signaling pathway being examined. For example, if the protein is a kinase, changes in its ability to phosphorylate one or more downstream substrates can be determined by various assays known in the art. Representative assays include, but are not limited to, immunoblotting and immunoprecipitation using antibodies, such as anti-phosphotyrosine antibodies, that recognize phosphorylated proteins. In addition, kinase activity can be detected by high-throughput chemiluminescence assays, such as AlphaScreen™ (available from PerkinElmer) and eTag™ assays (Chan-Hui, et al. (2003) Clinical Immunology 111:162-174).
[0203] When a protein involved in a biochemical signaling pathway is part of a signal transduction cascade that leads to fluctuations in intracellular pH conditions, a pH-sensitive molecule such as a fluorescent pH dye can be used as a reporter molecule. In another example, when the protein involved in a biochemical signaling pathway is an ion channel, fluctuations in membrane potential and / or intracellular ion concentration can be monitored. Many commercially available kits and high-throughput devices are particularly suitable for rapid and robust screening of ion channel modulators. Representative instruments include FLIPR™ (Molecular Devices, Inc.) and VIPR (Aurora Biosciences). These instruments are capable of simultaneously detecting reactions in over 1,000 sample wells in a microplate and providing real-time measurements and functional data within one second or even one millisecond.
[0204] In practicing any of the methods disclosed herein, suitable vectors can be introduced into cells or embryos by one or more methods known in the art, including, without limitation, microinjection, electroporation, sonoporation, biolistics, calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary drug-enhanced nucleic acid uptake, and delivery via liposomes, immunoliposomes, virosomes, or artificial virions. In some methods, vectors are introduced into embryos by microinjection. One or more vectors can be microinjected into the nucleus or cytoplasm of the embryo. In some methods, one or more vectors can be introduced into cells by nucleofection.
[0205] The target polynucleotide of CRISPR complex can be any polynucleotide that is endogenous or exogenous to eukaryotic cell.For example, target polynucleotide can be the polynucleotide that remains in the nucleus of eukaryotic cell.Target polynucleotide can be the sequence that codes gene product (for example, protein) or non-coding sequence (for example, regulatory polynucleotide or junk DNA).
[0206] Examples of target polynucleotides include sequences related to biochemical signaling pathways, such as biochemical signaling pathway-related genes or polynucleotides. Examples of target polynucleotides include disease-related genes or polynucleotides. A "disease-related" gene or polynucleotide refers to any gene or polynucleotide that produces a transcription or translation product at an abnormal level or in an abnormal form in cells derived from diseased tissue compared to non-disease control tissues or cells. It may be a gene that is expressed at an abnormally high level; or a gene that is expressed at an abnormally low level, where the change in expression correlates with the occurrence and / or progression of the disease. A disease-related gene also refers to a gene that has one or more mutations or genetic variations that are directly involved in the cause of the disease or that are in linkage disequilibrium with one or more genes involved in the cause of the disease. The transcription or translation product may be known or unknown, and may be at a normal or abnormal level.
[0207] The target polynucleotide of a CRISPR complex can be any polynucleotide, endogenous or exogenous to a eukaryotic cell. For example, the target polynucleotide can be a polynucleotide present in the nucleus of a eukaryotic cell. The target polynucleotide can be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or junk DNA). Without being bound by theory, it is believed that the target sequence must associate with a PAM (protospacer adjacent motif); i.e., a short sequence recognized by the CRISPR complex. While the exact sequence and length requirements for the PAM vary depending on the CRISPR enzyme used, the PAM is typically a 2-5 base pair sequence adjacent to the protospacer (i.e., the target sequence). Exemplary PAM sequences are provided in the Examples section below, and those skilled in the art can identify additional PAM sequences for use with a given CRISPR enzyme.
[0208] Target polynucleotides for CRISPR complexes can include many of the disease-associated genes and polynucleotides and signaling biochemical pathway-associated genes and polynucleotides listed in U.S. Provisional Patent Applications Nos. 61 / 736,527 and 61 / 748,427 (both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed December 12, 2012 and January 2, 2013, respectively), having Broad Reference Nos. BI-2011 / 008 / WSGR Docket No. 44063-701.101 and BI-2011 / 008 / WSGR Docket No. 44063-701.102, respectively, the entire contents of which are incorporated herein by reference in their entireties.
[0209] Examples of target polynucleotides include sequences related to signaling biochemical pathways, such as signaling biochemical pathway-related genes or polynucleotides. Examples of target polynucleotides include disease-related genes or polynucleotides. "Disease-related" genes or polynucleotides refer to any gene or polynucleotide that produces transcription or translation products at abnormal levels or in abnormal forms in cells derived from diseased tissues compared with tissues or cells of non-disease control. This can be a gene that is expressed at abnormally high levels; or a gene that is expressed at abnormally low levels, and expression changes correlate with the occurrence and / or progression of disease. Disease-related genes also refer to genes that are directly responsible for the pathogenesis of disease or have mutations or genetic variations that are in linkage disequilibrium with genes that are responsible for the pathogenesis of disease. The transcription or translation products can be known or unknown, and can be at normal or abnormal levels.
[0210] Examples of disease-associated genes and polynucleotides are available from the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and the National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), and are available on the World Wide Web.
[0211] Examples of disease-associated genes and polynucleotides are listed in Tables A and B. Disease-specific information is available from the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and the National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), and is available on the World Wide Web. Examples of signaling biochemical pathway-associated genes and polynucleotides are listed in Table C.
[0212] Mutations in these genes and pathways can result in the production of one or more inappropriate proteins in inappropriate amounts, which affect function.Further examples of genes, diseases and proteins are incorporated herein by reference from U.S. Provisional Patent Application No. 61 / 736,527, filed December 12, 2012, and U.S. Provisional Patent Application No. 61 / 748,427, filed January 2, 2013.Such genes, proteins and pathways can be the target polynucleotide of CRISPR complex.
[0213] [Table 6]
[0214] [Table 7]
[0215]
Table 8
[0216]
Table 9
[0217]
Table 10
[0218]
Table 11
[0219]
Table 12
[0220]
Table 13
[0221]
Table 14
[0222]
Table 15
[0223] Table 16
[0224] Table 17
[0225] [Table 18]
[0226] [Table 19]
[0227] [Table 20]
[0228] [Table 21]
[0229] Embodiments of the present invention also relate to methods and compositions related to gene knockout, gene amplification, and repair of specific mutations associated with DNA repeat instability and neurological diseases (Robert D. Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, October 13, 2011 - Medical). Tandem repeat sequences of defined nature have been found to be responsible for more than 20 human diseases (New insights into repeat instability: role of RNA-DNA hybrids. McIvor EI, Polak U, Napierala M. RNA Biol. 2010 September-Oct;7(5):551-8). The CRISPR-Cas system can be used to correct these abnormalities of genomic instability.
[0230] A further aspect of the present invention relates to the use of CRISPR-Cas systems to correct abnormalities in the EMP2A and EMP2B genes, which have been identified as being associated with Lafora disease. Lafora disease is an autosomal recessive condition characterized by progressive myoclonic epilepsy that may begin as epileptic seizures in adolescence. Some cases of the disease may be caused by mutations in as-yet-unidentified genes. The disease causes seizures, muscle spasms, difficulty walking, dementia, and ultimately death. Currently, no treatments have been proven effective against disease progression. Other genetic abnormalities associated with epilepsy can also be targeted using CRISPR-Cas systems, and the underlying genetics are further described in Genetics of Epilepsy and Genetic Epilepsies, edited by Giuliano Avanzini and Jeffrey L. Noebels, Mariani Foundation Paediatric Neurology: 20; 2009).
[0231] In yet another embodiment of the present invention, the CRISPR-Cas system can be used to correct eye defects resulting from several genetic mutations, as further described in Genetic Diseases of the Eye, Second Edition, edited by Elias I. Traboulsi, Oxford University Press, 2012.
[0232] Some further aspects of the present invention relate to the correction of abnormalities associated with a wide range of genetic diseases, which are further described on the National Institutes of Health website (website at health.nih.gov / topic / GeneticDisorders) under the topic subsection Genetic Disorders. Genetic brain diseases include, but are not limited to, adrenoleukodystrophy, agenesis of the corpus callosum, Aicardi syndrome, Alpers disease, Alzheimer's disease, Barth syndrome, Batten disease, CADASIL, cerebellar degeneration, Fabry disease, Gerstmann-Straussler-Scheinker disease, Huntington's disease and other triplet repeat diseases, Leigh disease, Lesch-Nyhan syndrome, Menkes disease, mitochondrial myopathy, and NINDS colpocephaly. These diseases are further described on the National Institutes of Health website under the subsection Genetic Brain Disorders.
[0233] In some embodiments, the condition is neoplasia. In some embodiments, where the condition may be neoplasia, the gene to be targeted may be any of those listed in Table A (such as PTEN in this case). In some embodiments, the condition may be age-related macular degeneration. In some embodiments, the condition may be schizophrenia. In some embodiments, the condition may be a trinucleotide repeat disorder. In some embodiments, the condition may be fragile X syndrome. In some embodiments, the condition may be a secretase-associated disorder. In some embodiments, the condition may be a prion-associated disorder. In some embodiments, the condition may be ALS. In some embodiments, the condition may be drug addiction. In some embodiments, the condition may be autism. In some embodiments, the condition may be Alzheimer's disease. In some embodiments, the condition may be inflammation. In some embodiments, the condition may be Parkinson's disease.
[0234] Examples of proteins associated with Parkinson's disease include, but are not limited to, alpha-synuclein, DJ-1, LRRK2, PINK1, parkin, UCHL1, synphilin-1, and NURR1.
[0235] An example of a preference-related protein is ABAT.
[0236] Examples of inflammation-related proteins include monocyte chemoattractant protein-1 (MCP1) encoded by the Ccr2 gene, CC chemokine receptor type 5 (CCR5) encoded by the Ccr5 gene, IgG receptor IIB (FCGR2b, also known as CD32) encoded by the Fcgr2b gene, or Fc epsilon R1g (FCER1g) protein encoded by the Fcer1g gene.
[0237] Examples of cardiovascular disease-related proteins include, for example, IL1B (interleukin 1, beta), XDH (xanthine dehydrogenase), TP53 (tumor protein p53), PTGIS (prostaglandin I2 (prostacyclin) synthase), MB (myoglobin), IL4 (interleukin 4), ANGPT1 (angiopoietin 1), ABCG8 (ATP-binding cassette, subfamily G (WHITE), member 8), or CTSK (cathepsin K).
[0238] Examples of Alzheimer's disease-related proteins include, for example, the very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, the ubiquitin-like modifier activating enzyme 1 (UBA1) encoded by the UBA1 gene, or the NEDD8 activating enzyme E1 catalytic subunit protein (UBE1C) encoded by the UBA3 gene.
[0239] Examples of proteins associated with autism spectrum disorders include, for example, benzodiazepine receptor (peripheral)-associated protein 1 (BZRAP1) encoded by the BZRAP1 gene, AF4 / FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also known as MFR2), fragile X mental retardation autosomal homolog 1 protein (FXR1) encoded by the FXR1 gene, or fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene.
[0240] Examples of proteins associated with macular degeneration include the ATP-binding cassette subfamily A (ABC1) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoprotein E protein (APOE) encoded by the APOE gene, or the chemokine (CC motif) ligand 2 protein (CCL2) encoded by the CCL2 gene.
[0241] Examples of proteins associated with schizophrenia include NRG1, ErbB4, CPLX1, TPH1, TPH2, NRXN1, GSK3A, BDNF, DISC1, GSK3B, and combinations thereof.
[0242] Examples of proteins involved in tumor suppression include ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch1, Notch2, Notch3, or Notch4.
[0243] Examples of proteins associated with secretase disorders can include, for example, PSENEN (presenilin enhancer 2 homolog (C. elegans)), CTSB (cathepsin B), PSEN1 (presenilin 1), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharyngeal defect 1 homolog B (C. elegans)), PSEN2 (presenilin 2 (Alzheimer's disease 4)), or BACE1 (beta-site APP cleaving enzyme 1).
[0244] Examples of proteins associated with amyotrophic lateral sclerosis include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
[0245] Examples of proteins associated with prion diseases can include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
[0246] Examples of proteins associated with neurodegenerative pathology in prion disorders include, for example, A2M (alpha-2-macroglobulin), AATF (apoptosis antagonistic transcription factor), ACPP (prostatic acid phosphatase), ACTA2 (aortic smooth muscle actin alpha 2), ADAM22 (ADAM metallopeptidase domain), ADORA3 (adenosine A3 receptor), or ADRA1D (alpha-1D adrenergic receptor for alpha-1D adrenoceptor).
[0247] Examples of proteins associated with immunodeficiency include, for example, A2M [alpha-2-macroglobulin]; AANAT [arylalkylamine N-acetyltransferase]; ABCA1 [ATP-binding cassette subfamily A (ABC1), member 1]; ABCA2 [ATP-binding cassette subfamily A (ABC1), member 2]; or ABCA3 [ATP-binding cassette subfamily A (ABC1), member 3].
[0248] Examples of proteins associated with trinucleotide repeat disorders include, for example, AR (androgen receptor), FMR1 (Fragile X Mental Retardation 1), HTT (Huntington's), or DMPK (Myotonic Dystrophy Protein Kinase), FXN (Frataxin), and ATXN2 (Ataxin 2).
[0249] Examples of proteins associated with impaired neurotransmission include, for example, SST (somatostatin), NOS1 (nitric oxide synthase 1 (neuronal type)), ADRA2A (adrenergic alpha-2A receptor), ADRA2C (adrenergic alpha-2C receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxytryptamine (serotonin) receptor 2C).
[0250] Examples of neurodevelopment-related sequences include, for example, A2BP1 [ataxin 2-binding protein 1], AADAT [aminoadipate aminotransferase], AANAT [arylalkylamine N-acetyltransferase], ABAT [4-aminobutyrate aminotransferase], ABCA1 [ATP-binding cassette subfamily A (ABC1) member 1], or ABCA13 [ATP-binding cassette subfamily A (ABC1) member 13].
[0251] Further examples of preferred conditions treatable by the system of the present invention can be selected from the following: Alcardi-Goutières syndrome; Alexander disease; Allan-Herndon-Dudley syndrome; POLG-related disorders; alpha-mannosidosis (types II and III); Alström syndrome; Angelman syndrome; ataxia-telangiectasia; neuronal ceroid lipofuscinosis; beta-thellasamia; bilateral optic atrophy and (infantile) optic atrophy type 1; retinoblastoma (bilateral); Canavan disease; cerebro-ocular-facial-skeletal syndrome 1 [COFS1]; cerebrotendinous xanthomas Cornelia de Lange syndrome; MAPT-related disorders; inherited prion diseases; Dravet syndrome; early-onset familial Alzheimer's disease; Friedreich ataxia [FRDA]; Flins syndrome; fucosidosis; Fukuyama-type congenital muscular dystrophy; galactosialidosis; Gaucher disease; organic acidemia; hemophagocytic lymphohistiocytosis; Hutchinson-Gilford progeria syndrome; mucolipidosis type II; infantile free sialic acid storage disease; PLA2G6-associated neurodegeneration; Jervell-Lange-Nielsen syndrome; junctional epidermolysis bullosa; Huntington's disease; Krabbe disease (infantile form) ; Mitochondrial DNA-related Leigh syndrome and NARP; Lesch-Nyhan syndrome; LIS1-related lissencephaly; Lowe syndrome; Maple syrup urine disease; MECP2 duplication syndrome; ATP7A-related copper transport disorders; LAMA2-related muscular dystrophy; Arylsulfatase A deficiency; Mucopolysaccharidosis type I, II, or III; Peroxisomal biogenesis disorders, Zellweger syndrome spectrum; Neurodegeneration with cerebral iron storage; Acid sphingomyelinase deficiency; Niemann-Pick disease type C; Glycine encephalopathy; ARX-related disorders; Urea cycle disorders; COL1A1 / 2-related diaphyseal dysplasia; mitochondrial DNA deletion syndrome; PLP1-related disorders; Perry syndrome; Phelan-McDermott syndrome; glycogen storage disease type II (Pompe disease) (infantile form); MAPT-related disorders; MECP2-related disorders; rhizomelic chondrodysplasia punctata type 1; Roberts syndrome; Sandhoff disease; Schindler disease type 1; adenosine deaminase deficiency; Smith-Lemli-Opitz syndrome; spinal muscular atrophy; childhood-onset spinocerebellar ataxia; hexosaminidase A deficiency; lethal dysplasia type 1; collagen type VI-related disorders; Usher syndrome type 1; congenital muscular dystrophy;Wolf-Hirschhorn syndrome; lysosomal acid lipase deficiency; and xeroderma pigmentosum.
[0252] It is clear that it is envisioned that the system of the present invention can be used to target any target polynucleotide sequence.Some examples of pathological conditions or diseases that can be usefully treated using the system of the present invention are included in the table above, and examples of genes currently associated with these pathological conditions are also provided in the table.However, the genes exemplified are not exclusive. [Example]
[0253] The following examples are given for the purpose of illustrating various embodiments of the present invention and are not meant to limit the invention in any manner. The examples, together with the methods described herein, are representative and exemplary of presently preferred embodiments and are not intended to limit the scope of the invention. Modifications thereof and other uses encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.
[0254] Example 1: Improvement of the Cas9 system for in vivo use We performed a metagenomic search for Cas9s with small molecular weights. Most Cas9 orthologs are quite large. Many known Cas9 orthologs are large, containing more than 1,300 amino acids. For example, SpCas9 is approximately 1,368 amino acids long, which is too large to easily package into a viral vector for delivery. A graph showing the length distribution of Cas9 homologs is shown in Figure 6. The graph is generated from sequences deposited in GenBank. Some sequences are misannotated, so the exact frequency for each length may not be correct. Nevertheless, this provides an overview of the distribution of Cas9 proteins and suggests the existence of shorter Cas9 homologs.
[0255] Through computational analysis, applicants have discovered that the bacterial strain Campylobacter has two Cas9 proteins with less than 1,000 amino acids. The sequence of one Cas9 from Campylobacter jejuni is provided below. At this length, CjCas9 can be easily packaged into AAV, lentivirus, adenovirus, and other viral vectors for robust delivery into primary cells and in vivo in animal models. In a preferred embodiment of the present invention, the Cas9 protein from Staphylococcus aureus is used.
[0256] Campylobacter jejuni Cas9 (CjCas9) [ka]
[0257] The putative tracrRNA element for this CjCas9 is: [ka]
[0258] The direct repeat sequence is: [ka]
[0259] An example of a chimeric guide RNA for CjCas9 is: [ka]
[0260] Example 2: Cas9 diversity and chimeric RNA Wild-type CRISPR-Cas systems are adaptive immune mechanisms against invading exogenous DNA used by a wide variety of species, including bacteria and archaea. Type II CRISPR-Cas systems consist of a set of genes encoding proteins responsible for "getting" foreign DNA into the CRISPR locus and a set of genes encoding the "execution" DNA cleavage mechanism; these include a DNA nuclease (Cas9), a non-coding transactivating crRNA (tracrRNA), and an array of spacers (crRNAs) derived from the foreign DNA flanked by direct repeats. Upon maturation by Cas9, the tracrRNA and crRNA duplex guide the Cas9 nuclease to the target DNA sequence specified by the spacer guide sequence, where it mediates a double-stranded break in DNA near a short sequence motif in the target DNA required for cleavage and specific to each CRISPR-Cas system. Type II CRISPR-Cas systems are found throughout the bacterial kingdom and are highly diverse in Cas9 protein sequence and size, tracrRNA and crRNA direct repeat sequences, genomic organization of these elements, and motif requirements for targeted cleavage. A given species may have multiple distinct CRISPR-Cas systems.
[0261] We evaluated 207 putative Cas9s from bacterial species that were identified based on sequence homology to known Cas9s and orthologous structures to known subdomains, e.g., the HNH and RuvC endonuclease domains (information from Eugene Koonin and Kira Makarova). Phylogenetic analysis of this set based on protein sequence conservation revealed five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids) (Figures 4 and 5A-F).
[0262] In some embodiments, the tracr mate sequence or direct repeat is downloaded from a CRISPR database or found in a 2 kb window of genomic sequence flanking the type II CRISPR locus, spanning from 20 to 50 bp; 3. Identification is performed in silico by searching for repeat motifs spaced every 20 to 50 bp. In some embodiments, two of these criteria can be used, e.g., 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all three criteria can be used. In some embodiments, candidate tracrRNAs are then predicted by: 1. sequence homology with the direct repeat (motif search in Geneious with a maximum mismatch of 18 bp), 2. the presence of a predicted Rho-independent transcription terminator in the direction of transcription, and 3. a stable hairpin secondary structure between the tracrRNA and the direct repeat. In some embodiments, two of these criteria can be used, e.g., 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all three criteria can be used. In some embodiments, the chimeric synthetic guide RNA (sgRNA) design incorporates at least 12 bp of double-stranded structure between the direct repeat and the tracrRNA.
[0263] A list of human codon-optimized Cas9 ortholog sequences for pairing with the chimeric RNAs provided in Figures 8A-J is provided in Figures 9A-O. Applicants also showed that Cas9 orthologs can cleave their targets in in vitro cleavage assays (Figure 16). CRISPR loci in some of these families are shown in Figure 11. The corresponding guide RNA sequences are shown in Figure 12. Applicants used a custom computational analysis code to systematically analyze genomic DNA sequences within approximately 2 kb of the Cas9 protein and identified direct repeats ranging from 35 bp to 50 bp with intervening spacers ranging from 29 bp to 35 bp. Based on the direct repeat sequences, we computationally searched for candidate tracrRNA sequences that met the following criteria: they were outside the crRNA array but contained a high degree of homology to the direct repeats (required for direct repeat:tracrRNA base pairing; custom computational analysis), were outside the coding region for the protein component, contained a Rho-independent transcription termination signal approximately 60-120 bp downstream from the region of homology to the direct repeats, and cofolded with the direct repeats to form a duplex, followed by two or more hairpin structures at the distal end of the tracrRNA sequence. Based on these predictive criteria, we selected an initial set of tracrRNAs distributed across 18 Cas9 proteins and their uniquely associated direct repeats, as well as all five Cas9 families. We further generated a set of 18 chimeric RNA structures that preserved the sequence and secondary structure of the native direct repeat:tracrRNA duplex while shortening the region that base-pairs and fuses the two RNA elements through an artificial loop (Figure 8A-J).
[0264] Example 3: Cas9 orthologs Applicants have generated codon-optimized Cas9 orthologs for improved expression in eukaryotic cells.
[0265] An example of a human codon-optimized sequence (i.e., optimized for expression in humans): SaCas9 is provided below. [ka] [ka]
[0266] Applicants analyzed Cas9 orthologs to identify related PAM sequences and corresponding chimeric guide RNAs, as shown in Figures 13A-II. This expanded set of PAMs provides broader targeting across the genome and also significantly increases the number of unique target sites, offering the potential to identify novel Cas9s with increased levels of specificity within the genome. Applicants determined that the PAM for Staphylococcus aureus (subspecies Aureus) Cas9 is NNGRR (Figure 14). Staphylococcus aureus (subspecies Aureus) Cas9 is also known as SaCas9. Figures 15a-d provide single and multiple vector designs for SaCas9.
[0267] Figure 7 shows sequence logos for putative PAMs, represented by the reverse complement. Cas9 orthologs and their respective sgRNAs were used to cleave a library of targets bearing randomized PAMs (7-bp sequences immediately 3' to the target sequence). Cleavage products were isolated and deep sequenced to generate 7-bp candidate sequences that allowed cleavage for each Cas9 ortholog. A consensus PAM was determined for each Cas9 ortholog by aligning all 7-bp candidate sequences (Figures 7 and 21).
[0268] Further experiments testing the thermodynamics and in vivo stability of sgRNA-DNA duplexes are likely to yield additional predictive power for off-target activity, while the development of SpCas9 mutants and orthologs may yield novel variants with improved specificity. The specificity of Cas9 orthologs can be further assessed by testing the ability of each Cas9 to tolerate mismatches between the guide RNA and its DNA target.
[0269] Example 4: Cas9 Mutations In this example, Applicants show that the following mutations can convert SpCas9 into a nicking enzyme: D10A, E762A, H840A, N854A, N863A, D986A.
[0270] We provide sequences showing where the mutations are located within the SpCas9 gene (Figures 10A-M). We also show that the nickase can still mediate homologous recombination. Furthermore, we show that SpCas9 with these mutations (individually) reduces the level of double-strand breaks. All Cas9 orthologs share the general organization of three to four RuvC domains and an HNH domain (Figure 19). The 5'-most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand. All notations refer to the guide sequence.
[0271] The catalytic residues in the 5' RuvC domain were identified by homology comparison of the target Cas9 with other Cas9 orthologs (from the S. pyogenes type II CRISPR locus, S. thermophilus CRISPR locus 1, S. thermophilus CRISPR locus 3, and Franciscilla novicida type II CRISPR locus). Mutation of the conserved Asp residue to alanine converted Cas9 into a complementary strand nicking enzyme. Similarly, mutation of the conserved His and Asn residues in the HNH domain to alanine converted Cas9 into a non-complementary strand nicking enzyme.
[0272] Example 5: Cas9 function optimization To improve or develop new functions, Applicants generated chimeric Cas9 proteins by combining fragments from different Cas9 orthologs.
[0273] For example, Applicants fused the N-terminus of St1Cas9 (a fragment from this protein is shown in bold) to the C-terminus of SpCas9 (a fragment from this protein is shown in underline). >St1(N)Sp(C)Cas9 [ka] >Sp(N)St1(C)Cas9 [ka]
[0274] Applicants also generated Sp_St3 chimeric proteins and demonstrated in vitro cleavage by SpCas9, St3Cas9, Sp_St3 chimeras, and St3_Sp chimeras (Figure 17).
[0275] Benefits of generating chimeric Cas9 include: a. Reduced toxicity b. Improved expression in eukaryotic cells c.Improved specificity d. Reducing the molecular weight of the protein, creating smaller proteins by combining minimal domains from different Cas9 homologs. e.PAM array requirement changes
[0276] Example 6: In vivo Cas9 delivery using AAV particles or vectors In vivo delivery - AAV method AAV is advantageous over other viral vectors for several reasons: Low toxicity (this may be due to the purification method not requiring ultracentrifugation of cellular particles that may activate an immune response) · It does not integrate into the host genome, so it has a low probability of causing insertional mutagenesis.
[0277] While some current AAV vectors can accommodate insert DNA up to 4300 bases as an upper limit or packaging limit, AAV can have insert DNA of 4.5 or 4.75 KB. This means that the DNA encoding the Cas9 enzyme, as well as the promoter and transcription terminator, must all fit into the same viral vector. Constructs larger than 4.5 or 4.75 KB result in significantly reduced virus production. SpCas9 is completely large, with the gene itself exceeding 4.1 kb, making it difficult to pack into AAV. Therefore, embodiments of the present invention include utilizing shorter Cas9 orthologs. For example:
[0278] [Table 22]
[0279] Figure 3 provides a schematic representation of AAV vectors that can be used in the methods and compositions of the invention. Packaging is discussed above.
[0280] Example 7: Engineering microalgae using Cas9 Methods for delivering Cas9
[0281] Method 1: Applicants deliver Cas9 and guide RNA using a vector that expresses Cas9 under the control of a constitutive promoter, e.g., Hsp70A-Rbc S2 or beta2-tubulin.
[0282] Method 2: We deliver Cas9 and T7 polymerase using vectors that express them under the control of a constitutive promoter, e.g., Hsp70A-Rbc S2 or beta2-tubulin. Guide RNA is delivered using a vector containing a T7 promoter driving the guide RNA.
[0283] Method 3: We deliver Cas9 mRNA and in vitro transcribed guide RNA into algal cells. RNA can be transcribed in vitro. Cas9 mRNA consists of the coding region for Cas9 and the 3'UTR from Cop1 to ensure stability of the Cas9 mRNA.
[0284] For homologous recombination, applicants provide additional homology-directed repair templates.
[0285] A cassette driving expression of Cas9 under the control of the beta-2 tubulin promoter, followed by the sequence for the 3'UTR of Cop1. [ka] [ka] [ka] [ka]
[0286] A cassette driving expression of T7 polymerase under the control of the beta-2 tubulin promoter, followed by the sequence for the 3'UTR of Cop1: [ka] [ka]
[0287] Sequence of guide RNA driven by T7 promoter (T7 promoter, N represents target sequence): [ka]
[0288] Gene delivery: Chlamydomonas reinhardtii strains CC-124 and CC-125 from the Chlamydomonas Resource Center are used for electroporation. The electroporation protocol follows the standard recommended protocol from the GeneArt Chlamydomonas Engineering kit (website information at tools.invitrogen.com / content / sfs / manuals / geneart_chlamy_kits_man.pdf).
[0289] Applicants also generate strains of Chlamydomonas reinhardtii that constitutively express Cas9. This can be done by using pChlamy1 (linearized with PvuI) and selecting for hygromycin-resistant colonies. The sequence for pChlamy1 containing Cas9 is shown below. In this approach to achieve gene knockout, it is only necessary to deliver RNA for the guide RNA. For homologous recombination, Applicants deliver the guide RNA and a linearized homologous recombination template.
[0290] pChlamy1-Cas9: [ka] [ka] [ka] [ka] [ka] [ka]
[0291] For all modified Chlamydomonas reinhardtii cells, Applicants confirmed successful modifications using PCR, SURVEYOR nuclease assay, and DNA sequencing.
[0292] Example 8: SaCas9 and PAM Recognition for In Vivo Applications Following the identification of the Streptococcus pyogenes (Sp) and Streptococcus thermophiles (St) CRISPR / Cas systems as functional genome engineering tools in mammalian cells, we initiated this project because we sought to further exploit the diversity of type II CRISPR / Cas systems.
[0293] By defining new functional Type II CRISPR / Cas systems for use in mammalian cells, Applicants can potentially discover: (1) CRISPR / Cas systems with higher efficiency and / or specificity (2) CRISPR / Cas systems with different protospacer adjacent motifs (PAMs) that enable targeting of a wider range of genomic loci. (3) CRISPR / Cas systems with smaller size (so that applicants can deliver them in vivo in a single vector by mammalian viral delivery systems, such as adeno-associated viral (AAV) vectors, which have packaging size limits (current Sp or St systems exceed this limit of 4.7 kb)) and other desirable traits.
[0294] Identification and design of a Sa CRISPR / Cas system for in vivo applications. Applicants tested a novel type II CRISPR / Cas system in Staphylococcus aureus (Sa) that functions in vitro in a dsDNA cleavage assay and identified a putative PAM for NNGRRT. The components of this system are the Cas9 protein from Sa, a guide CRISPR RNA with a direct repeat (DR) from Sa that forms a functional guide RNA complex with the tracrRNA from Sa. This three-component system is similar to all other type II CRISPR / Cas systems. Therefore, Applicants designed a two-component system in which they fused the Sa tracrRNA to the Sa guide CRISPR RNA via a short stem-loop to form a chimeric guide RNA, as Applicants did for the Streptococcus pyogenes (Sp) CRISPR / Cas system. This chimeric guide RNA was able to support dsDNA cleavage in vitro. Therefore, we decided to clone the complete two-component system: cas9 and the chimeric guide RNA into an AAV vector and test its functionality in a living organism.
[0295] Applicants chose the AAV system because it is a non-integrating, ssDNA-based, non-immunogenic mammalian virus with broad tropism in different tissues / organs depending on the serotype that has been shown to be safe for in vivo applications, and also supports long-term expression of transgenes in living organisms.
[0296] The initial AAV vector design contained (1) a CMV promoter driving the SaCas9 protein with a single NLS and HA epitope tag, and (2) a human U6 promoter driving a chimeric RNA, positioned between two inverted terminal repeats (ITRs) from the most well-studied AAV serotype 2, which function as viral packaging signals.
[0297] PAM sequence testing for endogenous mammalian genomes was performed as follows: SaCas9 target spacers were selected across multiple genes to cover different potential PAM sequences. Different spacers were cloned into U6-sgRNA (single guide RNA) expression dsDNA cassettes, which were then co-transfected into mammalian cell lines (293FT for human targets, N2a and Hepa for mouse targets). 72 hours after transfection, total genomic DNA was extracted and subjected to a surveyor nuclease assay. Genomic cleavage was detected by running the DNA on a TBE Page gel. Genomic DNA cleavage efficiency was quantified and plotted.
[0298] Summary of genome cleavage efficiencies and other statistics for all test targets
[0299] [Table 23]
[0300] Summary of genome cleavage efficiencies and other statistics for all test targets (cleaned up version)
[0301] [Table 24]
[0302] Results from PAM testing are shown in Figures 22-27. Comprehensive testing of over 100 targets identified a PAM for SaCas9 that can be described as NNGRR (not NNGRRT as above).
[0303] Summary of PAM studies: (1) NNGRR for general SaCas9 PAMs useful for designing new targets, (2) testing dual nickases with new targets, and (3) NNGRG may be a more potent PAM.
[0304] References 1.Cong,L.et al.Multiplex genome engineering using CRISPR / Cas systems.Science 339,819-823(2013) 2.Mali, P. et al.RNA-Guided Human Genome Engineering via Cas9.Science 339,823-826(2013). 3.Jinek,M.et al.RNA-programmed genome editing in human cells.eLife 2,e00471 (2013). 4. Cho, SW, Kim, S., Kim, JM & Kim, JSTargeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230-232 (2013). 5.Deltcheva, E. et al.CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.Nature 471,602-607(2011). 6.Jinek, M. et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science 337,816-821(2012). 7.Wang,H.et al.One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR / Cas-Mediated Genome Engineering.Cell 153,910-918(2013). 8.Guschin,D.Y.et al.A rapid and general assay for monitoring endogenous gene modification.Methods Mol Biol 649,247-256(2010). 9.Bogenhagen,D.F.&Brown,D.D.Nucleotide sequences in Xenopus 5S DNA required for transcription termination.Cell 24,261-270(1981). 10.Hwang,W.Y.et al.Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 31,227-229(2013). 11.Bultmann,S.et al.Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers.Nucleic Acids Res 40,5368-5377(2012). 12.Valton,J.et al.Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation.J Biol Chem 287,38427-38432 (2012). 13.Christian,M.et al.Targeting DNA double-strand breaks with TAL effector nucleases.Genetics 186,757-761(2010). 14.Miller,J.C.et al.A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29,143-148(2011). 15.Mussolino,C. et al.A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity.Nucleic acids research 39,9283-9293(2011). 16.Hsu,P.D.&Zhang,F.Dissecting neural function using targeted genome engineering technologies.ACS chemical neuroscience 3,603-610(2012). 17.Sanjana,N.E.et al.A transcription activator-like effector toolbox for genome engineering.Nature protocols 7,171-192(2012). 18.Porteus,M.H.&Baltimore,D.Chimeric nucleases stimulate gene targeting in human cells.Science 300,763(2003). 19.Miller,J.C.et al.An improved zinc-finger nuclease architecture for highly specific genome editing.Nat Biotechnol 25,778-785(2007). 20.Sander,J.D.et al.Selection-free zinc-finger-nuclease engineering by context-dependent assembly(CoDA).Nat Methods 8,67-69(2011). 21.Wood,A.J.et al.Targeted genome editing across species using ZFNs and TALENs.Science 333,307(2011). 22.Bobis-Wozowicz,S.,Osiak,A.,Rahman,S.H.&Cathomen,T.Targeted genome editing in pluripotent stem cells using zinc-finger nucleases.Methods 53,339-346(2011). 23.Jiang,W.,Bikard,D.,Cox,D.,Zhang,F.&Marraffini,L.A.RNA-guided editing of bacterial genomes using CRISPR-Cas systems.Nat Biotechnol 31,233-239(2013). 24.Qi,L.S.et al.Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression.Cell 152,1173-1183(2013). 25.Michaelis,L.M.,Maud“Die kinetik der invertinwirkung.”.Biochem.z(1913). 26.Mahfouz,M.M.et al.De novo-engineered transcription activator-like effector (TALE)hybrid nuclease with novel DNA binding specificity creates double-strand breaks.Proc Natl Acad Sci U S A 108,2623-2628(2011). 27.Wilson,E.B.Probable inference,the law of succession,and statistical inference.J Am Stat Assoc 22, 209-212(1927). 28.Ding,Q.et al.A TALEN genome-editing system for generating human stem cell-based disease models.Cell Stem Cell 12,238-251(2013). 29.Soldner,F.et al.Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.Cell 146,318-331(2011). 30.Carlson,D.F.et al.Efficient TALEN-mediated gene knockout in livestock.Proc Natl Acad Sci U S A 109,17382-17387(2012). 31.Geurts,A.M.et al.Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases.Science 325,433-433(2009). 32.Takasu,Y.et al.Targeted mutagenesis in the silkworm Bombyx mori using zinc finger nuclease mRNA injection.Insect Biochem Molec 40,759-765(2010). 33.Watanabe,T.et al.Non-transgenic genome modifications in a hemimetabolous insect using zinc-finger and TAL effector nucleases.Nat Commun 3(2012). 34.Reyon,D.et al.FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30,460-465(2012). 35.Boch,J.et al.Breaking the code of DNA binding specificity of TAL-type III effectors.Science 326,1509-1512(2009). 36.Moscou,M.J.&Bogdanove,A.J.A simple cipher governs DNA recognition by TAL effectors.Science 326,1501(2009). 37.Deveau,H.,Garneau,J.E.&Moineau,S.CRISPR / Cas system and its role in phage-bacteria interactions. Annu Rev Microbiol 64,475-493(2010). 38.Horvath,P.&Barrangou,R.CRISPR / Cas,the immune system of bacteria and archaea.Science 327,167-170 (2010). 39.Makarova,K.S.et al.Evolution and classification of the CRISPR-Cas systems.Nat Rev Microbiol 9,467-477(2011). 40.Bhaya,D.,Davison,M.&Barrangou,R.CRISPR-Cas systems in bacteria and archaea:versatile small RNAs for adaptive defense and regulation.Annu Rev Genet 45,273-297(2011). 41.Garneau,J.E.et al.The CRISPR / Cas bacterial immune system cleaves bacteriophage and plasmid DNA.Nature 468,67-71(2010). 42.Gasiunas,G.,Barrangou,R.,Horvath,P.&Siksnys,V.Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria.Proc Natl Acad Sci U S A 109,E2579-2586 (2012). 43.Urnov,F.D.,Rebar,E.J.,Holmes,M.C., Zhang, H.S.&Gregory,P.D.Genome editing with engineered zinc finger nucleases.Nat Rev Genet 11,636-646(2010). 44.Perez,E.E.et al.Establishment of HIV-1 resistance in CD4(+)T cells by genome editing using zinc-finger nucleases.Nat Biotechnol 26,808-816(2008). 45.Chen,F.Q.et al.High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases.Nat Methods 8,753-U796(2011). 46.Bedell,V.M.et al.In vivo genome editing using a high-efficiency TALEN system.Nature 491,114-U133(2012). 47.Saleh-Gohari,N.&Helleday,T.Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells.Nucleic Acids Res 32,3683-3688(2004). 48.Sapranauskas,R.et al.The Streptococcus thermophilus CRISPR / Cas system provides immunity in Escherichia coli.Nucleic Acids Res 39,9275-9282 (2011). 49.Shen,B.et al.Generation of gene-modified mice via Cas9 / RNA-mediated gene targeting.Cell Res 23, 720-723 (2013). 50.Tuschl,T.Expanding small RNA interference.Nat Biotechnol 20,446-448(2002). 51.Smithies,O.,Gregg,R.G.,Boggs,S.S.,Koralewski,M.A.&Kucherlapati,R.S.Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination.Nature 317,230-234(1985). 52.Thomas,K.R.,Folger,K.R.&Capecchi, M.R. High frequency targeting of genes to specific sites in the mammalian genome.Cell 44,419-428(1986). 53.Hasty,P.,Rivera-Perez,J.&Bradley,A.The length of homology required for gene targeting in embryonic stem cells.Mol Cell Biol 11,5586-5591(1991). 54.Wu,S.,Ying,G.X.,Wu,Q.&Capecchi,M.R.A protocol for constructing gene targeting vectors:generating knockout mice for the cadherin family and beyond.Nat Protoc 3,1056-1076(2008). 55.Oliveira,T.Y.et al.Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements.J Immunol Methods 375,176-181 (2012). 56.Tremblay et al.,Transcription Activator-Like Effector Proteins Induce the Expression of the Frataxin Gene;Human Gene Therapy.August 2012,23(8):883-890. 57.Shalek et al.Nanowire-mediated delivery enables functional interrogation of primary immune cells:application to the analysis of chronic lymphocytic leukemia.Nano Letters,2012,Dec 12;12(12):6498-504. 58.Pardridge et al. Preparation of Trojan horse liposomes(THLs)for gene transfer across the blood-brain barrier;Cold Spring Harb Protoc;2010;Apr;2010(4) 59.Plosker GL et al.Fluvastatin:a review of its pharmacology and use in the management of hypercholesterolaemia;Drugs 1996,51(3):433-459). 60.Trapani et al.Potential role of nonstatin cholesterol lowering agents;IUBMB Life,Volume 63,Issue 11,pages 964-971,November 2011 61.Birch AM et al.DGAT1 inhibitors as anti-obesity and anti-diabetic agents;Current Opinion in Drug Discovery&Development,2010,13(4):489-496 62.Fuchs et al.Killing of leukemic cells with a BCR / ABL fusion gene by RNA interference(RNAi),Oncogene 2002,21(37):5716-5724. 63. McManaman JL et al. Perilipin-2 Null Mice are Protected Against Diet-Induced Obesity, Adipose Inflammation and Fatty Liver Disease;The Journal of Lipid Research,jlr.M035063.First Published on February 12,2013. 64.Tang J et al.Inhibition of SREBP by a Small Molecule,Betulin,Improves Hyperlipidemia and Insulin Resistance and Reduces Atherosclerotic Plaques;Cell Metabolism,Volume 13,Issue 1,44-56,5 January 2011. 65.Dumitrache et al.Trex2 enables spontaneous sister chromatid exchanges without facilitating DNA double-strand break repair;Genetics.2011 August;188(4):787-797
[0305] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. [Sequence table] SEQUENCE LISTING <110> THE BROAD INSTITUTE, INC. <110> MASSACHUSETTS INSTITUTE OF TECHNOLOGY <110> PRESIDENT AND FELLOWS OF HARVARD COLLEGE <120> ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION <130> F74672D1 <140> JP2020-025253 <141> 2020-02-18 <150> US 61 / 836,101 <151> 2013-06-17 <150> US 61 / 835,931 <151> 2013-06-17 <150> US 61 / 828,130 <151> 2013-05-28 <150> US 61 / 819,803 <151> 2013-05-06 <150> US 61 / 814,263 <151> 2013-04-20 <150> US 61 / 806,375 <151> 2013-03-28 <150> US 61 / 802,174 <151> 2013-03-15 <150> US 61 / 791,409 <151> 2013-03-15 <150> US 61 / 769,046 <151> 2013-02-25 <150> US 61 / 758,468 <151> 2013-01-30 <150> US 61 / 748,427 <151> 2013-01-02 <150> US 61 / 736,527 <151> 2012-12-12 <160> 228 <170> PatentIn version 3.5 <210> 1 <211> 20 <212> DNA <213> Homo sapiens <400> 1 gagtccgagc agaagaagaa 20 <210> 2 <211> 20 <212> DNA <213> Homo sapiens <400> 2 gagtcctagc aggagaagaa 20 <210> 3 <211> 20 <212> DNA <213> Homo sapiens <400> 3 gagtctaagc agaagaagaa 20 <210> 4 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(44) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (47)..(60) <223> a, c, u, g, unknown or other <400> 4 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnnnn nnnnggnnnn nnnnnnnnnn 60 <210> 5 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(14) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (17)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 5 nnnnnnnnnn nnnnccnnnn nnnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 6 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(43) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (46)..(60) <223> a, c, u, g, unknown or other <400> 6 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnnnn nnnggnnnnn nnnnnnnnnn 60 <210> 7 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(15) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (18)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 7 nnnnnnnnnn nnnnnccnnn nnnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 8 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(42) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (45)..(60) <223> a, c, u, g, unknown or other <400> 8 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnnnn nnggnnnnnn nnnnnnnnnn 60 <210> 9 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(15) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (18)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 9 nnnnnnnnnn nnnnnccnnn nnnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 10 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(41) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (44)..(60) <223> a, c, u, g, unknown or other <400> 10 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnnnn nggnnnnnnn nnnnnnnnnn 60 <210> 11 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(17) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (20)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 11 nnnnnnnnnn nnnnnnnccn nnnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 12 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(40) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (43)..(60) <223> a, c, u, g, unknown or other <400> 12 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnnnn ggnnnnnnnn nnnnnnnnnn 60 <210> 13 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(18) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (21)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 13 nnnnnnnnnn nnnnnnnncc nnnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 14 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(39) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (42)..(60) <223> a, c, u, g, unknown or other <400> 14 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnnng gnnnnnnnnn nnnnnnnnnn 60 <210> 15 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(19) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (22)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 15 nnnnnnnnnn nnnnnnnnnc cnnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 16 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 16 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 17 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 17 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 18 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(37) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (40)..(60) <223> a, c, u, g, unknown or other <400> 18 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnnggn nnnnnnnnnn nnnnnnnnnn 60 <210> 19 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(21) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (24)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 19 nnnnnnnnnn nnnnnnnnnn nccnnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 20 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(36) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (39)..(60) <223> a, c, u, g, unknown or other <400> 20 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnnggnn nnnnnnnnnn nnnnnnnnnn 60 <210> 21 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(22) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (25)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 21 nnnnnnnnnn nnnnnnnnnn nnccnnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 22 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(60) <223> a, c, u, g, unknown or other <400> 22 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnnggnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 23 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(23) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (26)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 23 nnnnnnnnnn nnnnnnnnnn nnnccnnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 24 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(34) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (37)..(60) <223> a, c, u, g, unknown or other <400> 24 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnnggnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 25 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(24) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (27)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 25 nnnnnnnnnn nnnnnnnnnn nnnnccnnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 26 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(33) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (36)..(60) <223> a, c, u, g, unknown or other <400> 26 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnnggnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 27 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(25) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (28)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 27 nnnnnnnnnn nnnnnnnnnn nnnnnccnnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 28 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(32) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (35)..(60) <223> a, c, u, g, unknown or other <400> 28 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nnggnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 29 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(26) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (29)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 29 nnnnnnnnnn nnnnnnnnnn nnnnnnccnn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 30 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(31) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (34)..(60) <223> a, c, u, g, unknown or other <400> 30 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn nggnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 31 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(27) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (30)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 31 nnnnnnnnnn nnnnnnnnnn nnnnnnnccn nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 32 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(30) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (33)..(60) <223> a, c, u, g, unknown or other <400> 32 nnnnnnnnnn nnnnnnnnnn ccnnnnnnnn ggnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 33 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(28) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (31)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 33 nnnnnnnnnn nnnnnnnnnn nnnnnnnncc nnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 34 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(29) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (32)..(60) <223> a, c, u, g, unknown or other <400> 34 nnnnnnnnnn nnnnnnnnnn ccnnnnnnng gnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 35 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(29) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (32)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 35 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnc cnnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 36 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(28) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (31)..(60) <223> a, c, u, g, unknown or other <400> 36 nnnnnnnnnn nnnnnnnnnn ccnnnnnngg nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 37 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(30) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (33)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 37 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ccnnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 38 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(27) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (30)..(60) <223> a, c, u, g, unknown or other <400> 38 nnnnnnnnnn nnnnnnnnnn ccnnnnnggn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 39 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(31) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (34)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 39 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nccnnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 40 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(26) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (29)..(60) <223> a, c, u, g, unknown or other <400> 40 nnnnnnnnnn nnnnnnnnnn ccnnnnggnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 41 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(32) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (35)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 41 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnccnnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 42 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(25) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (28)..(60) <223> a, c, u, g, unknown or other <400> 42 nnnnnnnnnn nnnnnnnnnn ccnnnggnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 43 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(33) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (36)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 43 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnccnnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 44 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(24) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (27)..(60) <223> a, c, u, g, unknown or other <400> 44 nnnnnnnnnn nnnnnnnnnn ccnnggnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 45 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(34) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (37)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 45 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnccnngg nnnnnnnnnn nnnnnnnnnn 60 <210> 46 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (23)..(23) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (26)..(60) <223> a, c, u, g, unknown or other <400> 46 nnnnnnnnnn nnnnnnnnnn ccnggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 47 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(38) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (41)..(60) <223> a, c, u, g, unknown or other <400> 47 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnccngg nnnnnnnnnn nnnnnnnnnn 60 <210> 48 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(21) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (26)..(60) <223> a, c, u, g, unknown or other <400> 48 nnnnnnnnnn nnnnnnnnnn nccggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 49 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (40)..(60) <223> a, c, u, g, unknown or other <400> 49 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnccggn nnnnnnnnnn nnnnnnnnnn 60 <210> 50 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(23) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (26)..(60) <223> a, c, u, g, unknown or other <400> 50 nnnnnnnnnn nnnnnnnnnn nnnggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 51 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(33) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(60) <223> a, c, u, g, unknown or other <400> 51 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnggccnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 52 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(22) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (26)..(60) <223> a, c, u, g, unknown or other <400> 52 nnnnnnnnnn nnnnnnnnnn nncggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 53 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(32) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (35)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(60) <223> a, c, u, g, unknown or other <400> 53 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnggnccnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 54 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(31) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (34)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(60) <223> a, c, u, g, unknown or other <400> 54 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nggnnccnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 55 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(30) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (33)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(60) <223> a, c, u, g, unknown or other <400> 55 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ggnnnccnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 56 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(29) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (32)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(60) <223> a, c, u, g, unknown or other <400> 56 nnnnnnnnnn nnnnnnnnnn nnnnnnnnng gnnnnccnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 57 <211> 60 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(28) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (31)..(35) <223> a, c, u, g, unknown or other <220> <221> modified_base <222> (38)..(60) <223> a, c, u, g, unknown or other <400> 57 nnnnnnnnnn nnnnnnnnnn nnnnnnnngg nnnnnccnnn nnnnnnnnnn nnnnnnnnnn 60 <210> 58 <211> 12 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 58 guuuuagagc ua 12 <210> 59 <211> 7 <212> PRT <213> Simian virus 40 <400> 59 Pro Lys Lys Lys Arg Lys Val 1 5 <210> 60 <211> 16 <212> PRT <213> Unknown <220> <221> source <223> / note="Description of Unknown: Nucleoplasmin bipartite NLS sequence" <400> 60 Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys 1 5 10 15 <210> 61 <211> 9 <212> PRT <213> Unknown <220> <221> source <223> / note="Description of Unknown: C-myc NLS sequence" <400> 61 Pro Ala Ala Lys Arg Val Lys Leu Asp 1 5 <210> 62 <211> 11 <212> PRT <213> Unknown <220> <221> source <223> / note="Description of Unknown: C-myc NLS sequence" <400> 62 Arg Gln Arg Arg Asn Glu Leu Lys Arg Ser Pro 1 5 10 <210> 63 <211> 38 <212> PRT <213> Homo sapiens <400> 63 Asn Gln Ser Ser Asn Phe Gly Pro Met Lys Gly Gly Asn Phe Gly Gly 1 5 10 15 Arg Ser Ser Gly Pro Tyr Gly Gly Gly Gly Gln Tyr Phe Ala Lys Pro 20 25 30 Arg Asn Gln Gly Gly Tyr 35 <210> 64 <211> 42 <212> PRT <213> Unknown <220> <221> source <223> / note="Description of Unknown: IBB domain from importin-alpha sequence" <400> 64 Arg Met Arg Ile Glx Phe Lys Asn Lys Gly Lys Asp Thr Ala Glu Leu 1 5 10 15 Arg Arg Arg Arg Val Glu Val Ser Val Glu Leu Arg Lys Ala Lys Lys 20 25 30 Asp Glu Gln Ile Leu Lys Arg Arg Asn Val 35 40 <210> 65 <211> 8 <212> PRT <213> Unknown <220> <221> source <223> / note="Description of Unknown: Myoma T protein sequence" <400> 65 Val Ser Arg Lys Arg Pro Arg Pro 1 5 <210> 66 <211> 8 <212> PRT <213> Unknown <220> <221> source <223> / note="Description of Unknown: Myoma T protein sequence" <400> 66 Pro Pro Lys Lys Ala Arg Glu Asp 1 5 <210> 67 <211> 8 <212> PRT <213> Homo sapiens <400> 67 Pro Gln Pro Light Light Light Pro Leu 1 5 <210> 68 <211> 12 <212> PRT <213> Mus musculus <400> 68 Ser Ala Leu Ile Lys Lys Lys Lys Met Ala Pro 1 5 10 <210> 69 <211> 5 <212> PRT <213> Influenza virus <400> 69 Asp Arg Leu Arg Arg 1 5 <210> 70 <211> 7 <212> PRT <213> Influenza virus <400> 70 Pro Light Gln Light Light Arg Light 1 5 <210> 71 <211> 10 <212> PRT <213> Hepatitis delta virus <400> 71 Arg Lys Leu Lys Lys Lys Ile Lys Lys Leu 1 5 10 <210> 72 <211> 10 <212> PRT <213> Mus musculus <400> 72 Arg Glu Lys Lys Lys Phe Leu Lys Arg Arg 1 5 10 <210> 73 <211> 20 <212> PRT <213> Homo sapiens <400> 73 Light Arg Light Gly Asp Glu Val Asp Gly Val Asp Glu Val Ala Light Light 1 5 10 15 Light Sees Light Light 20 <210> 74 <211> 17 <212> PRT <213> Homo sapiens <400> 74 Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys 1 5 10 15 Light <210> 75 <211> 137 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 75 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60 gctacaaaga taaggcttca tgccgaaatc aacaccctgt cattttatgg cagggtgttt 120 tcgttattta atttttt 137 <210> 76 <211> 123 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 76 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaattt 120 ttt 123 <210> 77 <211> 110 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 77 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttttt 110 <210> 78 <211> 102 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 78 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60 cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt tt 102 <210> 79 <211> 88 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 79 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60 cgttatcaac ttgaaaaagt gttttttt 88 <210> 80 <211> 76 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 80 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60 cgttatcatt tttttt 76 <210> 81 <211> 984 <212> PRT <213> Campylobacter jejuni <400> 81 Met Ala Arg Ile Leu Ala Phe Asp Ile Gly Ile Ser Ser Ile Gly Trp 1 5 10 15 Ala Phe Ser Glu Asn Asp Glu Leu Lys Asp Cys Gly Val Arg Ile Phe 20 25 30 Thr Lys Val Glu Asn Pro Lys Thr Gly Glu Ser Leu Ala Leu Pro Arg 35 40 45 Arg Leu Ala Arg Ser Ala Arg Lys Arg Leu Ala Arg Arg Lys Ala Arg 50 55 60 Leu Asn His Leu Lys His Leu Ile Ala Asn Glu Phe Lys Leu Asn Tyr 65 70 75 80 Glu Asp Tyr Gln Ser Phe Asp Glu Ser Leu Ala Lys Ala Tyr Lys Gly 85 90 95 Ser Leu Ile Ser Pro Tyr Glu Leu Arg Phe Arg Ala Leu Asn Glu Leu 100 105 110 Leu Ser Lys Gln Asp Phe Ala Arg Val Ile Leu His Ile Ala Lys Arg 115 120 125 Arg Gly Tyr Asp Asp Ile Lys Asn Ser Asp Asp Lys Glu Lys Gly Ala 130 135 140 With Lys Only Only Only Only With Lys Gln Asn Glu Glu Lys Only On Tyr Gln 145 150 155 160 Ser Val Gly Glu Tyr Leu Tyr Lys Glu Tyr Phe Gln Lys Phe Lys Glu 165 170 175 Asn Ser Lys Glu Phe Thr Asn Val Arg Asn Lys Glu Ser Tyr Glu 180 185 190 Arg Cys With Gln Ser With Lys Asp Glu With Lys With Phe 195 200 205 Lys Lys Gln Arg Glu Phe Gly Phe Ser Phe Ser Lys Phe Glu Glu 210 215 220 Glu Val Leu Ser Val Ala Phe Tyr Lys Arg Ala Leu Lys Asp Phe Ser 225 230 235 240 His Leu Val Gly Asn Cys Ser Phe Phe Thr Asp Glu Lys Arg Ala Pro 245 250 255 Lys Asn Ser Pro Leu Ala Phe Met Phe Val Ala Leu Thr Arg Ile Ile 260 265 270 Asn Leu Leu Asn Asn Leu Lys Asn Thr Glu Gly Ile Leu Tyr Thr Lys 275 280 285 Asp Asp Leu Asn Ala Leu Leu Asn Glu Val Leu Lys Asn Gly Thr Leu 290 295 300 Thr Tyr Lys Gln Thr Lys Lys Leu Leu Gly Leu Ser Asp Asp Tyr Glu 305 310 315 320 Phe Lys Gly Glu Lys Gly Thr Tyr Phe Ile Glu Phe Lys Lys Tyr Lys 325 330 335 Glu Phe Ile Lys Ala Leu Gly Glu His Asn Leu Ser Gln Asp Asp Leu 340 345 350 Asn Glu Ile Ala Lys Asp Ile Thr Leu Ile Lys Asp Glu Ile Lys Leu 355 360 365 Lys Lys Ala Leu Ala Lys Tyr Asp Leu Asn Gln Asn Gln Ile Asp Ser 370 375 380 Leu Ser Lys Leu Glu Phe Lys Asp His Leu Asn Ile Ser Phe Lys Ala 385 390 395 400 Leu Lys Leu Val Thr Pro Leu Met Leu Glu Gly Lys Lys Tyr Asp Glu 405 410 415 Ala Cys Asn Glu Leu Asn Leu Lys Val Ala Ile Asn Glu Asp Lys Lys 420 425 430 Asp Phe Leu Pro Ala Phe Asn Glu Thr Tyr Tyr Lys Asp Glu Val Thr 435 440 445 Asn Pro Val Val Leu Arg Ala Ile Lys Glu Tyr Arg Lys Val Leu Asn 450 455 460 Ala Leu Leu Lys Lys Tyr Gly Lys Val His Lys Ile Asn Ile Glu Leu 465 470 475 480 Ala Arg Glu Val Gly Lys Asn His Ser Gln Arg Ala Lys Ile Glu Lys 485 490 495 Glu Gln Asn Glu Asn Tyr Lys Ala Lys Lys Asp Ala Glu Leu Glu Cys 500 505 510 Glu Lys Leu Gly Leu Lys Ile Asn Ser Lys Asn Ile Leu Lys Leu Arg 515 520 525 Leu Phe Lys Glu Gln Lys Glu Phe Cys Ala Tyr Ser Gly Glu Lys Ile 530 535 540 Lys Ile Ser Asp Leu Gln Asp Glu Lys Met Leu Glu Ile Asp His Ile 545 550 555 560 Tyr Pro Tyr Ser Arg Ser Phe Asp Asp Ser Tyr Met Asn Lys Val Leu 565 570 575 Val Phe Thr Lys Gln Asn Gln Glu Lys Leu Asn Gln Thr Pro Phe Glu 580 585 590 Ala Phe Gly Asn Asp Ser Ala Lys Trp Gln Lys Ile Glu Val Leu Ala 595 600 605 Lys Asn Leu Pro Thr Lys Lys Gln Lys Arg Ile Leu Asp Lys Asn Tyr 610 615 620 Lys Asp Lys Glu Gln Lys Asn Phe Lys Asp Arg Asn Leu Asn Asp Thr 625 630 635 640 Arg Tyr Ile Ala Arg Leu Val Leu Asn Tyr Thr Lys Asp Tyr Leu Asp 645,650,655 Phe Leu Pro Leu Ser Asp Asp Glu Asn Thr Lys Leu Asn Asp Thr Gln 660,665,670 Lys Gly Ser Lys Val His Val Glu Ala Lys Ser Gly Met Leu Thr Ser 675,680,685 Ala Leu Arg His Thr Trp Gly Phe Ser Ala Lys Asp Arg Asn Asn His 690,695,700 Leu His His Only Asp Only Val Only Only Tyr Only Asn Asn Ser 705 710 715 720 Ile Val Lys Ala Phe Ser Asp Phe Lys Lys Glu Gln Glu Ser Asn Ser 725 730 735 Glu Leu Tyr Ala Lys Lys Ser Glu Leu Asp Tyr Lys Asn Lys 740,745,750 Arg Lys Phe Glu Pro Phe Ser Gly Phe Arg Gln Lys Val Leu Asp 755,760,765 Lys Ile Asp Glu Ile Phe Val Ser Lys Pro Glu Arg Lys Lys Pro Ser 770,775,780 Gly Ala Leu His Glu Glu Thr Phe Arg Lys Glu Glu Glu Phe Tyr Gln 785,790,795,800 Ser Tyr Gly Gly Lys Glu Gly Val Leu Lys Ala Leu Glu Leu Gly Lys 805 810 815 Ile Arg Lys Val Asn Gly Lys Ile Val Lys Asn Gly Asp Met Phe Arg 820 825 830 Val Asp Ile Phe Lys His Lys Lys Thr Asn Lys Phe Tyr Ala Val Pro 835 840 845 Ile Tr Thr Met Asp Phe Ala Leu Lys Val Leu Pro Asn Lys Ala Val 850 855 860 Only Arg Ser Lys Lys Gly Glu Ile Lys Asp Trp Ile Leu Met Asp Glu 865 870 875 880 Asn Tyr Glu Phe Cys Phe Ser Leu Tyr Lys Asp Ser Leu Ile Leu Ile 885,890,895 Gln Thr Lys Asp Met Gln Glu Pro Glu Phe Val Tyr Tyr Asn Ala Phe 900 905 910 Thr Ser Ser Thr Val Ser Leu Ile Val Ser Lys His Asp Asn Lys Phe 915 920 925 Glu Thr Leu Ser Lys Asn Gln Lys Ile Leu Phe Lys Asn Ala Asn Glu 930 935 940 Lys Glu Val Ile Ala Lys Ser Ile Gly Ile Gln Asn Leu Lys Val Phe 945 950 955 960 Glu Lys Tyr Ile Val Ser Ala Leu Gly Glu Val Thr Lys Ala Glu Phe 965 970 975 Arg Gln Arg Glu Asp Phe Lys Lys 980 <210> 82 <211> 91 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 82 tataatctca taagaaattt aaaaagggac taaaataaag agtttgcggg actctgcggg 60 gttacaatcc cctaaaaccg cttttaaaat t 91 <210> 83 <211> 36 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 83 gttttagtcc ctttttaaat ttctttatgg taaaat 36 <210> 84 <211> 95 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <400> 84 nnnnnnnnn nnnnnnnnn guuuuagucc cgaaagggac uaaaauaaag aguuugcggg 60 acucugcggg guaacaucc ccuaaaacg cuuuu 95 <210> 85 <211> 3243 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide” <400> 85 accggtgcca ccatgtaccc atacgatgtt ccagattacg cttcgccgaa gaaaaagcgc 60 aaggtcgaag cgtccatgaa aaggaactac attctggggc tggacatcgg gattacaagc 120 gtggggtatg ggattattga ctatgaaaca agggacgtga tcgacgcagg cgtcagactg 180 ttcaaggagg ccaacgtgga aaacaatgag ggacggagaa gcaagagggg agccaggcgc 240 ctgaaacgac ggagaaggca cagaatccag agggtgaaga aactgctgtt cgattacaac 300 ctgctgaccg accattctga gctgagtgga attaatcctt atgaagccag ggtgaaaggc 360 ctgagtcaga agctgtcaga ggaagagttt tccgcagctc tgctgcacct ggctaagcgc 420 cgaggagtgc ataacgtcaa tgaggtggaa gaggacaccg gcaacgagct gtctacaaag 480 gaacagatct cacgcaatag caaagctctg gaagagaagt atgtcgcaga gctgcagctg 540 gaacggctga agaaagatgg cgaggtgaga gggtcaatta ataggttcaa gacaagcgac 600 tacgtcaaag aagccaagca gctgctgaaa gtgcagaagg cttaccacca gctgga...
Claims
1. A non-naturally occurring or engineered composition, comprising: (A) I. A first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, said polynucleotide sequence comprising: (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell; (b) a tracr mate sequence, and (c) tracr sequence A first regulatory element comprising: II. A second regulatory element operably linked to an enzyme coding sequence encoding a CRISPR enzyme comprising at least one nuclear localization sequence. Including, (a), (b) and (c) are arranged in a 5' to 3' orientation; Components I and II are on the same or different vectors of the system, When transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence; The CRISPR complex is a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising the CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence. or (B) I. A first regulatory element, (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one tracr mate sequence; A first regulatory element operably linked to II. A second regulatory element operably linked to an enzyme coding sequence encoding a CRISPR enzyme; and III. A third regulatory element operably linked to the tracr sequence Including, Components I, II, and III are on the same or different vectors of the system, When transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence; The CRISPR complex comprises: (1) the guide sequence hybridized to the target sequence; and (2) the CRISPR enzyme complexed with the tracr mate sequence hybridized to the tracr sequence; In (A) or (B), the CRISPR enzyme is selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaete, and the like. and a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors that are Cas9 orthologues of a genera from the group consisting of: Bacillus subtilis, Bacillus phaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter.
2. A modified CRISPR enzyme, comprising: Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaeroides ... Cas9 orthologues of genera belonging to the group consisting of Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter, with the following differences from the corresponding wild-type CRISPR enzyme: the modified CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme; or and / or the CRISPR enzyme has a length of at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids; and / or the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence, and / or the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic cell, and / or the CRISPR enzyme comprises one or more mutations; and / or The CRISPR enzyme comprises a chimeric CRISPR enzyme. A modified CRISPR enzyme comprising:
3. 3. The composition of claim 1, or the enzyme of claim 2, wherein the CRISPR enzyme has one or more mutations in any domain of the enzyme.
4. 4. The composition or enzyme of any one of claims 1 to 3, wherein the CRISPR enzyme has one or more mutations in the catalytic domain.
5. 5. The composition or enzyme of claim 3 or 4, wherein the one or more mutations are present in the RuvCI, RuvCII, RuvCIII or HNH domain of the CRISPR enzyme.
6. 6. The composition or enzyme of claim 4 or 5, wherein the CRISPR enzyme comprises one or more mutations corresponding to position numbering of SpCas9 at positions D10A, E762A, H840A, N854A, N863A or D986A.
7. The composition or enzyme of any one of claims 1 to 6, wherein the enzyme further comprises a functional domain.
8. The composition or enzyme of claim 7 , wherein the functional domain is a transcriptional activator domain.
9. 9. The composition or enzyme of claim 8, wherein the transcriptional activator domain is VP64.
10. The composition or enzyme according to any one of claims 7 to 9, wherein the functional domain is a transcriptional repressor domain.
11. 11. The composition or enzyme of claim 10, wherein the transcriptional repressor domain is KRAB, SID or SID4X.
12. 1. A method for modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest, comprising: Delivering a non-naturally occurring or engineered composition comprising a vector system operably encoding the composition of any one of claims 1 to 11 for its expression. The method includes:
13. The method of claim 12, wherein delivery is via one or more viral vectors.
14. I. A first regulatory element operably linked to a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, said first polynucleotide sequence comprising: (i) a first guide sequence capable of hybridizing to a first target sequence at a first genomic locus in a cell of the organism; (ii) a first tracr mate sequence, and (iii) a first tracr sequence A first regulatory element comprising: II. A second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, said second polynucleotide sequence comprising: (i) a second guide sequence capable of hybridizing to a second target sequence at a second genomic locus in said cell of said organism; (ii) a second tracr mate sequence, and (iii) a second tracr sequence and a second regulatory element comprising III. A third regulatory element operably linked to an enzyme coding sequence encoding a first CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a first functional domain; IV. A fourth regulatory element operably linked to an enzyme coding sequence that includes at least one nuclear localization sequence and encodes a second CRISPR enzyme that is operably linked to a second functional domain. Including, (i), (ii) and (iii) of I and II are arranged in a 5' to 3' orientation; Components I, II, III and IV are on the same or different vectors of the system, When transcribed, each tracr mate sequence hybridizes to its corresponding tracr sequence, and the first and second guide sequences direct sequence-specific binding of the first and second CRISPR complexes to the first and second target sequences; the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence, wherein expression of the CRISPR enzyme provides for manipulation of the target sequence; wherein the first and second CRISPR enzymes each comprise two or more mutations; The first and second CRISPR enzymes are selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaete, and the like. and a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors that are Cas9 orthologues of a genera from the group consisting of: Bacillus subtilis, Bacillus erochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter.
15. 1. A method for modulating expression of two or more genomic loci of interest in an organism, comprising: I. A first regulatory element operably linked to a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, said first polynucleotide sequence comprising: (i) a first guide sequence capable of hybridizing to a first target sequence at a first genomic locus in a cell of the organism; (ii) a first tracr mate sequence, and (iii) a first tracr sequence A first regulatory element comprising: II. A second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, said second polynucleotide sequence comprising: (i) a second guide sequence capable of hybridizing to a second target sequence at a second genomic locus in said cell of said organism; (ii) a second tracr mate sequence, and (iii) a second tracr sequence and a second regulatory element comprising III. A third regulatory element operably linked to an enzyme coding sequence encoding a first CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a first functional domain; IV. A fourth regulatory element operably linked to an enzyme coding sequence that includes at least one nuclear localization sequence and encodes a second CRISPR enzyme that is operably linked to a second functional domain. Including, (i), (ii) and (iii) of I and II are arranged in a 5' to 3' orientation; Components I, II, III and IV are on the same or different vectors of the system, When transcribed, each tracr mate sequence hybridizes to its corresponding tracr sequence, and the first and second guide sequences direct sequence-specific binding of the first and second CRISPR complexes to the first and second target sequences; the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence, wherein expression of the CRISPR enzyme provides for manipulation of the target sequence; wherein the first and second CRISPR enzymes each comprise two or more mutations; The first and second CRISPR enzymes are selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerocheta, and the like. aeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter; The first genomic locus is modulated by the activity of the first functional domain and the second genomic locus is modulated by the activity of the second functional domain.
16. 16. The composition of claim 14 or the method of claim 15, wherein the first functional domain is selected from the group consisting of a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, and a light-inducible / regulatory domain or a chemically-inducible / regulatory domain.
17. The composition of claim 14 or 16, or the method of claim 15 or 16, wherein the second functional domain is selected from the group consisting of a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, and a light-inducible / regulatory domain or a chemically-inducible / regulatory domain.
18. 18. The composition or method of claim 16 or 17, wherein the first or second functional domain is a transcriptional activator domain.
19. 48. The composition or method of claim 47, wherein the transcriptional activator domain is VP64.
20. 18. The composition or method of claim 16 or 17, wherein the first or second functional domain is a transcriptional repressor domain.
21. 21. The composition or method of claim 20, wherein the transcriptional repressor domain is KRAB, SID or SID4X.
22. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Sutterella wadsworthensis Cas9.
23. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Filifactor alocis Cas9.
24. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Lactobacillus johnsonii Cas9.
25. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Campylobacter lari Cas9.
26. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Corynebacter diptheriae Cas9.
27. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Parvibaculum lavamentivorans Cas9.
28. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Mycoplasma gallisepticum Cas9.
29. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Staphylococcus aureus subsubspecies Aureus Cas9.
30. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Legionella pneumophila Paris Cas9.
31. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Treponema denticola Cas9.
32. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Staphylococcus pseudointermedius Cas9.
33. 22. The composition or method of any one of claims 14 to 21, wherein the first or second CRISPR enzyme is Neisseria cinerea Cas9.
34. 1. A method of treating or inhibiting a pathology caused by an abnormality in a target sequence in a genomic locus of interest in a subject or non-human subject in need thereof, the method comprising modifying the subject or non-human subject by manipulation of the target sequence, the pathology being: Delivering a non-naturally occurring or engineered composition comprising an AAV vector system comprising one or more AAV vectors operably encoding for expression of the composition of any one of claims 1 or 3-11. wherein the target sequence is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing a treatment comprising the steps of:
35. 35. The method of claim 34, comprising inducing expression.
36. 36. The method of claim 34 or 35, wherein the organism or subject is a eukaryote or a non-human eukaryote.
37. The method according to any one of claims 34 to 36, wherein the organism or subject is a plant.
38. The method according to any one of claims 34 to 36, wherein the organism or subject is a mammal or a non-human mammal.
39. 38. The method of any one of claims 34 to 37, wherein the organism or subject is algae.
40. The method of any one of claims 34 to 39, wherein the viral vector is AAV.
41. 34. A composition or enzyme according to any one of claims 1 to 11, 14 or 16 to 33 for use in medicine or for use in therapy.
42. A composition or enzyme according to any one of claims 1 to 11, 14 or 16 to 33 for use in a method according to any one of claims 12, 13 or 15 to 40.
43. 36. Use of a composition or enzyme according to any one of claims 1 to 11, 14 or 16 to 33 in ex vivo gene or genome editing.
44. 36. Use of a composition or enzyme according to any one of claims 1 to 11, 14 or 16 to 33 in the manufacture of a medicament for ex vivo gene or genome editing or for use in a method according to any one of claims 12, 13 or 15 to 40.
45. 34. A composition or enzyme according to any one of claims 1 to 11, 14 or 16 to 33, wherein the target sequence is flanked at its 3' end by 5'-NRG (wherein N is any nucleotide), particularly when the Cas9 is (or is derived from) a S. pyogenes or S. aureus Cas9.
46. A method of preparing an AAV for delivery of a composition or enzyme according to any one of claims 1 to 11, 14 or 16 to 33, comprising transfecting into an AAV infected cell a plasmid containing or consisting essentially of a nucleic acid molecule encoding an AAV, and providing AAV rep and / or cap essential for replication and packaging of said AAV.
47. 47. The method of claim 46, wherein the cells are transfected with a helper plasmid or helper virus to supply the AAV rep and / or cap necessary for replication and packaging of the AAV.
48. 48. The method of claim 47, wherein the helper virus is a poxvirus, adenovirus, herpesvirus or baculovirus.
49. 49. The method of claim 48, wherein the poxvirus is a cowpox virus.
50. - the cell is a mammalian cell; or - the cell is an insect cell and the helper virus is a baculovirus, 50. The method according to any one of claims 46 to 49.
51. A method for delivering the CRISPR enzyme according to any one of claims 2 to 11, comprising delivering to a cell an mRNA encoding said CRISPR enzyme.
52. A chimeric Cas enzyme comprising one or more fragments from a first Cas ortholog and one or more fragments from a second Cas ortholog.
53. 53. The enzyme of claim 52, wherein the one or more fragments of the first or second Cas ortholog are from the C- or N-terminus of the first or second Cas ortholog.
54. The first or second Cas ortholog is selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacter, and the like.
54. The enzyme of claim 52 or 53, which is selected from the genera belonging to the group consisting of: Bacillus subtilis, Bacillus anguium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.
55. 55. Use of a composition or enzyme according to any one of claims 1 to 11, 14, 16 to 33 or 52 to 54 in the preparation of a medicament for the modification of a target sequence.
56. 12. The composition of any one of claims 1 to 11, wherein the CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme or wherein the CRISPR enzyme comprises between 500 and 2000 amino acids.
57. 57. The composition of any one of claims 1-11 or 56, wherein the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or wherein the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence.
58. 58. The composition of any one of claims 1-11 or 56-57, wherein the guide sequence comprises at least 15 nucleotides.
59. 60. The composition of any one of claims 1-11 or 56-58, wherein the CRISPR enzyme is codon-optimized or is codon-optimized for expression in a eukaryotic cell.
60. 60. The composition of any one of claims 1-11 or 56-59, wherein the CRISPR enzyme comprises one or more mutations.
61. 61. The composition of any one of claims 1-11 or 56-60, wherein the CRISPR enzyme comprises a chimeric CRISPR enzyme.
62. A non-naturally occurring or engineered composition, comprising: A)-I. A CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell; (b) a tracr mate sequence, and (c) tracr sequence A polynucleotide sequence comprising: II. Polynucleotides encoding CRISPR enzymes containing at least one nuclear localization sequence Chid sequence Including, (a), (b) and (c) are arranged in a 5' to 3' orientation; When transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence; The CRISPR complex comprises: (1) the guide sequence hybridized to the target sequence; and (2) the CRISPR enzyme complexed with the tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA. Non-Naturally Occurring or Engineered Compositions or (B) I. A polynucleotide comprising: (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one tracr mate sequence; A polynucleotide comprising II. A polynucleotide sequence encoding a CRISPR enzyme, and III. Polynucleotide sequences containing tracr sequences Including, When transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific target binding of a CRISPR complex to the target sequence; the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA; The CRISPR enzyme is selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, and the like. erium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter are Cas9 orthologs of genera belonging to the group consisting of Non-naturally occurring or engineered compositions.
63. 1. A method for modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest, comprising: A)-I. A CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell; (b) a tracr mate sequence, and (c) tracr sequence A polynucleotide sequence comprising: II. Polynucleotide sequences encoding CRISPR enzymes containing at least one nuclear localization sequence Including, (a), (b) and (c) are arranged in a 5' to 3' orientation; When transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence; The CRISPR complex comprises: (1) the guide sequence hybridized to the target sequence; and (2) the CRISPR enzyme complexed with the tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA. Non-Naturally Occurring or Engineered Compositions or (B) I. A polynucleotide comprising: (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one tracr mate sequence; A polynucleotide comprising II. A polynucleotide sequence encoding a CRISPR enzyme, and III. Polynucleotide sequences containing tracr sequences Including, When transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific target binding of a CRISPR complex to the target sequence; the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA; The CRISPR enzyme is selected from the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, and the like. erium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter are Cas9 orthologs of genera belonging to the group consisting of A method comprising delivering a non-naturally occurring or engineered composition.
64. 64. The composition of claim 62 or the method of claim 63, wherein the CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme, or the CRISPR enzyme comprises between 500 and 2000 amino acids.
65. 65. The composition or method of any one of claims 62 to 64, wherein the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or wherein the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence.
66. 66. The composition or method of any one of claims 62-65, wherein the guide sequence comprises at least 15 nucleotides.
67. 67. The composition or method of any one of claims 62-66, wherein the CRISPR enzyme is codon-optimized or is codon-optimized for expression in a eukaryotic cell.
68. 68. The composition or method of any one of claims 62-67, wherein the CRISPR enzyme comprises one or more mutations.
69. 69. The composition or method of any one of claims 62-68, wherein the CRISPR enzyme comprises a chimeric CRISPR enzyme.
Citation Information
Patent Citations
Method for detecting interaction of biopolymers
JP2010115192A
Crispr-CAS system materials and methods
WO2015071474A2
Antisense inhibition of hepatitis b virus replication
WO1997003211A1
